Cover Page โ Protocol  
 
 
 
 
 
Study Official Title: A Phase 2 Randomized, Placebo-
Controlled Trial of Tocilizumab in Amyotrophic Lateral 
Sclerosis (ALS)  
 
 
NCT #: [STUDY_ID_REMOVED] 
 
Version Date of the Document: May 30, 2017  
 
A Phase 2 Randomized, Placebo-Controlled Trial of Tocilizumab in Amyotrophic Lateral 
Sclerosis (ALS)
Regulatory Sponsor: Barrow Neurological Institute
Funding Sponsor: ALS Association (ALSA)
Neurological Clinical Research Institute (NCRI)
Genentech, Inc.Barrow Neurological Foundation (BNF)
MAP ALS Partnership (ALSA, ALS ONE, ALS Finding 
a Cure) 
Study Product: Tocilizumab (Actemraโข)
Protocol Number: TCZALS-001
IND Number: 121,214
Original Version/Date: 1.0 / 02 December 2013
Amended Version Number/Date: 8.0 / 30 May 2017
The information contained herein is confidential and proprietary in nature, and will not be
disclosed to any third party without written approval of authorized designee.
This document may be disclosed to the appropriate institutional review boards or to duly
authorized representatives of the US Food and Drug Administration or a national
regulatory authority under the condition  that they maintain confidentiality.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 2 of 90STATEMENT OF COMPLIANCE
This study will be conducted in compliance with the protocol, International Conference on 
Harmonisation of Technical Requirements for Re gistration of Pharmaceuticals for Human Use 
(ICH), Good Clinical Practice (GCP), and the app licable regulatory requirements, United States 
Code of Federal Regulations (CFR) Title 45 CFR Part 46 and Title 21 CFR Parts 50, 56, and 
312.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 3 of 90SIGNATURE PAGE
I have read the attached protocol entitled, โ A Phase 2 Randomized, Placebo-Controlled Trial 
of Tocilizumab in Amyotrophic Lateral Sclerosis (ALS) โ dated 30 May 2017 (Version 8.0)
and agree to abide by all describe d protocol procedures.  I agree to  comply with the International 
Conference on Harmonisation Trip artite Guideline on Good Clinical  Practice, applicable FDA 
regulations and guidelines identified in 21  CFR Parts 11, 50, 54, and 312, local Institutional 
Review Board (IRB) guidelines and policies, and the Health Insurance Portability and 
Accountability Act (HIPAA).
Site Investigator: _______________________________________________________________
Signed: Date:
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 4 of 90TABLE OF CONTENTS
STATEMENT OF COMPLIANCE ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท2  
SIGNATURE PAGE ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท3  
LIST OF ABBREVIATIONSยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท7  
PROTOCOL SUMMARY ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท9  
1 ETHICS/PROTECTION OF HUMAN SUBJECTS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 15  
1.1 INSTITUTIONAL REVIEW BOARD (IRB) ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 15  
1.2 ETHICAL CONDUCT OF STUDY ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 15  
1.3 SUBJECT INFORMATION AND CONSENT ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 15  
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALEยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 16  
2.1 BACKGROUND INFORMATION ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 16  
2.2 RATIONALE ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 16  
2.3 PRELIMINARY DATAยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยท 17  
2.3.3 Tocilizumab ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยท 22  
2.4 POTENTIAL RISKS AND BENEFITS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 22  
2.4.1 Potential Risks ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 22  
3 OBJECTIVES ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 26  
3.1 STUDY OBJECTIVES ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยท 26  
3.2.1 Primary Outcome Measures ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 26  
3.2.2 Secondary Outcom e Measuresยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 27  
4 STUDY DESIGNยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 29  
4.1 OVERALL STUDY DESIGN AND PLANยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 29  
4.2 STUDY CENTERS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยทยท 29  
4.3 STUDY DURATION ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยท 29  
4.4 PROTOCOL ADHERENCE ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยท2 9 
5 STUDY ENROLLMENT AND WITHDRAWALยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 30  
5.1 NUMBER OF STUDY SUBJECTS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 30  
5.2 INCLUSION AND EXCLUSION CRITERIA ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 30  
5.2.1 Inclusion Criteriaยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 30  
5.2.3 IMMUNIZATION DURING TCZ THERAPY ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 33  
5.3. TREATMENT ASSIGNMENT PROCEDURES ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 34  
5.3.1 Randomization Proceduresยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 34  
5.3.2 Reasons for Withdrawal ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 34  
5.3.3 Handling of Withdrawalsยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 34  
5.3.4 Termination of Study ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 35  
6 TREATMENTS ADMINISTERED ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 36  
6.1 TREATMENTS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 36  
6.1.1 Study Product Description ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 36  
6.1.2 Placeboยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 36  
6.2 ACQUISITION ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 36  
6.2.1 Formulation, Packagin g, and Labeling ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 37  
6.2.2 Product Storage and Stability ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 37  
6.3 DOSAGE ,PREPARATION AND ADMINISTRATION OF STUDY INTERVENTION /INVESTIGATIONAL PRODUCT ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท37  
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 5 of 906.3.1 TOCILIZUMAB STORAGE ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยท3 8 
6.4 MODIFICATION OF STUDY INTERVENTION /INVESTIGATIONAL PRODUCT FOR A SUBJECT ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท39  
6.4.1.  Dosage Discontinuation ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 43  
6.5 ACCOUNTABILITY PROCEDURES FOR TOCILIZUMAB ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 44  
6.6 PRIOR AND CONCOMITANT THERAPY ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 45  
6.6.1 Prohibited Medications and Contraindications ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 45  
7 STUDY SCHEDULEยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 48  
7.1 SCREENING VISITยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยท 48  
7.1.1 Screen Failuresยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 49  
7.2 BASELINE VISITยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยทยทยท 49  
7.3 WEEK 4( V ISIT 1)ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยท 50  
7.4 WEEK 8( V ISIT 2)ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยท 50  
7.5 WEEK 12 (V ISIT 3)ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยท 51  
7.6 WEEK 16 (EOS V ISIT)ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยท 51  
7.7 FINAL SAFETY VISIT &T ELEPHONE CALLยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 52  
7.8 PROTOCOL DEVIATIONS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยท 52 
7.9 MISSED VISITS AND PROCEDURES ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 53  
8 CLINICAL ASSESSMENTS AND OUTCOME MEASURES ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 54  
8.1 CLINICAL VARIABLES ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยท 54  
8.1.1 Vital Signs, Height & Weight ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 54  
8.1.2 PBMC Blood Collection, hs-CRP concentration and Cytokine Levelsยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 54  
8.1.4 12-Lead Electrocardiogram (ECG)ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 54  
8.1.5 Chest X-Ray ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 54  
8.1.6 Physical Examinationยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 55  
8.1.7 Neurological Examination ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 55  
8.1.8 Columbia Suicide Severity Rating Scale (C-SSRS)ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 55  
8.1.10  Lumbar Puncture ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 55  
8.1.11  Adverse Eventsยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 56  
8.1.12  Exit Questionnaire ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 57  
8.2 OUTCOME MEASURE ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยท 57  
8.2.1 ALSFRS-Rยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 57  
8.2.2 Slow Vital Capacity  (SVC) Testing ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 57  
8.2.3 Hand-held Dynamometry (HHD) and Grip Strengthยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 57  
8.2.4 Training and Validation ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 58  
8.2.5  Neuroimaging ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 58  
9 SAFETY AND ADVERSE EVENTS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 61  
9.1 DEFINITIONS OF AES,SUSPECTED ADVERSE DRUG REACTIONS &S A E Sยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 61  
9.1.1 Adverse Event and Suspected Adverse Drug Reactionsยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 61  
9.1.3 Serious Adverse Events ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 63  
9.2 ASSESSMENT AND RECORDING OF ADVERSE EVENTS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 64  
9.2.1 Assessment of Adverse Events ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 64  
9.2.2 Relatedness of Adverse Event to Investigational Productยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 65  
9.2.3 Recording of Adverse Events ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 66  
9.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS -REPORTABLE EVENTS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 66  
10 DATA AND SAFETY MONITORING A ND STATISTICAL ANALYSIS PLAN ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 69  
10.1 DATA AND SAFETY MONITORING BOARD ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 69  
10.2 SAFETY MONITORING ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยท 70  
10.2.1  Safety Management Resource Team ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 70  
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 6 of 9010.2.2  Medical Monitoringยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 70  
10.3 STATISTICAL CONSIDERATIONS ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 70  
10.3.1  Statistical Methods ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 70  
10.3.2  Analysis Populationsยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 72  
10.4 MISSING DATA ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยทยทยทยทยทยทยทยทยทยทยทยท 72  
10.4.1  Stopping Rules ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 72  
11 DATA COLLECTION, MANAGE MENT AND MONITORING ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 73  
11.1 ROLE OF DATA MANAGEMENT ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 73  
11.1.1  Data Entry and Checks ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 73  
11.1.2  Data Lock Processยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 73  
11.1.3  Quality Assuranceยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 74  
11.2 CLINICAL MONITORING ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท ยทยท 74 
11.3 DATA HANDLING AND RECORD KEEPING ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 74  
11.3.1  Confidentiality ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 74  
11.3.2  Study Discontinuation ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 75  
11.3.3  Retention of Recordsยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 75  
11.3.4  Publicationsยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 75  
12 LITERATURE REFERENCESยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 76  
13 APPENDICES ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 78  
13.1 A PPENDIX I: ELESCORIAL WORLD FEDERATION OF NEUROLOGY CRITERIA FOR THE DIAGNOSIS OF ALSยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท78  
13.2 A PPENDIX II: ALS F UNCTIONAL RATING SCALE โREVISED (ALSFRS-R) ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 80  
13.3 A PPENDIX III: C OLUMBIA -SUICIDE SEVERITY RATING SCALE (C-SSRS) B ASELINE VERSION ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท83  
13.4 A PPENDIX IV: C OLUMBIA -SUICIDE SEVERITY RATING SCALE (C-SSRS) S INCE LASTVISIT VERSION ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท86  
13.6 A PPENDIX V: SAFETY REPORTING FAX COVER SHEET ยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยทยท 89  
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 7 of 90LIST OF ABBREVIATIONS
ADR Adverse Drug Reaction
AE Adverse Event/Adverse Experience
ALS Amyotrophic Lateral Sclerosis
ALSFRS-R Amyotrophic Lateral Sclerosi s Functional Rating Scale - Revised
ALT Alanine Aminotransferase
ANC Absolute Neutrophil Count
AST Aspartate Aminotransferase
BiPAP Bilevel Positive Airway Pressure
ยบC Degrees Celsius
CBC Complete Blood Count
CC Coordination Center
CFR Code of Federal Regulations
CMP Complete Metabolic Panel
CRF Case Report Form
CSF Cerebrospinal Fluid 
CYP450 Cytochrome P450
DM Data Management
DPS Diaphragm Pacing System
DSMB Data and Safety Monitoring Board
ECG Electrocardiogram
EDC Electronic Data Capture
EOS End of Study
ยบF Degrees Fahrenheit
FDA Food and Drug Administration
GCP Good Clinical Practice
hCG Human Chorionic Gonadotrophin
HHD Handheld Dynamometry
HIPAA Health Insurance Portability and Accountability Act
HIV Human Immunodeficiency Virus
hs- CRP Highly sensitive C-reactive protein
ICF Informed Consent Form
ICH International Conference on Harmonisation
IL-6 Interleukin-6
IND Investigational New Drug Application
IRB Institutional Review Board
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 8 of 90ITT Intent to Treat
IV Intravenous
LP Lumbar Puncture
LFT Liver Function Test
mg Milligram
mg/kg Milligram per kilogram
mL Milliliter
mm3Millimeter cubed
mmHg Millimeter of mercury
MR-PET Magnetic Resonance Imaging - PBR28 Positron Emission Tomography
N Number (typically refers to subjects)
NEALS Northeast ALS Consortium
NMDA N-methyl-D-aspartate
OHRP Office for Human Research Protections
pg/mL Picogram per milliliter
PA Posterioranterior
PBMC Peripheral Bl ood Mononuclear Cell
PBR28 Peripheral Benzodiazepine Receptor 28
PET Positron Emission Tomography
PLPH Post-LP Headache
RNA Ribonucleic Acid
SAE Serious Adverse Event/Serious Adverse Experience
SDT Source Document Templates
SI Site Investigator
sIL-6r Soluble IL-6 Receptor
SOD1 Superoxide dismutase 1
SVC Slow Vital Capacity
TB Tuberculosis
TSPO Translocator Protein
ULN Upper Limit of Normal
UMNB Upper Motor Neuron Burden Scale
US United States
ฮผg/kg Microgram per kilogram
WOCBP Women of Childbearing Potential
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 9 of 90PROTOCOL SUMMARY
Study Title
A Phase 2 Randomized, Placebo-Controlled Tria l of Tocilizumab in Amyotrophic Lateral 
Sclerosis (ALS)
Version Number
8.0Study Indication
Amyotrophic Lateral Sclerosis (ALS)Phase of Development
2
Rationale for the Study
Despite the aggressive nature of Amyotrophic La teral Sclerosis (ALS) and decades of research 
there has been no cure or highly efficaci ous therapy. In 1995, the FDA approved the only 
treatment for ALS, riluzole (Rilutekยฎ). Although the mechanism of action is not clear, it is felt 
to act upon multiple targets to reduce excitatory neurotoxicity in motor neurons. It may do this 
through inhibition of sodium channels, by inhibiting glutamate or other excitatory 
neurotransmitter release and by N-methyl-D-asp artate (NMDA) receptor antagonism [1]. Since 
riluzoleโs approval, various agents have been  tested for efficacy and uniformly failed to 
demonstrate a survival benefit. 
This failure has been attributed to several fact ors [2]. The first and primary reason is that the 
pathophysiology of the disease is poorly under stood, especially with regard to early or 
precipitating cellular triggers. There is evidence that oxidative stress, excitoxicity, mitochondrial 
dysfunction, and aberrant ribonucleic acid (RNA) p rocessing all contribute to eventual motor 
neuron death. The second reason is that current c linical trials lack a meaningful and robust 
surrogate marker of disease activity. This results in longer, more costly trials that are not able to properly stratify or randomize patients. 
In this study, we hope to address these two issues by focusing on the pathophysiologic immune 
mechanisms involved in motor neuron death and by utilizing the peripheral blood mononuclear 
cells (PBMC) gene expression pr ofile to quantify the immune res ponse in ALS patients. If this 
profile is found to mirror disease progression, as  our preliminary data suggests, this expression 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 10 of 90profile could be used in a future phase 3 efficacy trial as a selection criteria as well as a surrogate 
marker of disease progression. 
We will also measure the effect of tocilizumab in reducing glial activation as measured by 
PBR28 positron emission tomography (PET) in a subset of study participants. 
Study Design
This is a multicenter, randomized, double-bli nd, placebo-controlled 16-week study evaluating 
the safety and tolerability of tocilizumab in subjects with sporadic ALS.
Study Objectives and Endpoints 
The primary objective of the study is to determin e the safety and tolerability of intravenous 
administration of 8 mg/kg of tocilizumab ev ery 4 weeks vs. matched intravenous placebo 
administered every 4 weeks over an 8 week period.
The primary outcome measure will be safety and tolerability of tocilizumab.
The secondary objective of the study is to descri be the expression of pro-inflammatory genes in 
PBMCs of sporadic ALS patients, to assess the ability of tocilizumab to reduce the expression of pro-inflammatory genes in PBMCs and pro-inflammatory cytokine s in the cerebrospinal fluid 
(CSF) of patients with sporad ic ALS and to assess the CSF penetration of tocilizumab.
Exploratory measures will include clinical meas ures of disease progression such as ALSFRS-R, 
forced vital capacity, and handheld dynamometry.  In addition, genotyping of the IL-6 receptor 
gene will be performed to look for polymorphism s that might affect the inflammatory state 
mediated by the IL-6 pathway.
Subjects enrolled at Massachusetts General Hosp ital only will have an additional exploratory 
measure.  A [
11C]PBR28-PET scan will be performed at the Baseline visit (Pre-dose), and once 
at Week 8 visit (Post-dose).
Study Locations
Approximately 5 Northeast ALS Consortium (NEALS) Centers in the US will participate in the 
study. 
Number of Planned Subjects
Approximately 24 subjects will be randomized in the study.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 11 of 90Study Population
This study will be conducted in subjects who meet  the El Escorial criteri a of possible, laboratory-
supported probable, probable, or de finite criteria for a diagnosis of ALS. At screening, eligible 
subjects must be at least 18 years old, mu st have a slow vital capacity (SVC) ย40% of predicted 
capacity for age, height and gender, and must provide written informed consent prior to screening.  Subjects on a stable dose of riluzole  and those not taking riluzole, and women of 
child-bearing age at screening are eligible for inclusion as long as they meet specific protocol 
requirements.  Detailed criteria are de scribed in the body of the protocol.
Treatment Groups
Subjects will be randomly assigned in a 2:1 ra tio to intravenous tocilizumab 8 mg/kg or 
matching placebo every 4 weeks over an 8 week period.
This research study protocol allows the subject  to receive up to 3 infusions of Tocilizumab.
Even if the treatment is shown to  be of benefit, additional infu sions of Tocilizumab beyond that 
allowed in the protocol cannot be given to the subj ect while she/he is participating in this study.
Duration of Treatment and Follow-up
Subjects will remain on randomized, placebo-cont rolled, double-blind treatment until the Week 8
visit.  Each randomized subject will also have a Week 12 Follow-up visit and Week 16 End-of-
Study visit to assess for adverse events (AEs), changes in concomitant medications, to administer 
the ALSFRS-R and selected study procedures.
Tocilizumab in ALS
Version 5.0
Version date 06/25/2016
Page 12 of 90SCHEDULE OF ACTIVITES
1 Screening procedures must be completed within 28 days prior to Baseline Visit.
2Vital signs include systolic and diastolic pressure in mmHg, respiratory rate/minute, heart rate/minute and temperature.  Activity Screening Visit1 Baseline VisitWeek   4 Week    8 Week 12 Week 16
Visit 1 Visit 2 Visit 3 EOS Visit
Written Informed Consent X
Inclusion/Exclusion Review X X
Medical History X
Demographics X
ALS Diagnosis History X
Physical Examination X X
Neurological Exam X X
Columbia Suicide Severity Rating Scale (C-SSRS) XXXXX
Vital Signs2including Height3a n d  W e i g h t XXXXXX
Lumbar Puncture (LP)4X4X4
ALSFRS-R XXXXX
S l o w  V i t a l  C a p a c i t y  ( S V C ) XXXXXX
Hand Held Dynamometry (HHD) and Grip Strength X X X
Electrocardiogram (12-Lead ECG) X
PA and Lateral Chest X-Ray X
Quantiferon or T-SPOT TB Blood Test X
Safety Labs5XXXX X X
PBMC Collection X6X7XX XX
Plasma Biomarker Collection X X X XX
Blood Collection for IL-6R genotype, Genentech sample X
C o n c o m i t a n t  M e d i c a t i o n  R e v i e w XXXXXX
Adverse Event Review8 XXXXXX
Randomization9 X
Administer Study Drug XXX
Exit  Questionnaire X
[11C]PBR28-PET X* X**
MRI Safety Questionnaire X X X
Upper Motor Neuron Burden Scale X X X
Blood draw for TSPO X***
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 13 of 903 Height measured at Screening Visit only.
4 Telephone call will be made 24-48 hours post lumbar puncture (LP) to assess for adverse events (AEs) related to the LP.
5Safety labs include Hematology (CBC with differential), ChemistryPanel, Hepatitis B panel, , Urinalysis and pregnancy test (WOCBP)  as required 
throughout the study. Serum hCG will be collected at Screening Visit, and urine pregnancy tests will be collected at each subseq uent visit for all 
WOCBP. 
6 Plasma Biomarkers will not be collected at the screening visit.
7  Collection at Baseline to occur prior to infusion 
8Adverse events that occur AFTER signing the informed consent form will be recorded.
9 Randomization should occur immediately prior to the Baseline Visit.
*Pre-dose [11C]PBR28-PET will be performed one time only at the Baseline visits. ( -2 Weeks)
**Post-dose [11C]PBR28-PET will be performed one time only at the Week 8 visit ( -2 Weeks).
***Blood draw for TSPO affinity testing to occur at the Screening visit, if not previously determined.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 14 of 90STUDY WORKFLOW  
           ~ 50 Screened
- Study drug infusion at Baseline, Visit 1 and Visit 2. 
- Subjects who discontinue study drug early but agree to be fol lowed will be asked to remain in the study and to attend all as signed visits until the Week 16 End-
of- study visit.  - Subjects who discontinue study drug early and do not agree to  be followed will be asked to return to the study site for a fi nal safety assessment, and will be 
asked to have a final follow-up telephone call 28 days (+5 days ) after taking their last dose of study drug.8 weeks 8 weeks 28 days
Screening Baseline Visit Week 4
Visit 1Week 8
Visit 2Week 12
Visit 3Week 16
EOS VisitScreening Period On Active Treatment Follow-up PeriodPlacebo Group B
N=8Group A
N=16Tocilizumab 
8 mg/kg Low inflammation group or indeterminate excluded 
High inflammation group
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 15 of 901 ETHICS/PROTECTION OF HUMAN SUBJECTS
1.1 Institutional Review Board (IRB)
This study will be conducted in  compliance with current Good Clinical Practices (GCP) and 
Title 21 Part 56 of the United States of America Code of Federal Regulations (CFR) relating to 
IRBs. 
1.2 Ethical Conduct of Study
The study will be conducted in accordance with GC P defined by the International Conference on 
Harmonization (ICH) and the ethical princi ples of the Declaration of Helsinki.
1.3 Subject Information and Consent
This study will be conducted in compliance with  Title 21 Part 50 of the United States of America 
Code of Federal Regulations (CFR), Federa l Regulations and ICH Guidance Documents 
pertaining to informed consent.  At the first visit, prior to initiation of any study-related procedures, subjects will be informed about the nature and purpose of the study, participation/termination conditions, and risks and benefits. Subjects will be given adequate time 
to ask questions and become familiar with the study prior to providing consent to participate. 
Subjects who wish to will give their written cons ent to participate in the study and will be 
provided with a copy of the fully ex ecuted consent form for their records.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 16 of 902 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE
2.1 Background Information
Despite the aggressive nature of Amyotrophic La teral Sclerosis (ALS) and decades of research,
there has been no cure or highly efficaci ous therapy. In 1995, the FDA approved the only 
treatment for ALS, riluzole (Rilutekยฎ). Although the mechanism of action is not clear, it is believed to act upon multiple targets to reduce exc itatory neurotoxicity in motor neurons. It may 
do this through inhibition of sodium channels, by inhibiting glutamate or other excitatory 
neurotransmitter release, and by N-methyl-D-aspartate (NMDA) receptor antagonism [1]. Since riluzoleโs approval, various agents have been  tested for efficacy and uniformly failed to 
demonstrate a survival benefit. 
This failure has been attributed to several factors [2]. The primary reason is that the 
pathophysiology of the disease is poorly under stood, especially with regard to early or 
precipitating cellular triggers. There is evidence that oxidative stress, excitoxicity, mitochondrial 
dysfunction, and aberrant ribonucle ic acid (RNA) processing all c ontribute to eventual motor 
neuron death. The second reason is that current clinical trials lack a surrogate marker of disease activity. This results in longer, more costly trials that are not able to properly target patients for 
enrollment and do not advance underst anding of ALS pathophysiology.
In this study, we hope to address these two i ssues by focusing on the pathophysiologic immune 
mechanisms involved in motor neuron death and by utilizing the peripheral blood mononuclear 
cells (PBMC) gene expression profile to select patients for enrollment and to quantify the immune response in ALS patients. If this profile is found to mirror disease progression, as our 
preliminary data suggests, this expression profile could be used in a future phase 3 efficacy trial 
as surrogate marker of disease progression. 
2.2 Rationale
Tocilizumab is a humanized monoclonal antibod y against the IL-6 receptor distributed by 
Genentech, Inc. under the trade name Actemraยฎ . It was FDA approved for treatment of 
refractory moderate to severe rheumatoid arthr itis. It is delivered by intravenous infusion 
monthly at a standard dose of 4-8 mg/kg [3]. W e propose that tocilizumab treatment will reduce 
inflammation in ALS patients by impeding both the classical and trans-signaling IL-6 pathways.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 17 of 90The anti-inflammatory approach to treat ALS by tocilizumab is based on basic science 
discoveries and information related to inflammatory signaling by the cytokine IL-6 [4-9].  IL-6 is 
one of the most important mediat ors of fever and acute phase responses, is capable of crossing 
the blood-brain barrier, and is secreted by macropha ges in response to pathogens.  IL-6 binds to 
cell surface IL-6 receptors (IL6-R) present on numerous cell types.  In the spinal fluid and in the spinal cord of sporadic ALS patients, IL-6 may also transmit its inflammatory signal through a 
soluble IL6 receptor (sIL6-R) containing only the extracellular portion of the IL6-R, which then 
binds to a ubiquitous cell surface receptor called gp130 and activates numerous signaling 
pathways, including the JAK/STAT and Ras-Raf- MAPK pathways. This process is called IL-6
โtrans-signalingโ and can activate intracellular pathways in cell types that lack the cell surface 
IL6-R. Interestingly, many CNS cell types only respond to IL-6 via IL-6 trans-signaling [10, 11].We have shown that the spinal fluid of ALS pa tients contains up to nanogram amounts of sIL6-R
but only 100 pg/mL (mean) of IL-6 protein. Howe ver, macrophages infiltrating the ALS spinal 
cord strongly express IL-6 suggesting that IL-6 signaling may be occurring in the spinal cord 
through both trans-signaling via the sIL-6R and classical signaling through the membrane receptor. The significance of IL-6 signaling lie s in the stimulation of phagocytosis of motor 
neurons by inflammatory m acrophages expressing IL-6 [5].
The study hypothesis is that tocilizumab is safe in AL S patients, penetrates the blood brain 
barrier and reduces expression of pro-in flammatory genes in patients with ALS.
2.2.1 Rationale for Dose
The dosing rationale of tocilizumab in this study is based on the FDA labeling for its use in rheumatoid arthritis. In general, it is administered at a dose of 8 mg/kg as an intravenous infusion 
over 1 hour every 4 weeks with the drug mixed with normal saline to a total volume of 100 mL.
2.3 PRELIMINARY DATA
2.3.1 Gene expression of pro-inflammatory cytokines
Peripheral blood mononuclear cells (PBMCs) is olated from ALS patients and treated with 
aggregated SOD1 (2 ฮผg/mL) exhibit increased gene expression and protein levels for multiple 
cytokines [4].  Addition of tocilizumab (10 ฮผg/mL) inhibited the expre ssion of pro-inflammatory 
cytokines induced by aggregated SOD1 (Figure 1).
We analyzed gene expression of activated PBMC s from 10 sporadic ALS patients, 5 of whom 
were treated with tocilizumab infusions, and four healthy controls [7]. Among our sample of
sporadic ALS patients, the innate immune system was highly inflammatory in 50% of the patients (Group 1, mean age +/- S.E of 53.4 +/- 1.6 years) and nearly non-inflammatory in the 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 18 of 90other 50% (Group 2, age 55.2 +/- 7.9 years) based on analysis of PBMC gene expression by RT-
PCR (Figure 2).  Group 1 patie nts were defined as those w hose PBMCs show up-regulation 
(compared to healthy controls, mean age 62 +/- 10.2 years) of the transcription of inflammatory 
genes for cytokines/chemokines IL- ฤฎIL-ศ,/ -6, IL-8, CXCL3, CXCL5, CCL20, MMP1, and 
COX-2 ( p<0.05 Group 1 vs. healthy controls), wherea s the โGroup 2โ PBMCs show normal or 
low inflammatory activation except for elevated transcription of CXCL 9, 10, 11 when compared 
to healthy controls [4]. In one Group 1 patie nt, we observed a reduction over 12 weeks in 
inflammatory gene expression and inflammatory biomarkers, such as serum C-reactive protein, 
IL-6 and IL-1 cytokines, after tocilizumab infusion therapy, followed by recurrence from 4 to 5
months after start of therapy, and subsequent  remission of inflamma tion.  Serum level of 
tocilizumab in this patient was 12.3 ฮผg/mL before infusion (trough level from prior infusion) and 
109 ฮผg/mL after infusion, with CSF levels of 0.18 ฮผg/mL after infusion, demonstrating that drug 
was reaching the CNS.  The patientโs rate of  progression by ALSFRS-R slowed from 2.6 points 
per month to 0.4 points per month. The patient discontinued tocilizumab after 8 months of 
therapy and the disease course accelerated by ALSFRS-R measurements. ALSFRS-Rprogression slowed from 1.3 points per month to  0.75 points per month in another Group 1 
patients treated with tocilizumab for 2 months. I n one Group 2 patient, the effect of tocilizumab 
infusion therapy on inflammatory gene expression was minimal, but the patientโs rate of 
progression by ALSFRS-R reversed course, changi ng from a 0.7 point per month decline to a 1.0 
point per month improvement over 4 months  of treatment. One other Group 2 patient 
experienced an acceleration of progression during 5 months of tocilizumab  treatment.  The small 
number of patients in this pilot clinical study makes these findings difficult to generalize to the ALS population as a whole.  However these c linical findings merit continued study of 
tocilizumab in a larger and more carefully controlled clinical trial.  Specifically, an important 
goal of the proposed clinical trial will be to  demonstrate that our gene expression profile 
biomarker of PBMCs can be used to demonstrate target engagement and a biological effect [4, 
7].
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 19 of 90
FIGURE 1: Reduction of cytokine levels after tocilizumab treatment
Levels of IL- ศ ,/ -6, GM-CSF and TNF- Din PBMCโs from Group 1 ALS patients before 
(magenta) and after (yellow) overnight tocilizumab treatment, compared to healthy controls (black, 
null).  Drug treatment led to significantly reduced levels of cytokines released from activated 
PBMCs.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 20 of 90FIGURE 2: Gene expression profiling iden tifies two inflammation groups in ALS

Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 21 of 902.3.2 PBR28 preliminary data
Imaging Neuroinflammation using [11C]PBR28-
PET
[11C]PBR28 is a novel radiotracer of 
neuroinflammation. It binds to the 18 kDa 
translocator protein (TSPO), which is highly 
expressed in activated microglia and monocytes.  We have shown that [
11C]PBR28 uptake is increased in 
the motor cortices of symptomatic ALS patients [12].
We have administered [11C]PBR28 to more than 50 
ALS participants and 25 healthy volunteers at MGH. Below is a summary of our main published and unpublished preliminary findings to date: 
I. [
11C]PBR28 uptake is significantly increased 
in the motor cortices and subcortical regions in ALS participants compared to healthy controls [12](Figure 3A,B,C).
II. The anatomical dist ribution of increased 
[
11C]PBR28 uptake corresponds to ALS 
clinical presentation; ALS participants with limb-onset weakness had elevated [
11C]PBR28 retention in the motor cortices, 
whereas participants with bulbar-onset weakness had increased retention in the brainstem [12].
III. Increased [
11C]PBR-28 uptake strongly 
correlates with increased upper motor neuron dysfunction as measured by the Upper Motor Neuron Burden (UMNB) scale (Figure 3D) [12].
IV. Using our combined Positron emission 
tomography/magnetic resonance imaging MR/PET scanner, we demonstrated that [
11C]PBR-28 uptake (molecular measure of inflammation) co-localizes and correlates Figure 3: PBR28 PET study in 46 ALS participants and 21 
healthy volunteers (unpublished data) .PBR28 uptake in the 
motor cortices is increased in ALS subjects (A)compared to 
healthy volunteers (B).Statistical maps with family-wise 
corrections for multiple testing show increased PBR28 uptake 
in the motor cortices in the ALS group (C). PBR28 uptake in 
the motor cortices is highly correlated with upper motor neuron 
burden (UMNB) (D). 

Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 22 of 90with axonal loss (anatomical change) measured by fractional anisotropy FA and cortical 
thinning (anatomical change), providing unique in vivo evidence of the anatomical 
connection between motor ne uron degeneration and the surrounding inflammation [13].
2.3.3 Tocilizumab
Tocilizumab (TCZ), formerly known as myeloma receptor antibody (MRA) is a recombinant 
humanized antihuman monoclonal antibody of th e immunoglobulin IgG1 subclass directed 
against the IL-6R and produced by recombinant DNA technology. Clinical efficacy and safety 
studies of TCZ have been conducted or are ongo ing in various disease areas, including adult-
onset RA, systemic-onset juvenile  idiopathic arthritis and polyarticular juvenile idiopathic 
arthritis.
The half-life of TCZ is approximately 7 days. The TCZ exposures were stable over 2- years of 
treatment. The observed mean (ยฑ SD) Ctrough at 8 mg/kg IV was 15.9 ยฑ 12.0 at
week 24 and 19.9 ยฑ 17.0 at week 104. The observed mean (ยฑ SD) Ctrough at 4 mg/kg was 1.02 ยฑ6.14 at week 24 and 1.09 ยฑ 2.77 at week 104.
The Roche clinical development program in adult RA, comprised five pivotal Phase 3 trials and 
two open-label, long-term tr eatment extension studies. 
Further information on TCZ can be found in the Investigatorโs Brochure (IB).
2.4 POTENTIAL RISKS AND BENEFITS2.4.1 Potential Risks
The main risks associated with the study relate  to exposure to tocilizumab and lumbar puncture
(LP). Tocilizumab has both short-term and long-term risks associated with it. As with any 
intravenous (IV) drug, there is a chance for inj ection reactions such as anaphylaxis. These 
reactions are usually mild and responsive to an tipyretics, antihistamines, and analgesics. The 
experience with tocilizumab in rheumatoid arthritis patients suggests that serious reactions occur 
at a rate of 0.1%-0.2% [3]. The most common l ong-term AEs  were upper respiratory tract 
infections (7%), nasopharyngitis (7%), headache (7%), hypertension (6%) and elevated liver functions tests (6%), reversible neutropenia, and elevated choles terol (13%). Serious infections 
have been reported with tocilizumab use a nd include opportunistic infections such as 
tuberculosis. Finally, tociliz umab reverses inflammation-i nduced CYP450 enzyme inhibition, 
effectively increasing drug metabolism via this  pathway and decreasing CYP450 metabolized 
drug exposure. Although this has been studied in the rheumatoid arthritis population, it is unclear 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 23 of 90if ALS patients have clinically significant inflammation-induced CYP 450 alterations [14, 15].
Unfortunately, no other anti IL-6 receptor agents are available as an alternative to tocilizumab. 
Given our hypothesis that IL-6 activity is central to the role of the inflammatory cascade in 
motor neuron death, exposure to tocilizumab is unavoidable if we wish to test the effect of altering IL-6 receptor activity.
Lumbar puncture poses short-term risks to patients unrelated to study drug exposure. As with 
any procedure, there is a low risk of bleedi ng or infection. Pain and post-lumbar puncture 
headache (PLPH) are more common risks that may impact quality of life. Pain is localized, short 
lived and responds to over-the-counter analgesics . PLPH occurs in 10-30% of cases depending 
on technique and patient population and may lead  to hospitalization or the need for an 
autologous blood patch procedure [16]. This risk ca n be greatly reduced by the use of atraumatic 
needles. In a retrospective study of ALS patient  receiving LPs for CSF biomarker studies, the use 
of atraumatic needles reduced the risk of PLPH by 50% compared to traditional cutting needles 
[17]. No patient in the atraumatic needle gr oup required a blood patch procedure. A fundamental 
tenet of the proposed therapy is that the mo noclonal antibody tocilizumab should cross the 
blood-brain barrier. There is no systematic data available to establish that the CSF contains 
sufficient concentrations of tocilizumab to be effective. A full characterization of the 
pharmacokinetics of tocilizumab would require serial sampling of blood and CSF over several 
weeks with a lumbar catheter. Instead, we propose to sample CSF from patients in this study
prior to treatment and 2.5 hours after their third infusion to estima te maximal CSF concentration
and change in cytokine levels and IL-6 receptor  levels in the CSF. Given the critical importance 
of these data, LP is unavoidable.
To minimize the risk to patients, the protocol includes criteria and algorithms for interrupting or 
stopping therapy in patients with serious infe ctions, low absolute neutrophil count (ANC), 
elevated liver enzymes, and thrombocytopenia.  It will also include criteria to exclude patients at 
risk for opportunistic infections. To minimize risk  of hypersensitivity, the protocol will utilize 
pre-treatment anti-histamines as described in the site SOP, and require all infusions to occur in a hospital or clinic-based infusion center with experienced infusion staff and the ability to rapidly treat anaphylaxis.  We will exclude patients who concomitantly recei ve CYP450 metabolized 
drugs whose reduced exposure may pose a short-te rm risk. Finally, the proposed study will 
utilize atraumatic needles, standard LP procedures and exclude anticoagulated patients to minimize the risks of LPs.  
No socioeconomic or psychological ri sks are associated with the study. 
Risk of Magnetic  Resonance Imaging: People who have electrically, magnetically or 
mechanically activated implants (such as hear t pacemakers) or those who have clips on blood 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 24 of 90vessels in their brain will not be allowed to participate in the study due to associated risks with 
MRI scanning. The MRI systems will be operate d in a manner accepted by the Food and Drug 
Administration (FDA). The scanner makes loud knoc king or beeping sounds as it takes images. 
Subjects will be given earplugs to help reduce this noise. If a subject notices any discomfort while in the MRI scanner, (s) he should notify th e administrator immediately. If the discomfort 
cannot be stopped, the scanni ng session may be stopped. 
All credit cards and other items w ith magnetic strips should also be kept out of the MRI room.
The MRI has the potential, during normal routine us e, to cause localized warming of the skin and 
the underlying tissues. Subjects should immediately in form the study staff if they experience 
discomfort due to warming of the sk in and the procedure will be stopped.
The MRI can be stopped at any time at the subject โs request. Subjects with  severe claustrophobia
are excluded from the study.
Imaging will be stopped should any untoward reac tion be observed during the imaging session or 
if the subject so requests for wh atever reason. Some subjects fi nd it unpleasant or feel anxious 
when confined in the enclosed space of the scanner. If this happens, the subject will be unable to participate in the study.
Risk of Positron Emission Tomography Imaging: For the PET scan, no side effects from the 
radioligand [11C]PBR28. Subjects will be exposed to a small amount of radiation that will be 
significantly less than the yearly amount of radiation allowed for persons who work with 
radiation. The total amount of ra diation exposure subjects will rece ive from participation in this 
study is equal to a whole body exposure of approximately ~3.7 milliSieverts (mSv). This amount of radiation is about the sa me as one would normally recei ve in 15 months from natural 
background sources from the earth and the sky.  
The radiation exposure in this study will be small and there is no evidence that it represents a 
major health risk.  If subjects have participated in other research studies in the past 12 months 
that have involved radiation expos ure, they will be asked to info rm the investigators or study 
staff (by writing initials on the consent form verifying that they have not been exposed to other radiation in the past 12 months).  If it is dete rmined that their prior radiation exposure exceeds 
the current institutional guidelines, they will not be allowed to participate in this study.  
Subjects will be required to lie still in the PET camera several times during an approximately 1 
hour 45 minute period, and subjects may find it unco mfortable to remain still over this time. In 
order to insure that subjects do not move thei r heads during the imaging procedure cushions 
could be placed around the head. Subjects will be re quired to lie still on the imaging table with 
their heads in the scanner. This is usually well tolerated by most subjects.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 25 of 90We will use [11C]PBR28 produced by the cyclotron/radiochemistry/radiopharmacy facility at the 
A.A. Martinos Center for Biomedical Imaging. We  will follow the safety standards approved by 
the Radiation Safety Com mittee for the use of radioligands. The IV injection will be 
administered either by a physician or by a trained tec hnician. Should there be an adverse event 
related to a study procedure, the principal investigator, co-investigator or study staff will be 
responsible for communicating with the IRB within the stipul ated timeframe. At the time of 
continuing review a cumulative log of adverse events will be submitted, regardless of 
relatedness.
The PET scan can be stopped at any time at the subjectโs request. Subjects with severe 
claustrophobia are excluded from the study.
Imaging will be stopped should any untoward reac tion be observed during the imaging session or 
if the subject so requests for whatever reason. So me subjects find it unpleasant or feel anxious 
when confined in the enclosed space of the scanner. If this happens, the subject will be unable to participate in the study.
2.4.2 Known Potential Benefits
There are no specific anticipated potential benefits to subjects for participating in this study, although subjects may benefit from the close follo w-up and detailed medical care associated with 
study participation. It is not known whether tr eatment with tocilizumab  will be helpful or 
harmful for ALS subjects. It is possible that results from the study may yield benefits to future ALS patients.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 26 of 903 OBJECTIVES
3.1 Study Objectives
The study objective is to demonstrate that tocilizumab is safe and well tolerated in patients with 
sporadic ALS and determine its effect on immune markers and clinical progression in patients 
with sporadic ALS. Successful completion of  this study will support further clinical 
investigation to test the efficacy of tocilizumab in patients with sporadic ALS and define patient enrichment criteria and biomarkers that c ould be used in subsequent clinical studies.
3.1.1 Primary ObjectiveThe primary objective of the study is to assess the short-term safety and tolerability of 
tocilizumab in patients with sporadic ALS.
3.1.1 Secondary Objectives
The secondary objectives of this study are: 
xTo describe the inflammatory gene expr ession profiles in PBMCs of sporadic ALS 
patients and to assess the ability of tocilizumab to reduce expression of pro-inflammatory genes in PBMCs of patients with sporadic AL S and a high inflammation state at baseline.
xTo assess whether tocilizumab achieves a concentration in the CSF sufficient to block IL-
6 signaling. 
xTo gather preliminary data on the concentrati on of key inflammatory cytokines (IL-6, IL-
8, IL-17, IL- ศ71) -ฤฎV,/ -6 receptor, or hs-CRP) in the plasma and CSF before and 
after treatment with tocilizumab vs. placebo.
xTo identify polymorphisms that might affect the inflammatory state mediated by the IL-6
receptor.
xMeasure the effects of tocilizumab on reducing glial activation measured by PBR28 PET 
in a subset of trial participants. 
3.2 Study Outcome Measures
3.2.1 Primary Outcome Measures
We will assess safety of tocilizumab treatment based on mortality, occurrence of SAEs, overall rates of AEs, clinically significant abnormal laboratory tests, and changes in vital signs. We will 
focus on events at least possibly related to st udy drug of moderate or severe intensity by 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 27 of 90comparing participants receiving at least one dos e of tocilizumab to those on placebo for time to 
mortality and time to first SAE by  Cox regression, for overall rate  of AEs or abnormal laboratory 
tests by negative binomial regression, and for rates of  change in vital signs.
Tolerance of tocilizumab treatment  will be judged on the proportion of participants remaining on 
study drug through all 3 doses and remaining on  study and free from possibly drug-related and 
dose-limiting SAEs to the end of follow-up.
3.2.2 Secondary Outcome Measures
Secondary outcome measures will be descriptive and include meas ures of efficacy as well as 
measures of biochemical change. Efficacy outcome measures include change in the rate of 
change of ALSFRS-R, HHD, and SVC. Biochemical  measures will include change in cytokine 
levels in the serum and CSF, change in PBMC pro-inflammatory gene expression, and change in 
CSF sIL-6 receptor concentrations. We will estimate the proportion of participants who 
experience a 2-fold or greater decline between baseline and the average of all follow-up 
assessments in at least 2 of the 3 pro-inflammatory genes. These measures will serve several purposes. First, they will be used to establis h a correlation between the biochemical responses 
and drug exposure. Second, they will be used to identify the proportion of ALS patients who 
display a pro-inflammatory PBMC gene expression profile. This information will be useful when 
designing future trials, especially if an enrichment design is used. Finally, the measures will serve to demonstrate target engagement of the sIL-6 receptor. Mean PBR28 uptake will be 
measured in the motor cortices as regions of interest (ROIs), and will be compared between pre-
and post-dose.
3.2.3 Safety Measures
The following laboratory tests will be performed for safety:
xHematology with differential panel: complete blood count with differential (hematocrit, 
hemoglobin, platelet count, RBC indices, tota l RBC, total WBC, and WBC differential) 
xBlood chemistry panel/Liver f unction tests (LFTs): alanine aminotransferase (ALT 
(SGPT)), aspartate aminotransferase (AST (SGOT)),  albumin, alkaline phosphatase, 
bicarbonate, blood urea nitrogen, calcium, chlo ride, creatinine, glucose, magnesium, 
phosphate, potassium, sodium, total bilir ubin, total protein and, carbon dioxide.
xUrinalysis: albumin, bilirubin, blood, clarity, colo r, glucose, ketones, nitrate, pH, protein, 
specific gravity, urobilinogen and WBC screen 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 28 of 90xHepatitis B panel (collected only at Screening Visit)
xSerum human chorionic gonadotrophin (hCG ) for women of childbearing potential 
(WOCBP) (collected only at Screening Visit). Urine pregnancy tests will be performed 
on all WOCBP at each subsequent visit throughout the study.
All subjects will have safety laboratory tests at the designated visits outlined in the protocol. 
These samples will be analyzed at a central laboratory.  The SI may order additional testing, if 
needed, to further assess an AE, or if there is  any suspicion that a subject may be pregnant, 
throughout the course of the study.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 29 of 904 STUDY DESIGN
4.1 Overall Study Design and Plan
During the enrollment period, approximately 50 subjects will be screened from approximately 4
Northeast ALS Consortium (NEALS) Centers in the US.  Twenty-four of these subjects (or 
more, if some randomized partic ipants never initiated treatment) will be randomly assigned in a 
2:1 ratio to intravenous tocilizumab 8 mg/kg vs. matching placebo every 4 weeks for 8 weeks (3 
doses).  After screening and randomization, subj ects will undergo baseline measures, undergo LP 
and receive their first dose of study drug in clin ic. Clinic visits will occur at 4 week intervals 
with total study duration of 16 weeks. A second LP will occur at the 8 week visit.
All visit windows are consecutive calendar days a nd are calculated from the day the participant 
starts study treatment (Day 0, th e day of the Baseline Visit).
4.2 Study Centers
This study will be conducted at approximately 5 NEALS Centers in the US.  Sites will be 
selected based on recruitment record from prior trials, compliance with prior study protocols and 
regulations, clinical research expertise and availability of necessary resources.
4.3 Study Duration
Subjects will remain on randomized, placebo-cont rolled, double-blind treatment until the Week 8
visit.  Each randomized subject will also ha ve a Week 12 Follow-up visit and Week 16 End-of-
Study visit to assess for AEs, changes in concomitant medications and to administer selected study procedures.
4.4 Protocol Adherence
Each (SI) must adhere to the prot ocol detailed in this document and agree that any changes to the 
protocol must be approved by the Coordination Center (CC) or  their representative prior to 
seeking approval from the site IRB.  Each SI wi ll be responsible for enrolling only those study 
subjects who have met protocol eligibility criteria.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 30 of 905 STUDY ENROLLMENT AND WITHDRAWAL
5.1 Number of Study Subjects
Twenty-four (24) subjects will be randomized in a 2:1 ratio to intravenous tocilizumab or 
matching placebo. Additional subjects may be ra ndomized if any randomized subjects withdraw 
from the study prior to initiating study drug.
5.2 Inclusion and Exclusion Criteria5.2.1 Inclusion Criteria
Study subjects meeting all of the following criteria will be allowed to enroll in the study: 
1. Participants with ALS diagnosed as possibl e, laboratory-supported probable, probable or 
definite according to the World Federa tion of Neurology El Escorial criteria.
2. Male or female, aged 18-75.3. Capable of providing informed consen t and complying with trial procedures.
4. High inflammatory profile of PBMC gene  expression defined as having one of the 
following:
i. A three-fold up-regulation (compared to pooled control levels) of IL-6
expression
OR
ii. A two-fold up-regulation  (compared to pooled controls) of IL-6 and either IL-8
or MMP1 expression.
5. UpULJKW69&ย 40% of predicted value for gender, heig ht and age at the Screening Visit
and in the opinion of the investigator is able to comply with and complete the trial.
6. Women must not be able to become pregnant  (e.g., post menopausal, surgically sterile, or 
using adequate birth control methods) for the duration of the study.
7. Negative tuberculosis (TB) skin test, Quantiferon or T-SPOT TB blood test at the 
Screening Visit.
8. Not taking riluzole, or on a stable dosage for at least thirty (30) days prior to the 
Screening Visit.Riluzole. Subjects taking concomitant riluzole at study entry must be on a stable dose for 
at least 30 days prior to the Screening Visit and must continue taking the same dosage throughout the study, unless the SI determines that riluzole should be discontinued for 
medical reasons.    
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 31 of 909. Subjects medically able to undergo lumbar  puncture (LP) as determined by the 
investigator (i.e., no bleeding disorder, allergy to local anesthetics, a skin infection at or 
near the LP site, or evidence of high intracranial pressure ).
10. Subjects must agree not to take live atte nuated vaccines (includi ng seasonal nasal flu 
vaccine, varicella vaccine for shingles or chickenpox, MMR or MMRV, oral polio 
vaccine and vaccines for yellow fever, measles, mumps or rubella) thirty (30) days before the Screening Visit, throughout the duration of  the trial and for sixty (60) days following 
the subjectโs last dose of study drug.
11. Geographic accessibility to the study site.
MR-PET Inclusion Criteria (MGH only):
12. High or mixed affinity to bind TSPO prot ein (Ala/Ala or Ala/Thr) (see section 7.1)
13. Upper Motor Neuron Burden (UMNB) Scale 6FRUHยRXWRIDWWKH6FUHHQLQJ
Visit.
14. Able to safely undergo PET/MRI scans base d on the opinion of the site investigator. 
5.2.2 Subject Exclusion Criteria
Study subjects meeting any of the following criteria during screening evaluations will be 
excluded from entry into the study:
1. Prior use of:
xTocilizumab (Actemraยฎ)
xCell-depleting therapies, including inves tigational agents or approved therapies 
(some examples are CAMPATH, anti-CD4, anti-CD5, antiยฌCD3, anti-CD19 and 
anti-CD20)
xAlkylating agents such as chlorambucil
xTotal lymphoid irradiation
xStem cell therapies (either investigational or approved therapies)
2. Presence of tracheostomy at Screening Visit.
3. Exposure to any anti-inflammatory agent currently under investigation for the treatment of 
patients with ALS (off-label use or investigational) within 30 days prior to the Screening Visit. Examples include NP001 or Lunasi n. Medications that do not have an anti-
inflammatory mechanism such as mexilitine or retigabine are allowed if on a stable dose for 30 days prior to the Screening Visit.
4. Treatment with a prohibi ted medication within 30 days of the ScreeningVisit:
xNuedexta
xTheophylline
xWarfarin
xCyclosporine
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 32 of 905. Treatment with intravenous gamma globulin, pl asmapheresis or Prosor ba column within 6 
months of screening.
6. Presence of diaphragm pacing system (DPS) at Screening Visit. 
7. Primary or secondary immunodeficiency (history  of or currently activ e) unless related to 
primary disease under investigation.
8. History of or active diverticulitis, diverticulosis requiring antibiotic treatment, peptic ulcer 
disease, or GI tract perforation, or chronic ulcerative lower GI disease such as Crohnโs 
disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations.
9. Known active current or history of recurrent ba cterial, viral, fungal, mycobacterial or other 
opportunistic infections (includi ng but not limited to tuberculosis  and atypical mycobacterial 
disease, Hepatitis B and C, EBV, CMV, and herpes zoster, but excluding fungal infections of 
nail beds).
10. History of severe allergic or anaphylac tic reactions to human, humanized or murine 
monoclonal antibodies.
11. Presence of any of the following clinical conditions:
xPharmacologic or hereditary bleeding diathesis, or any other clinical condition 
that would, in the opinion of the investigator, place the patient at increased risk 
during LP.
xDrug abuse or alcoholism within the past 12 months.
xUnstable cardiac, pulmonary, renal, hepa tic, endocrine, hematologic, or active 
infectious disease, including current or prior malignancy.
xRheumatic autoimmune disease, including Systemic lupus erythematsus, Mixed 
connective tissue disease, scleroderma, polymyositis, or significant systemic 
involvement secondary to RA (e.g., vasculitis, pulmona ry fibrosis or Feltyโs 
syndrome).
xEvidence of active malignant disease, malignancies diagnosed within the previous 
5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured, or Stage I uterine cancer), or breast cancer diagnosed within the previous 5 years.
xHuman immunodeficiency virus (HIV) inf ection or other immunodeficient state.
xUncontrolled hypertension de fined as systolic blood pre ssure > 170 or diastolic blood 
pressure > 110.
xUnstable psychiatric illness defined as psychosis or untreated major depression 
within 90 days of the Screening Visit.
12. Any major episode of infection requiring hospitalization or treatment with IV antibiotics 
within 4 weeks of screening 
13. Laboratory values: Screening alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), or total bilirubin > than 1.5 times th e upper limit of normal, serum creatinine > 1.6 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 33 of 90mg/dL (141 ฮผmol/L) in female patie nts and > 1.9 mg/dL (168 ฮผmol/L) in male patients 
(patients with serum creatinine values exceeding limits may be eligible for the study if their 
estimated glomerular filtration rates (GFR) are >30), hemoglobin < 85 g/L (8.5 g/dL; 5.3 
mmol/L), white Blood Cells < 3.0 x 109/L (3000/mm3), absolute neutrophil count of 
<2000/mm3, absolute lymphocyte count < 0.5 x 109/L (500/mm3), platelet concentration of 
<100,000/mm3, positive Hepatitis B surface antigen (HBsAg).
14. Pregnant women or women currently breastfeeding.
15. No history of chicken pox infection by se lf report and no history of varicella zoster 
vaccination
16. Any reason in the opinion of the investigator th at the patient may not be able to comply with 
study procedures, complete the study or is unsuitable for immunosuppressive therapy.
MR-PET Exclusion Criteria (MGH only):
17. Any contraindication to undergo MRI studies such as 
xHistory of a cardiac pacemaker or pacemaker wires
xMetallic particles in the body
xVascular clips in the head
xProsthetic heart valves
xClaustrophobia
18. Radiation exposure that exceeds the siteโs current guidelines 19. Current use of tobacco products including ciga rettes, e-cigarettes, cigars, snuff and chewing 
tobacco, or nicotine replacement products such as gum, or patch
20. Taking any other anti-inflammatory or imm une modulating medications except for over the 
counter NSAIDs
21.Unwilling or unable to discontinue benzodiazepine usage (other than Lorazepam, 
Clonazepam, or Zolpidem) for one day prior to scanning
5.2.3 Immunization during TCZ therapy
Live/attenuated vaccines should not be given w ithin 4 weeks prior to baseline and during the 
study as clinical safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving Tocilizumab. 
No data are available on the effectiveness of  vaccination in patients receiving Tocilizumab. 
Because IL-6 inhibition may interfere with the normal immune response to new antigens, patients should be brought up to date on all r ecommended vaccinations, except for live vaccines, 
prior to initiation of therapy with Tocilizumab.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 34 of 905.3. Treatment Assign ment Procedures
5.3.1 Randomization Procedures
Each subject who meets all eligibility criteria and signs an informed consent form will be 
randomized to receive either 8 mg/kg of tocilizum ab every 4 weeks or matching placebo for 8
weeks.
The randomization scheme will be developed by the study statistician and will indicate the group
assignment and the subject numbers to be used by each site. Subjects will be randomized in a 2:1 
ratio to intravenous tocilizumab 8 mg/kg or ma tching placebo using permuted random blocks 
stratified by site. If a randomized subject withdraws from the study prior to initiating study 
drug, their assignment will be released and re-used.
5.3.2 Reasons for Withdrawal
A study subject will be discontinued from participation in the study if:
xAny clinical AE (AE), laboratory abnorma lity, concurrent illness, or other 
medical condition or situation occurs such that continued participation in the study would not be in the best interest of the subject. Note, however, that any 
subject who has initiated treatment should only discontinue study drug and remain 
on study if the safety concern relates to study drug and not to study procedures.
Subjects are free to withdraw from participa tion in the study at any time upon request.
5.3.3 Handling of Withdrawals
A subject may choose to discontinue  participation in the study at  any time.  However, the SI or 
designee will encourage subjects to continue with follow-up visits, regardless of their 
compliance with study drug.  If the SI or desi gnee is concerned about the use of a prohibited 
medication or other safety issues, then study drug  may be modified or discontinued.  If a subject 
who initiated study drug permanently discontinue s study drug, the SI or designee should still 
encourage subjects to follow the study protocol u nder the modified intent to treat principle (ITT). 
These subjects will be encouraged to follow the study visits, off drug, up to the Week 16 EOS 
Visit. Loss to follow-up should be prevented whenever possible.
Any subject who is on study drug and needs to begin the use of any prohibited medication, must 
immediately discontinue use of study drug and should not begin use of the prohibited medication
before an appropriate wash-out period occurs.  Subjects who permanently discontinue study drug 
should complete early study drug discontinuatio n procedures without any study drug unblinding, 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 35 of 90if possible.  Subjects who must permanently di scontinue study drug may continue in the ITT 
portion of the study, per protocol.
Early termination occurs when a subject withdraws consent, i.e., withdrawing his or her 
participation in future study procedures. The subject will be asked to return to the study site for a final safety visit. At that visit, the subject will be asked to have a final telephone call 28 days (+ 5 
days) after taking their last dose of study dr ug. Subjects who withdraw from the study due to 
AEs will be followed for outcome measures under the ITT protocol as noted above.  
5.3.4 Termination of Study 
This study may be prematurely terminated if, in  the opinion of the principle investigator, DSMB,
or the sponsor, there is sufficient reasonable caus e.  Written notification, documenting the reason 
for study termination, will be provided to the PI by the terminating party.
Circumstances that may warrant termination include, but are not limited to:
1. Determination of unexpec ted, significant, or unacceptable risk to subjects.
2. Enrollment is unsatisfactory.
3. Insufficient adherence to  protocol requirements.
4. Data that are not sufficientl y complete and/or evaluable. 
5. Plans to modify, suspend or disconti nue the development of the study drug.
If the study is prematurely terminated or su spended, the sponsor will promptly inform the 
investigators/institutions, and the regulatory authority(ies) of the termination or suspension and the reason(s) for the termination or suspension.  The IRB/IEC will also be informed promptly 
and provided the reason(s) for the terminatio n or suspension by the sponsor or by the 
PI/institution, as specified by the applicable regulatory requirement(s).
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 36 of 906 TREATMENTS ADMINISTERED
6.1 Treatments6.1.1 Study Product Description
Tocilizumab (Actemraยฎ) is a recombinant humanized anti-human interleukin 6 (IL-6) receptor
monoclonal antibody of the immunoglobulin ,J*ศJDPPDNDSSDVXEFODVVZLWKDW\SLFDO
H2L2 polypeptide structure. Each light chain and heavy chain consists of 214 and 448 amino 
acids, respectively. The four polypeptide chains are linked intra- and inter-molecularly by 
disulfide bonds. Tocilizumab has a molecula r weight of approximately 148 kDa.
It is supplied as a sterile, preservative-free solution for intravenous (IV) infusion at a 
concentration of 20 mg per mL. It is a colorless to pale yellow liquid, with a pH of about 6.5. 
Single-use vials are available containing 80 mg per 4 mL, 200 mg per 10 mL, or 400 mg per 20 mL of tocilizumab. Injectable solutions are formulated in an aqueous solution containing 
disodium phosphate dodecahydrate and sodium dihydrogen phosphate dehydrate (as a 15 mmol 
per L phosphate buffer), polysorbate 80 (0.5 mg  per mL), and sucrose (50 mg per mL).
Tocilizumab will be provided free of charge by Ge nentech. The Sponsor or designee of the study 
will ensure maintenance of complete and accurate records of the receipt, dispensation, and 
disposal or return of all study drug in accord ance with 21 Code of Fede ral Regulations (C.F.R.), 
Part 312.57 and 312.62 and Genentech requirements.
6.1.2 Placebo
A matched placebo will be used to maintain the dosage-blind.  The site pharmacy will prepare 
equivolume doses of normal saline as placebo. Administration of matching placebo will be the 
same as for subjects in the treatment group.
6.2 Acquisition
Upon receipt of the of the study treatment supplie s, an inventory must be performed and a drug 
receipt log filled out and signed by the person ac cepting the shipment.  It is important that the 
designated study staff counts and verifies that the shipment cont ains all the items noted in the 
shipment inventory.  Any damaged or unusable  study drug in a given shipment will be 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 37 of 90documented in the study files.  The SI must no tify study sponsor of any damaged or unusable 
study treatments that were supplied to the SIโs site.
6.2.1 Formulation, Packaging, and Labeling
The study drug is prepackaged in vials containing 80 mg, 200 mg or 400 mg that will be mixed 
with normal saline to a total volume of 100 mL by the site research pharmacist. The 
Investigational Pharmacist has the responsibility to ensure that the integrity of packaged study 
drug is not jeopardized prior to dispensing.  Ea ch individual subjectโs vial s must be dispensed as 
provided with no further repackag ing or labeling done at the inve stigational site, unless required 
by the institution per institutional polices.
6.2.2 Product Storage  and Stability
Tocilizumab must be refrigerated at 2ยฐC to 8ยฐC (36ยฐF to 46ยฐF). It should not be frozen and 
should be protected from light by storage in th e original package until time of use. Vials should 
be inspected visually for particulate matter and discoloration prior to ad ministration. If visibly 
opaque particles, discolor ation or other foreign particles ar e observed, the solution should not be 
used.
The SI must ensure that all investigational drug supplies are kept in a locked, safe area at 
controlled temperature (2ยฐC to 8ยฐC) with access limite d to those directly involved in the study. 
Investigational drug supplies should not be repackaged in any way. 
6.3 Dosage, Preparation and Administration  of Study Intervention/Investigational 
Product
Tocilizumab concentrate for intravenous infusion should be diluted to 100 mL by the research 
pharmacist using aseptic technique as follows:
xWithdraw the required amount of tociliz umab for a dose of 8 mg/kg (Equivalent
to 0.4 mL/kg).
xWithdraw the same amount of sterile, non-pyrogenic 0.9% w/v sodium chloride 
solution from the infusion bag and discard.
xSlowly add the withdrawn tocilizumab concentrate into the infusion bag. The final
volume in the infusion bag should total 100 mL.
xTo mix the solution, gently invert the bag to avoid foaming.
xAllow the fully diluted tocilizumab solution to reach room temperature prior to 
infusion.
xThe infusion should be administered over 60 minutes, and must be administered 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 38 of 90with an infusion set. Do not administer as an intravenous push or bolus.
Subjects should be weighed prior to each infusi on, and dosage should be adjusted accordingly. 
One vial containing 400 mg tocilizumab or two vials containing 200 mg tocilizumab will be 
required for each 50 kg body weight to achieve an 8 mg/kg dose. The number of vials to be used 
depends on the patientโs body weight as follows:
1. One 400-mg vial (or two 200- PJYLDOVLVXVHGIRUSDWLHQWVZLWKDERG\ZHLJKWย
kg.
2. Two 400-mg vials (or four 200-mg vials) are used for patients with a body weight 
>50 kg combination of the 400-mg and 200-mg  vials may be used but the total dose 
should not exceed 800 mg
For individuals whose body weight is more th an 100 kg, doses exceeding 800 mg per infusion 
are not recommended .
Tocilizumab solutions do not contain preservativ es; therefore, unused product remaining in the 
vials should not be used.
Parenteral drug products should be inspected visu ally for particulate ma tter and discoloration 
prior to administration by the site research pharmacist, whenever solution and container permit. Tocilizumab is a colorless to pale, yellow liquid. If particulates or discolorations are noted, the 
product should not be used.
Fully diluted solutions are compatible with polypropylene, polyethylene and polyvinyl chloride 
infusion bags and polypropylene, polyethylene and glass infusion bottles. Tocilizumab should not be infused concomitantly in the same intravenous line with other drugs. No physical or 
biochemical compatibility studies  have been conducted to evalua te the co-administration of 
tocilizumab with other drugs.
6.3.1 Tocilizumab Storage
Tocilizumab should not be used after the expiry date (EXP) shown on the pack.
For vials: Store between 2ยบC โ 8ยบC, do not freez e. Keep the container in the outer carton
in order to protect from light.
For prepared infusion solution: Tocilizuma b does not contain preservatives, therefore
reconstitution and dilution of the product shoul d be performed under aseptic conditions. The
prepared infusion solution of tocilizumab is ph ysically and chemically stable in 0.9% w/v
sodium chloride solution at 30ยบC for 24 hours.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 39 of 90From a microbiological point of view, the prepar ed infusion should be used immediately. If not 
used immediately, in-use storage times and conditi ons prior to use are the responsibility of the 
user and would not be longer than 24 hours at  2ยบC โ 8ยบC, unless dilution has taken place in 
controlled and validated  aseptic conditions.
6.3.2 Tocilizumab Overdosage
There are limited data available on overdoses with Tocilizumab. One case of accidental overdose 
was reported in which a patient with multiple myeloma received a dose of 40 mg/kg. No adverse drug reactions were observed. No serious adve rse drug reactions were observed in healthy 
volunteers who received single doses of up to 28 mg/kg, although all 5 patients at the highest 
dose of 28 mg/kg developed dose-limiting neutropenia.In case of an overdose, it is recommended that the patient be monitored for signs and symptoms 
of adverse reactions. Patients who develop adverse reactions  should receive appropriate 
symptomatic treatment.
6.4 Modification of Study Intervention/Investigational Product for a Subject
Any dosage adjustment, including the reason for and dates of adjustment, will be documented in 
the CRF for each subject requiring this manipula tion. In consultation with the Medical Monitor, 
the SI or licensed physician Sub-Investigator may reduce the dosage of study drug or discontinue 
the study drug in its entirety for AEs (AEs) thought to be related to the study drug or for other reason during the trial (the reason for, and dates of suspension or dose reduction must be 
documented). 
Opportunistic Infections and Serious Infections 
Tociluzimab should not be adminis tered in patients with active infection. The effects of TCZ on 
CRP, neutrophils, and the signs and symptoms of infection should be considered when 
evaluating a patient for a potential infection. 
Vigilance for timely detection of serious infection is recommended for patients receiving 
biologic agents for treatment of moderate to severe RA as signs and symptoms of acute 
inflammation may be lessened due to suppression  of the acute phase reaction. Patients must be 
instructed to contact their physician immediately when any symptoms suggesting infection 
appear, in order to assure rapid evaluation and appr opriate treatment. 
If a patient develops a serious infection, adminis tration of TCZ is to be interrupted until the 
infection is controlled. The clinic ian should consider the benefit- risk before resuming treatment 
with tocilizumab.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 40 of 90Gastrointestinal Perforations  
Timely diagnosis and appropria te treatment may reduce the potential for complications of 
diverticulitis and thus reduce the risk of GI perforations. Therefore, patients should be made 
aware of the symptomatology potentially indicative of diverticular disease, and they should be 
instructed to alert their health care provider as soon as possibl e if these symptoms arise.  
Discontinuation of TCZ is recommended fo r patients who develop GI perforations.
Demyelinating Disorders 
The impact of treatment with TCZ on demyelinating disorders is not known; events were rarely 
reported.  Patients should be closely monitored for signs and symptoms potentially indicative of 
central demyelinating disorders.  Physicians should exercise caution in considering the use of TCZ in patients with pre-existing or recent onset demyelinating disorders. Treatment with 
tocilizumab should be interrupted during assessm ent of a potential demyelination event and only 
resumed if the benefit of conti nuing study drug is favorable.  
Hematologic Abnormalities and Bleeding Events
Decreases in neutrophil and platel et counts have been observed following treatment with TCZ in 
combination with MTX. In addition, there may be an increased risk of neutropenia in patients 
who have previously been treated with a TNF antagonist.
The risk mitigation strategies for neutropenia and thrombocytopenia are summarized below. For 
patients with concomitant medications associated with hematologic toxicity, the reduction or interruption of the suspected medication is recommended prior to modifying TCZ.
Low Absolute Neutrophil Count (ANC)
 (cells per mm3) Recommendation
ANC greater 
than 1000 Maintain dose 
ANC 500 to 1000 Interrupt study dru g dosing and check Complete Blood Count (CBC) weekly.  
When ANC greater than 1000 cells per mm3 resume tocilizumab at 4 mg per 
k g  a n d  i n c r e a s e  t o  8  m g  p e r  k g  t h e  n e x t  i n f u s i o n  i f  A N C  r e m a i n s  g r e a t e r  
than 1000. 
ANC less than 
500 Discontinue study drug
Patients withdrawn from tocilizumab treatment due to a reduced neutrophil count should be 
monitored for signs of infection, with treatm ent as deemed appropriate by the sponsor or 
designee, and should have a repeat white blood ce ll count with differen tial performed weekly 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 41 of 90until the ANC is above 1000 cells/mm3(1.0 x 109/L). If the ANC does not return to above 1000 
cells/mm3(1.0 x 109/L) within 2 months (or sooner if deemed necessary by the sponsor or 
designee), a hematology referral is recommended.
Low Platelet Count
Lab Value 
 (cells per mm3) Recommendation
Greater than 
100,000 Maintain dose 
50,000 to 
100,000Interrupt tocilizumabdosing and check CBC weekly. When platelet  count is 
greater than 100,000 cells per mm3 resume study drug at 4 mg per kg and 
increase to 8 mg per kg if plate lets remain greater than 100,00 0 
Less than 50,000 Discontinue tocilizumab
Patients withdrawn from tocilizumab treatment due  to a reduced platelet count should have a 
repeat platelet count performed w eekly until the count is above 100,000 cells/mm3(100 x 109/L). 
If the platelets do not return to above 100,000 cells/mm3(100 x 109/L) within 2 months (or 
sooner if deemed necessary by the sponsor or designee), a hematology referral is recommended.
Elevated Liver Enzymes and Hepatic Events
Elevations in ALT and AST have been obs erved during treatment with the study
medications
Liver Enzyme Abnormalities   
Lab Value  Recommendation  
Greater than 1 to 3x 
Upper limit of normal 
(ULN)  Dose modify concomitant disease modifying anti-rheumatic drugs 
(DMARD)if appropriate
For persistent increases in this range, reduce tocilizumab
dose to 4 mg/kg or interrupt tocilizumab until ALT/AST
have normalized. Check Complete Metabolic  Panel (CMP) every 2 
weeks until ALT/AST normal.
Restart with 4 mg/kg or 8 mg/kg, once ALT/AST normal and after 
discussion with medical monitor.  
Greater than 3 to 5x ULN 
(confirmed by repeat 
testing)  Check CMP every 2 weeks until no rmal. If still g reater than 3x ULN 
after 4 weeks, discontinue study dru g 
Greater than 5x ULN  Discontinue study drug 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 42 of 90Patients withdrawn from tocilizumab treatment due  to elevated liver function tests should have 
repeat tests performed, as  clinically appropriate, un til levels return to baseline.  If the patientโs 
liver function tests have not returned to baseline within 6 months (or sooner, if deemed necessary 
by the sponsor or designee), an ultrasound and/or liver biopsy should be considered.
Cardiovascular Events and Elevated Lipids
Patients with RA have an increased risk for cardiovascular disorders, therefore, risk factors for 
cardiovascular disease (eg, hypertension, hyperlip idemia) should be manage d as part of their 
standard of care.  See section on Drug Interactions.  
)RUSDWLHQWVZLWK/'/FKROHVWHUROยPJG/LWLVVWURQJO\UH FRPPHQGHGWKDWLQYHVWLJDWRUV
advise therapeutic lifestyle changes that may include initiation lipid-lowering agents. Lipid-
lowering agents should also be considered for pati ents with lower LDL cholesterol levels as part 
of their therapeutic lifestyle changes depending on their overall risk as defined in NCEP ATP III 
or other national guidelines.
Malignancies
The impact of immunosuppression on the developm ent of malignancies is not known, however 
an increased rate of some malig nancies, notably lymphoma, has been observed in RA patients. 
Although no imbalance of malignancies was observ ed in controlled clinical trials of TCZ, 
malignancies have been identified as a concern for other biologics.  It is recognized that 
identification of such events in TCZ-treated patients may require a longer period of surveillance.  
TCZ should be discontinued in patie nts with malignancies (with th e exception of local basal or 
squamous cell carcinoma of the skin that is completely excised with free margins).
Hypersensitivity or Anaphylaxis
An infusion/dose reaction is defined as an a dverse event occurring during and within 24 hours 
after the infusion or subcutaneous injection of tocilizumab. This may include hypersensitivity 
reactions or anaphylactic reactions. 
Signs of a possible hypersensitivity reaction include but are not limited to: 
xfever, chills, pruritus, urticaria, angioedema, and skin rash.
xcardiopulmonary reactions, including chest pa in, dyspnea, hypotension or hypertension.
Healthcare professionals adminis tering TCZ infusions  should be trained in the appropriate 
administrative procedures, be able to recognize the symptoms associated with potential 
anaphylactic or hypersensitivity reactions, and have the appropriate medication available for immediate use in case of anaphylaxis or hypersensitivity reaction during or after administration 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 43 of 90of TCZ.  Healthcare professionals should also inst ruct patients to seek medical attention if they 
experience symptoms of a hypersensitivity reaction outside of the clinic.
If a patient has symptoms of anaphylaxis or serious hypersensitivity, or requires an interruption 
of the study drug because of symptoms of anaphylaxis or hypersensitivity, administration of TCZ must be discontinued permanentl y and the patient should be withdrawn from the study.  The 
patient should be treated according to the standard of care for management of the 
hypersensitivity reaction.  A blood sample for the presence of anti-tocilizumab antibodies should 
be obtained at time of event and at least 6 weeks after the last dose*.
*6 weeks for the RA indication. For other i ndications consultation with the clinical 
pharmacology group will be required to assess how many weeks after the last dose testing should 
be conducted. 
Viral Reactivation
Though rarely reported within the TCZ program  due to exclusion criteria at study entry,
reactivation of viral and other serious infections (e.g. EBV or TB) has been observed with
biologic therapies for RA, including TCZ.
Drug Interaction
The formation of CYP450 enzymes may be suppressed  by increased levels of cytokines (eg, IL-
6) during chronic inflammation. Therefore, it is expected that for molecules that antagonize 
cytokine activity, such as TCZ, the formati on of CYP450 enzymes coul d be normalized. Given 
its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may 
persist for several weeks after stopping therapy.
6.4.1. Dosage Discontinuation
Subjects who meet the following criteri a should discontinue study medication:
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 44 of 906.4.1.1. Tocilizumab-Specific Criteria
xAnaphylaxis or hypersensitivity reaction or requires an interruption of the study drug 
because of symptoms of anaphylaxis or hypersensitivity (tocilizumab should be 
permanently discontinued from these patients)
xALT or AST value > 5X ULN or persistent elevation > 3X ULN
xPlatelet count (cells/mm3) < 50,000
xANC (cells/mm3) < 500
6.4.1.2. General Criteria
xAE
xSponsor termination
xProtocol deviation/Lost to follow-up
xPatient request
xDeath
xInability of subject to comply with study requirements
xDetermination by the Medical Monitor or Site Investigator that it is no longer safe for 
the subject to continue therapy
All serious AEs (SAEs) that occur in a subject who has discontinued early must be recorded and 
reported to the CC within 24-hours of awareness.  
Study subjects who discontinue study drug pr ematurely (early termination from study) and 
decide to not remain in the ITT portion of the study will be encouraged to return for a Final 
Safety Visit and participate in a Follow-Up Telephone Call 28 days (+ 5 days) after the last dose 
of study drug. 
All subjects who discontinue study drug early an d choose to remain in the ITT portion of the 
study will be encouraged to follow the study visits, off drug, up through the last visit (Week 16
EOS Visit).  
SAEs will be followed for resolution for 28 days (+5 days) after a subjectโs last dose of study 
drug, regardless if they prematurely discontinued study drug or complete d 4 weeks of treatment. 
6.5 Accountability Procedures for tocilizumab
At the completion of the study, there will be a final reconciliation of drug shipped, drug 
consumed, and drug remaining.  This reconciliation will be logged on the drug reconciliation form, signed and dated.  Any discrepancies noted will be investigated, resolved, and documented 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 45 of 90prior to return or destruction of unused study drug.  Drug destroyed on site will be documented 
in the study files.
6.6 Prior and Concomitant Therapy
Throughout the study, SIs may prescribe conc omitant medications or  treatments including 
edaravone (Radicavaยฎ), deemed necessary to provide adequate supportive care provided that the 
medications are licensed in the United Stat es. Study subjects should not receive other 
experimental agents during the study. This includes marketed agents at experimental dosages 
that are being tested for the treatment of ALS and experimental procedures such as stem cell therapies or diaphragm pacing devices. All concomitant medications and/or treatments and significant non-drug therapies including supplements  and assistive devices, received by a subject 
should be recorded on the appropriate sour ce document and eCRF at each study visit.
Any investigational pharmacotherapy being used  or evaluated for the treatment of ALS is 
prohibited beginning 30 days prior to the Screening Visit and throughout the study.  This 
includes, but is not limited to, the following:
xPioglitazone
xArimoclomol
xOlanzapine
xNuedexta
xNP001
xIbudilast
xFingolimod
xGSK 1223249
xRasagiline
xMemantine
xEzogabine
6.6.1 Prohibited Medications  and Contraindications
Prohibited Medications
Throughout the course of the trial, study subj ects should not be treated with the following 
medications.  If an investigator learns that a patient has begun therapy with any of these 
medications, this should be reported to the CC immediately and action should be taken to 
discontinue the prohibited medication.  If, for safety or health  reasons, or by subject choice, the 
prohibited medication cannot be  stopped, then the study medication should be stopped.
Prohibited medications include:
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 46 of 90xNuedexta
xTheophylline
xCyclosporine
xWarfarin
xLive vaccines
Pregnancy & Nursing Mothers
There are no adequate and well-controlled studies in pregnant women.  Subjects or partners of 
male subjects should not become pregnant durin g the study or within 6 months after stopping 
study drug. If a female subject becomes preg nant, study treatment must be discontinued 
immediately. 
It is not known whether tocilizumab is excreted in human milk or absorbed systemically after 
ingestion. Caution should be exercised; theref ore, no subject should nurse her infant while 
participating in this study.
MR-PET (MGH only): Additionally, subjects should withhol d taking benzodiazepines for 24 
hours prior to scanning. Lorazepam, Clonazepam,  and Zolpidem are allowed under the protocol 
within this timeframe.
6.7 Blinding of Study Drug
The Randomization ID will be used to identify the subject's electronic case report forms 
(eCRFs), laboratory tests, study me dication and all communications.  
Study Subjects, Site Investigators, Coordinators, Clinical Evaluators (and all other study site 
staff), Study Monitors, Project Management, Da ta Management personnel,  and the Sponsor will 
be blinded to treatme nt group assignment throughout the study. 
Only the Biostatistician who develops the randomization schedule, the Research Pharmacists at 
the Central Pharmacy and the Site Pharmacist (if applicable) storing and distributing the study drug at each site will be unblinded to the individual drug assignments in this study.
6.7.1. Emergency Unblinding
An emergency unblinding procedure will allow the Site Investigator (SI) the option of learning 
the treatment assignment for an individual subject if clinical circumstances require it.  For 
unblinding, the SI must contact the Medical Monito r (MM).  The SI should attempt to contact the 
MGH Coordination Center (CC) prior to completing emergency unblinding if time allows. If this 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 47 of 90is not possible, the site must inform the MGH CC as soon as possible regarding the emergency 
unblinding and the circumstances surrounding it.  The SI must document the reason for 
unblinding in the subjectโs source documents. 
Rarely should such an extreme action be take n.  Experimental medications can usually be 
withdrawn without the need for unblinding.  Sites should take care to unblind only those study 
staff member(s) and other persons whose knowledge of the treatment assignment is necessary for 
the clinical safety of the subject.  Sites should ta ke all reasonable measures to keep study staff 
(especially those completing any Final Safety Visit procedures), MGH CC staff and the subject 
blinded to treatment assi gnment if possible.  
In the event that emergency disclosure of treatment assignment is necessary, the study subject 
will be withdrawn from further participation in the trial.  All adverse events (AEs) resulting in 
emergency unblinding will be followed for resolution.  
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 48 of 907 STUDY SCHEDULE
No study procedures should be performed prior to the signing of the informed consent form
(ICF). All subjects will sign an ICF prior to unde rgoing any study tests or procedures. The slow 
vital capacity (SVC) should be performed first at the visits so as not to fatigue the subject with other testing, however the order of testing will be at the discretion of each SI.
Visit windows are consecutive calendar days and th e target visit dates are calculated from the 
Baseline Visit.  
7.1 Screening Visit
The following procedures will be performed at an office visit to determine the subjectโs 
eligibility for the study:
1. Obtain written informed consent from subject
2. Assess inclusion and exclusion criteria3. Obtain medical history and demographics4. Obtain ALS diagnosis history5. Measure vital signs including height and weight6. Perform neurological examination7. Perform physical examination8. Perform slow vital capacity (SVC)9. Perform 12-lead electrocardiogram (ECG)10. PA and Lateral Chest X-Ray11. Collect blood samples for baseline clinical la boratory assessments (CBC with differential 
and chemistry panel), Quantiferon or T-SPOT TB test (or TB skin test), Hepatitis B paneland serum pregnancy test (for woma n of childbearing potential [WOCBP])
12. Collect urine sample for urinalysis13. Collect blood samples for PBMC collection14. Review and document concomitant medications and therapies15. Assess and document AEs (AEs) after subj ect signs informed consent form (ICF)
16. Tentatively schedule the Baseline Visit  
Pregnancy Test: Serum pregnancy test will be done at the Screening Visit for women of child
bearing potential (WOCBP).  Thereafter, urine pregnancy testing will be performed on an as needed basis throughout the study.
MR-PET (MGH only):
17. Blood Draw for TSPO Binding Affinity Test (**If not previously determined)
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 49 of 9018. Upper Motor Neuron Burden Scale.
19. MRI Safety Questionnaire
Binding affinity: Venous blood will be collected and sent to  the Partners Healthcare Center for 
Personalized Genetic Medi cine to genotype for the Ala147Thr  TSPO polymorphism in the TSPO 
gene (rs6971) [18] . About 10% of human subjects show low binding to PBR28.  High and mixed affinity binders (Ala/Ala or Ala/Thr) will be eligible, whereas the low affinity binders 
(Thr/Thr) will be ineligible to enroll.
7.1.1 Screen Failures
Any subject who signs consent will be considered enrolled in the study.  If a subject fails 
screening, at a minimum , the following information should be captured and entered in the 
Electronic Data Capture (EDC) System:
oInclusion and Exclusion Criteria
oDemographics
oReason for screen failure
7.2 Baseline Visit
This visit will take place within 28 days of the Screening Visit.  The following procedures will 
be performed:
1. Randomize subject (approximately 24 hours prior to the subjectโs Baseline visit)
2. Review inclusion a nd exclusion criteria 
3. Measure vital signs including weight4. Administer C-SSRS5. Administer ALSFRS-R questionnaire 6. Perform SVC [Note: Baseline Visit SVC is  not exclusionary, even if below 40%]
7. Perform Hand-held Dynamometry (HHD) and Grip Strength 8. Collect blood samples for clin ical laboratory assessments
9. Collect blood samples for cytokine levels , hs-CRP concentratio n and PBMC collection
10. Collect blood sample for IL-6 receptor genotyping11. Collect a blood sample for Genentech12. Collect urine sample for urinalysis13. Review and document concomitant medications and therapies14. Assess and document AEs15. Perform LP for CSF collection16. Schedule next Study Visit17. Administer 1
stdose of study drug after all baseline study procedures are complete. The 
subject should be observed at the site for 60 minutes after the infusion by an appropriate 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 50 of 90healthcare staff member according to the site โs institutional/state regulations to assess 
medical status and any immediat e reaction to the study drug.
Post-Lumbar Puncture Follow-up Telephone Call 
Subjects will receive a phone call 24-48 hours a fter their LP to assess and document AEs. 
MR-PET (MGH only) (* -2 Week window for these procedures to be conducted):
1.Pre-dose neuroimaging study (MRI/PET) will be performed one time
2. Upper Motor Neuron Burden Scale.3. MRI Safety Questionnaire
7.3 Week 4 (Visit 1)
This visit will take place 28 ยฑ 3 days after the Baseline Visit.  The following procedures will be 
performed:
1. Measure vital signs including weight
2. Administer C-SSRS3. Administer ALSFRS-R questionnaire 4. Perform SVC5. Collect blood samples for clin ical laboratory assessments 
6. Collect urine sample for urinalysis7. Collect blood samples for cytokine levels , hs-CRP concentratio n and PBMC collection
8. Review and document concomitant medications and therapies9. Assess and document AEs10. Administer 2
nddose of study drug.  The subject should be observed at the site for 30
minutes after the infusion by an appropriate healthcare staff member according to the siteโs institutional/state regulations to assess medical status and any immediate reaction to the study drug.
11. Schedule next Study Visit 
7.4 Week 8 (Visit 2)
This visit will take place 56 ยฑ 3 days after the Baseline Visit. The following procedures will be 
performed:
1. Measure vital signs including weight
2. Administer C-SSRS3. Administer ALSFRS-R questionnaire 4. Perform SVC5. Perform HHD and Grip Strength
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 51 of 906. Collect blood samples for clin ical laboratory assessments 
7. Collect urine sample for urinalysis8. Collect blood samples for cytokine levels , hs-CRP concentratio n and PBMC collection
9. Review and document concomitant medications and therapies10. Assess and document AEs11. Administer 3
rddose of study drug.  The subject should be observed at the site for 30 
minutes after the infusion by an appropriate healthcare staff member according to the siteโs institutional/state regulations to assess medical status and any immediate reaction to the study drug.
12. Perform 2
ndLP CSF collection 3 hours +/- 30 minutes after the start of study drug 
infusion.
13. Schedule next Study Visit 
Post-Lumbar Puncture Follow-up Telephone Call 
Subjects will receive a phone call 24-48 hours af ter their LP to assess and document AEs that 
may be directly related to the LP. 
MR-PET (MGH only) (* -2 Week window for these procedures to be conducted):
1.Post-dose neuroimaging study (MRI/PET) will be performed one time
2. Upper Motor Neuron Burden Scale.3. MRI Safety Questionnaire
7.5 Week 12 (Visit 3)
This visit will take place 84 ยฑ 3 days after the Baseline Visit. The following procedures will be 
performed:
1. Measure vital signs including weight
2. Administer C-SSRS3. Administer ALSFRS-R questionnaire 4. Perform SVC5. Collect blood samples for clin ical laboratory assessments 
6. Collect urine sample for urinalysis7. Collect blood samples for cytokine levels , hs-CRP concentratio n and PBMC collection
8. Review and document concomitant medications and therapies9. Assess and document AEs10. Schedule next Study Visit 
7.6 Week 16 (EOS Visit)
This visit will take place 112 ยฑ 3 days after the Ba seline Visit. The following procedures will be 
performed:
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 52 of 901. Perform neurological examination
2. Perform physical examination3. Measure vital signs including weight4. Administer C-SSRS5. Administer ALSFRS-R questionnaire 6. Perform SVC7. Perform HHD and Grip Strength8. Collect blood samples for clin ical laboratory assessments
9. Collect urine sample for urinalysis10. Collect blood samples for cytokine levels , hs-CRP concentratio n and PBMC collection
11. Review and document concomitant medications and therapies12. Assess and document AEs13. Exit questionnaire
7.7 Final Safety Visit & Telephone Call
Subjects who withdraw consent and do not agree to be followed for ITT will be asked to come in 
for a Final Safety Visit and will be asked to have a final Follow-Up Telephone Call 28 (+ 5) days 
after the subjectโs last dose of study drug.
1. The final visit should be scheduled as soon as possible. The following will be performed:
2. Perform neurological examination
3. Perform physical examination4. Measure vital signs including weight5. Administer C-SSRS6. Administer ALSFRS-R questionnaire 7. Perform SVC8. Perform HHD and Grip Strength9. Collect blood samples for clin ical laboratory assessments
10. Collect urine sample for urinalysis11. Collect blood samples for cytokine levels , hs-CRP concentratio n and PBMC collection
12. Review and document concomitant medications and therapies13. Assess and document AEs
This phone call will take place 28 days after the subj ectโs last dose of study drug.  The following 
procedures will be performed:
14. Review and document concomitant medications and therapies
15. Assess and document AEs
7.8 Protocol Deviations
A protocol deviation is any non-compliance with  the clinical trial protocol, Good Clinical 
Practice (GCP), or Manual of Procedures requi rements.  The noncompliance may be either on 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 53 of 90the part of the subject, the SI, or the study site st aff.  As a result of deviations, corrective actions 
are to be developed by the s ite and implemented promptly.
All deviations from the protocol must be addressed in the subject โs source documents.  Protocol 
deviations must be sent to the local IRB pe r their guidelines and entered in the Protocol 
Deviations Log in the Electroni c Data Capture (EDC) System.
7.9 Missed Visits and Procedures 
Missed visits and any procedures not performed (not attempted) for reasons other than illness, 
injury or progressive disability (i.e. subject is physically unable to perform test) will be reported as protocol deviations.
Procedures or visits not performed due to illness, injury or disability, including procedures that 
were attempted but faile d (i.e. blood samples unable to be drawn after multiple attempts, or 
weight unable to be obtained due to subject  immobility) will not be reported as protocol 
deviations unless there is a patient safety concern.
In the event of illness, injury or disability, every attempt will be made to complete each visit.  In 
the event that the visit is not completed, a phone visit will be performed to review concomitant 
medications, perform the ALSFRS-R, and record AEs.
Study drug compliance that is outside the limits set in the study operations manual will be 
reported as a protocol deviation. 
Details and specific instructions regarding protocol deviations, in cluding any exceptions to this 
standard procedure, are found in the study operations manual.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 54 of 908 CLINICAL ASSESSMENTS AND OUTCOME MEASURES
8.1 Clinical Variables
Assessments will be performed at designated time-points throughout the study for clinical 
evaluation.  In addition to the assessments evalua ted below, subjects will provide information on 
their demographics, past medical history, including ALS, as well as concomitant medication usage.
8.1.1 Vital Signs, Height & Weight
Vital signs will be obtained after the subject has been in a seated position for several minutes.  Vital signs, including systolic and diastolic bl ood pressure, pulse rate (radial artery)/minute, 
respiratory rate/minute, temperature and weight will be assessed at specified visits.  Height will 
be measured and recorded at the Screening Visit only.  
8.1.2 PBMC Blood Collection, hs-CRP concentration and Cytokine Levels
Blood will be collected to measure the expressi on of inflammatory ge nes in peripheral blood 
mononuclear cells (PBMCs).  Plasma cyt okine levels, including IL-6, IL-17A, IL- ศIL-8,
MMP1, TNF- ฤฎV,/ -6 receptor and hs-CRP, will also be assessed. These samples will be sent to 
Dr. Robert Bowserโs laboratory at the Barrow Neurological Institute (BNI) for analysis.  
In addition, a blood sample will be sent to Genentech, Inc. in Cali fornia at baseline and again at 
the time of a hypersensitivity, anaphylaxis or drug discontinuation event. All samples will be 
labeled with a code.  The code will not include any identifiable information.
8.1.4 12-Lead Electrocardiogram (ECG)
A standard 12-lead ECG will be performed at the Screening Visit only. Tracings will be reviewed by a site cardiologist and a copy of the tracin gs will be kept on site as part of the source 
documents.
8.1.5 Chest X-Ray
A standard PA and Lateral Chest X-Ray will be performed at the Screening Visit to assess for 
evidence of active pulmonary tuberculosis (TB). A co py of the report will be kept on site as part 
of the source documents.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 55 of 908.1.6 Physical Examination
A physical examination will be performed and recorded at the Baseline Visit.  The following systems will be examined: head/neck, eyes, ears , nose/throat, cardiovascular, lungs, abdomen, 
musculoskeletal, central nervous system, extremities, and skin.  
8.1.7 Neurological Examination
A complete neurological examination will be performed and recorded at the Baseline Visit.
8.1.8 Columbia Suicide Severi ty Rating Scale (C-SSRS)
The US FDA recommends the use of a suicidality assessment instrument that maps to the 
Columbia Classification Algorithm for Suicide Assessment (C-CASA)[19]. The C-CASA was developed to assist the FDA in coding suicidality data accumulated during the conduct of clinical 
trials of antidepressant drugs. One such assessment instrument is the Columbia Suicide Severity 
Rating Scale (C-SSRS). The C-SSRS involves a seri es of probing questions to inquire about 
possible suicidal thinking and behavior.
At the Baseline Visit, the C-SSRS Baseline version will be administered.  This version is used to 
assess suicidality over the subjectโs lifetime and specifically for the previous 6 month time period.
At all other study visits, the Since Last Visit version of the C-SSRS will  be administered. This 
version of the scale assesses suicidality since the subjectโs last visit.
8.1.9 IL-6 Genotyping
Blood will be collected and sent to the Hawkins lab at Wake Forest. DNA will be isolated and 
the IL-6 receptor gene will be sequenced. Co mmon polymorphisms, including one previously 
described in patients with asthma, will be identified and be entered into the EDC record of each 
patient.
8.1.10 Lumbar Puncture
Lumbar punctures will be performed and CSF will be  collected at the Baseline Visit and Visit 2. 
All patients will receive the Base line Visit LP prior to receiving the first dose of study drug.
Patients will receive the visit 2 LP 2 hours +/- 30 minutes after completion of the Visit 2 study 
drug infusion administration .The SI will discuss all potential LP risks to the subjects including:
oLocal pain at injection site;
oReaction to anesthetic agents;
oBleeding at needle entrance site; 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 56 of 90oInfection at needle entrance site; and,
oPost-LP low-pressure headache.  
Extensive experience with research LP in Alzheimerโs disease reveals a very low incidence of 
complication, including the incidence of PLPH3.  Fewer than 2.6% of patients in a memory 
disorder clinic developed PLPH, and only a single patient in a cohort of over 1000 had a 
headache lasting more than 5 days [20]. No other local or generalized complications occurred.  
The procedure must be performed by the SI or another licensed practitioner with experience and 
training in performing LPs, and who is listed on the site delegation log. LPs will be performed 
with an atraumatic Sprotte needle to reduce the risk of PLPH. CSF samples will be sent to Dr. 
Bowserโs laboratory at BNI to determine the conc entration of inflammatory cytokines (IL-6, IL-
ศDQG sIL-6 receptor) in the CSF before and afte r treatment with tocilizumab vs. placebo. In 
addition, CSF will be sent to the Hawkins lab at Wake Forest for measurement of sIL-6 receptor 
levels.
Remaining CSF samples will be stored in a sample repository.  These samples will be used for 
future research in motor neuron diseases.  All samples will be labeled with a code.  The code will 
not include any identifiable information.  
Any research performed on the samples is for research purposes only.  Although genetic 
information may be analyzed, no genetic information will be given to the subject nor will the information that may be obtained be pl aced in a subjectโs medical records. 
There is no scheduled date on which the samples will be destroyed.  Samples may be stored for 
research until they are used, damaged, decayed or otherwise unfit for analysis. Subjects have the option of declining participation in this portion of the study at any time by withdrawing their 
consent to have their sample used.  However, it will not be possible to destroy samples that may 
have already been used.
8.1.11 Adverse Events
Adverse events will be documented at each study visit, including the Screening Visit once the 
informed consent form has been signed by th e subject, and at all study visits. Information on 
adverse effects of study medicati on and on inter-current events w ill be determined at each visit 
by direct questioning of the subjects, review of concomitant medications, and vital sign results. 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 57 of 908.1.12 Exit Questionnaire
An exit questionnaire will be comple ted by subjects and Site Investigators at the End Of Study 
Visit (Week 16). This will include questions regarding blindedness, LP and infusion experiences, 
and overall views of the quality of the trial. 
8.2 Outcome Measure8.2.1 ALSFRS-R
The ALSFRS-R is a quickly administered (5 minutes) instrument used to determine subjects' 
assessment of their capability and independence in 12 functional activities, each rated on an 
ordinal scale (ratings 0-4).  All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in 
strength over time, was closely associated with quality of life measures, and predicted survival. 
The test-retest reliability is greater than 0.88 for all test items. The advantages of the ALSFRS-R
are that the categories are relevant to ALS, it is a sensitive and reliable tool for assessing activities of daily living function in those with ALS, and it is quickly administered.  With 
appropriate training the ALSFRS-R can be administered with high inter-rater reliability and test-
retest reliability.  The ALSFRS-R can be admin istered by phone with go od inter-rater and test-
retest reliability.  The equivale ncy of phone versus in-person te sting, and the equivalency of 
study subject versus caregiver responses have also recently been established. Therefore, if 
necessary, the ALSFRS-R may be given to th e study subject over the phone. All ALSFRS-R
evaluators must be NEALS certified.
8.2.2 Slow Vital Capacity (SVC) Testing
The vital capacity (VC) (percent of predicted normal) will be determined, using the upright slow 
VC method. The VC can be measured using conven tional spirometers that have had a calibration 
check prior to subject testing.  A printout from the spirometer of all VC trials will be retained. All VC evaluators must be NEALS certified. Three VC trials are required for each testing 
session, however up to 5 trials may be performed  if the variability between the highest and 
second highest VC is 10% or greater for the firs t 3 trials with variability being calculated as 
[(Highest VC-Second highest VC)/ Highest VC] x 100. Only the 3 best trials are recorded on the 
CRF. The highest VC recorded is utilized for eligibility. 
8.2.3 Hand-held Dynamometry (HHD) and Grip Strength
Hand Held Dynamometry (HHD): Hand held dynamometry (HHD) will be used as a
quantitative measure of muscle st rength for this study.  Six proximal muscle groups will be 
examined bilaterally in both upper and lower extremities (shoulde r flexion, elbow flexion, elbow 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 58 of 90extension, hip flexion, knee flex ion, and knee extension), all of which have been validated 
against maximum voluntary isometric contrac tion (MVIC) testing [21]. In addition, wrist 
extension, first dorsal interosseous contrac tion and ankle dorsiflexion will be measured
bilaterally; these muscles are often affected in ALS.  Mean and standard deviation for each muscle group will be established fro m the initial values for each subject in this trial, so that 
strength determinations can be  converted to Z scores and averaged to provide an HHD 
megascore for both upper a nd lower extremities.   
Grip Strength:  Bilateral hand grip will be measured using a study approved dynamometer to test 
the maximum isometric strength of the hand and forearm muscles.  
8.2.4 Training and Validation
All evaluators must be NEALS certified to perform the ALSFRS-R, SVC and HHD; specific 
certification requirements are outlined in the study operations manual. Repeat NEALS 
certification will be requi red on a bi-annual basis for all outco me measures. It is strongly 
preferred that a single evaluator performs all me asures throughout the study, if possible. NEALS 
certification is required for all evaluators prior to performing any study tests.
8.2.5 Neuroimaging
MGH Subjects will undergo Magnetic Resonance Imaging (MRI) / PBR28 Positron Emission 
Tomography (PET) twice during the course of the study. The goal of these scans is to measure activated microglia in study participants before treatment and after several weeks of treatment. 
The first scan will occur at the Baseline visit ( Pre-dose ), after subject eligibility has been 
confirmed by TSPO affinity binding assay. Th e second scan will occur at the Week 8 (Post-
dose). Neuroimaging will be performed at the MGH Martinos Center for Biomedical Imaging.  
Subjects will be asked to lie still in a supine position for the duration of the study, which will 
take approximately 90 min. 
Each PET scan will include one administration of up to 15 mCi of [
11C]PBR28 (which is 
equivalent to ~3.7 mSv), injected intravenous ly with a slow bolus over a 30 s period. The 
catheter will be flushed post-inj ection with 0.9% saline solution. Dy namic data will be collected 
over approximately 90 minutes in lis t mode, and frame d post-collection. 
 
8.2.5.1 Imaging Data Acquisition and Proccessing (MGH Only)
Simultaneous PET-MRI Data Acquisition
The proposed studies will benefit from our expe rience using a unique PET-MRI scanner called 
BrainPET .This scanner consists of a dedicated br ain avalanche photodiode-based PET scanner 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 59 of 90that operates in the bore of a 3T whole body MR  scanner. Our center has over seven yearsโ 
experience using this scanner and has successf ully completed over 200 human studies. Our data 
suggest that high quality PET data can be ac quired fully simultaneously  with conventional and 
advanced MRI data without subs tantial artifacts. The simultane ous acquisition of PET and MRI 
data reduces scan time, which minimizes the discomfort experienced by our ALS patient population. In addition, the simultaneous PET/MR I acquisition allows us to apply our novel 
MRI-based methods for generating attenuation correction maps, which enable PET motion 
correction and improve image quality [22, 23].
PET DataUp to 15 mCi of [
11C]PBR28 or ~5 mCi (4.8 ยฑ 0.4 mCi) of [11C]PBR28 will be injected 
intravenously with a slow bolus over a 30 second  period [24]. The catheter will be flushed post-
injection with 0.9% saline so lution. Dynamic data will be co llected over approximately 90 
minutes in list mode, and framed post-collection. The PET list-mode data will first be sorted in 
the line-of-response (LOR) space and motion correct ed using MRI-derived motion estimates for 
each individual frame [22, 23]. Next, the data w ill be rebinned in the sinogram space, generating 
prompt and random coincidences sino grams. The head attenuation map ( ฮผ-map) will be obtained 
using a recently implemented MR-based atte nuation correction method [22, 23]. The scatter 
sinogram will be obtained using a calculated method based on the sing le scatter estimation 
method[25]. The images will be r econstructed using the Ordinary Poisson Ordered Subset 
Expectation Maximization (OP-OSEM) 3D al gorithm from prompt and expected random 
coincidences, normalizati on, attenuation and scatter coincidences sinograms using 16 subsets and 
six iterations [26]. The recons tructed volume consists of 153 slices with 256ร256 pixels 
(1.25ร1.25ร1.25 mm3). Regional uptake of the tracer w ill be estimated as described below.
MRI Data
A high resolution structural volume will be collect ed for the purposes of anatomical localization, 
ROI definition, and structural analyses. A multi- echo MPRAGE pulse sequence will be utilized, 
with an isotropic voxel of 1 mm. Cortical reconstruction and volumetric segmentation will be performed with the Freesurfer image analysis suite ( http://surfer.nmr.mgh.harvard.edu/ ). A dual-
echo ultrashort echo time MRI sequence (DUTE) will be collected to determine attenuation 
correction for PET data. Other routine exploratory MRI sequences will be acquired including:  a) 
Magnetic Resonance Spectroscopy (MRS) to me asure NAA, Choline, Creatine, and MyoInositol 
in the motor cortices; and b) Diffusion tensors imaging (DTI) to detect changes in the 
corticospinal tract in correlation with PBR28 uptake.
Tocilizumab in ALS
Version 8.0
Version date 04/25/2017
Page 60 of 908.2.5.2 Imaging Analysis Plan
Region of interest (ROI) analyses will be conduct ed to detect differen ces in brain uptake of 
PBR28 (Pre-dose compared to Post-dose) as described in [12, 13].
Standard uptake volumes (SUV) images for PBR28 will be created for radioactivity in the field 
of view 60โ90 minutes post-radioligand injection. To account for motion that may have occurred 
between MP-RAGE acquisition and the 60โ90 minute post-injection time point corresponding to 
the PET frame of interest, SUV 60โ90 min will be generated in a two-step procedure. First, a 
SUV 60โ90 min image will be created for each subject using an attenuation correction map 
computed from the native MP-RAGE. Subsequent ly, a new attenuation map will be created 
based on the registration of the native MP-RAGE with the SUV 60โ90 min image obtained in the 
first reconstruction using FreeSurfer3s spmregister. A final SUV 60โ90 min will then be 
reconstructed based on this ne w attenuation correction image well registered with the 60โ90 min 
PET data. Individual SUV 60โ90 min images will then be registered to MNI (Montreal 
Neuroogical Institute) space, spatially smoothe d (6 mm full width at half maximum), and 
intensity-normalized to a mean of 1 (SUVR 60โ90 min ) in order to account for differences in 
global signal across subjects, as prev iously described [12]. Average SUVR 60โ90 min in 
predetermined ROIs for the left and right precentral gyri for both the gray matter and the 
underlying white matter will be derived from the automatic T1 segmentation in Freesurfer (20)
will be estimated from [11C]-PBR28 SUVR in the ROIs. 
8.2.6 Upper Motor Neuron Burden (UMNB) Scale
The Upper Motor Neuron-Burden (UMNB) Sc ale assesses pathological UMN signs on 
examination.  The UMNB measures the following  deep tendon (scores 0โ4) and pathological 
reflexes (present โ 1 or absent  โ 0): biceps, brachioradialis, triceps, knee jerk, ankle jerk, 
Hoffman, Babinski, and jaw jerk. The total UMNB score ranges from 0 to 45, with 0 
representing no reflex involveme nt, and 45 maxima l abnormal UMNB
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 61 of 909 SAFETY AND ADVERSE EVENTS
The AE definitions and reporting procedures provided in this protocol comply with all applicable 
United States Food and Drug Administration (FDA) regulations and International Conference on 
Harmonization (ICH) guidelines.  The SI will caref ully monitor each subject throughout the 
study for possible AEs.  All AEs will be documented on CRFs designed specifically for this 
purpose.  It is also important to report all AEs, especially those that result in permanent 
discontinuation of the investig ational product being studied, whether serious or non-serious.
9.1 Definitions of AEs, Suspected  Adverse Drug Reactions & SAEs
9.1.1 Adverse Event and Suspected  Adverse Drug Reactions
An AE is any unfavorable and unintended sign (i ncluding a clinically significant abnormal 
laboratory finding, for example), sy mptom, or disease temporally associated with a study, use of 
a drug product or device whether or not consider ed related to the drug  product or device. 
Adverse drug reactions (ADR) are all noxious and unintended responses to a medicinal product 
related to any dose.  The phrase โresponses to  a medicinal productโ means that a causal 
relationship between a medicinal product and an AE is at least a reasonable possibility, i.e., the 
relationship cannot be ruled out.  Therefore, a s ubset of AEs can be cl assified as suspected 
ADRs, if there is a possible causal relationship to the medicinal product.
Examples of AEs include: new conditions, wors ening of pre-existing conditions, clinically 
significant abnormal physical examination signs (e .g., skin rash, peripheral edema), or clinically 
significant abnormal test results (e.g., lab values or vital si gns), with the exception of outcome 
measure results, which are not being recorded as AEs in this trial (they are being collected, but analyzed separately). Stable chronic conditions (e.g., diabetes, arthritis) that are present prior to 
the start of the study and do not worsen during the trial are NOT considered AEs.  Chronic 
conditions that occur more frequently (for inte rmittent conditions) or with greater severity, 
would be considered as worsened and therefore would be recorded as AEs.
AEs are generally detected in two ways:
Clinical รsymptoms reported by the subject or signs detected on examination.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 62 of 90Ancillary Tests รabnormalities of vita l signs, laboratory test s, and other diagnostic 
procedures (other than the outcome measures, the results of which are not being captured 
as AEs).
For the purposes of this study, symptoms of pr ogression/worsening of ALS, including โnormalโ 
progression, will be recorded as AEs.    
The following measures of disease progression will not be recorded as AEs even if they worsen 
(they are being recorded and analyzed separately): vital capacity results and ALSFRS-R results. 
If discernible at the time of completing the AE log, a specific disease or syndrome rather than 
individual associated signs and symptoms should be identified by the SI and recorded on the AE 
log.  However, if an observed or reported sign, symptom, or clinically significant laboratory 
anomaly is not considered by the SI to be a component of a specific disease or syndrome, then it should be recorded as a separate AE on the AE log.  Clinically significant laboratory 
abnormalities, such as those that require interven tion, are those that are identified as such by the 
SI.
Subjects will be monitored for AEs from the time they sign consent until completion of their 
participation in the study (defined as death, consent withdrawal, loss to follow up, early study 
termination for other reasons, or followi ng completion of the entire study).  
An unexpected AE is any AE, the specificity or severity of which is not consistent with the 
current Investigatorโs Brochure.  An unexpect ed, suspected adverse drug reaction is any 
unexpected AE for which, in the opinion of the SI or Sponsor, there is a reasonable possibility 
that the investigational product caused the event.
9.1.2 Adverse Events of Special Interest
Adverse events of special interest (non-serious  and serious) are required to be reported by the 
Investigator to the CC within 24 hours after lear ning of the event. The CC must forward this 
information to Genentech Drug safety within 24 hours of receipt (see Section 9.3 for reporting 
instructions ).  Non-serious and serious AEs of special interest for this study include the 
following:
xInfections including all opportunistic infections and non-serious infections as
defined by those treated with IV anti-infectives.
xSuspected transmission of an infectious ag ent by the medicinal product (STIAMP). Any 
organism, virus, or infectious particle (e.g., prion protein transmitting transmissible 
spongiform encephalopathy), pathogenic or non- pathogenic, is considered an infectious 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 63 of 90agent. A transmission of an infectious agent may be suspected from clinical symptoms 
or laboratory findings that i ndicate an infection in a patie nt exposed to a medicinal 
product. This term applies only when a conta mination of the study drug is suspected.
xMyocardial infarction/ac ute coronary syndrome.
xGI perforation and related events.
xMalignancies.
xHypersensitivity reactions.
xDemyelinating disorders.
xStroke.
xBleeding events.
xHepatic events.
Guided questionnaires have been prepar ed for the AEs of special interest.  
The notification of AEs of special interest (including non-serious events of special interest) will 
follow the established procedures for AEs and SAEs  in the study (i.e., documented and reported 
to the CC within 24 hoursGuided questionnaires ha ve been prepared for the AEs of special 
interest and will be sent to the investigator(s) to obtain more de tailed information, as necessary.  
The documentation and reporting requirements for those AEs of special interest will be further described in a separate document (Actemra Events of Special Interest Guidance Document).
9.1.3 Serious Ad verse Events
A SAE is defined as an AE that m eets any of the following criteria:
oResults in death.
oIs life threatening: that is, poses an immediate risk of death as the event occurred.
xThis criterion applies if the study subject, in the view of the SI or Sponsor, is at 
immediate risk of death from the AE as it occurred.  It does not apply if an AE 
that hypothetically might cause death if it were more severe.
oRequires inpatient hos pitalization or prolongation of existing hospitalization.
xHospitalization for an elective procedure (including elective PEG tube/g-
tube/feeding tube placement) or a routinel y scheduled treatment is not an SAE by 
this criterion because an elective or scheduled โprocedureโ or a โtreatmentโ is not an untoward medical occurrence.
oResults in persistent or significant disability or incapacity.
xThis criterion applies if the โdisabilityโ caused by the reported AE results in a 
substantial disruption of the subjectโs ability to carry out normal life functions.
oResults in congenital anomaly or birth defect in the offspring of the subject (whether the 
subject is male or female).  
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 64 of 90oNecessitates medical or surgical intervention to preclude permanent impairment of a 
body function or permanent damage to a body structure.
oImportant medical events that may not result in death, are not life-threatening, or do not 
require hospitalization may also be consid ered SAEs when, based upon appropriate 
medical judgment, they may jeopardize the s ubject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include serious  infections, blood dyscrasias or convulsions that do not 
result in inpatient hospitaliza tion, or the development of dr ug dependency or drug abuse.
An inpatient hospital admission in the absence of a precipitating, treatment-emergent, clinical 
AE may meet criteria for "seriousness" but is not an adverse experience, and will therefore, not be considered an SAE.  An example of this would include a social admission (subject admitted 
for other reasons than medical, e.g., lives far from the hospital, has no place to sleep).
A serious, suspected adverse drug reaction is an SAE for which, in the opinion of the SI or 
Sponsor, there is a reasonable possibility that the investigational product caused the event.
The SI is responsible for classifying AEs as serious or non-serious.
9.2 Assessment and Recording of Adverse Events
The SI will carefully monitor each subject throughout  the study for possible AEs.  All AEs will 
be documented on CRFs designed specifically for this purpose.  All AEs will be collected and reported in the electronic data capture (E DC) system and compiled into reports for 
monthlyreviewing by the Medical Monitor. Th e Medical Monitor shall promptly review all 
information relevant to the safe ty of the investigational product,  including all SAEs.  Special 
attention will be paid to those that result in permanent discontinuation of the investigational product being studied, whethe r serious or non-serious.
9.2.1 Assessment of Adverse Events
At each visit (including telephone interviews), the subject will be asked if they have had any 
problems or symptoms since their last visit in order to determine the occurrence of AEs. If the subject reports an AE, the Investigator will probe further to determine:
xType of event
xDate of onset and resolution (duration)
xSeverity (mild, m oderate, severe)
xSeriousness (does the event meet the above definition for an SAE)
xCausality, relation to inves tigational product and disease
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 65 of 90xAction taken regarding investigational product
xOutcome
9.2.2 Relatedness of Adverse Event to Investigational Product
The relationship of the AE to the investigationa l product should be specified by the SI, using the 
following definitions:
1.  Not Related:         Concomitant illness, accident or event with no reasonable 
association with treatment.
2.  Unlikely: The reaction has little or no temporal sequence from 
administration of the investigational product, and/or a more likely 
alternative etiology exists.
3.  Possibly Related: The reaction follows  a reasonably temporal sequence from 
administration of the investiga tional product and follows a known 
response pattern to the suspect ed investigational product; the 
reaction could have been produced by the investigational product 
or could have been produced by th e subjectโs clinical state or by 
other modes of therapy administered to the subject. (Suspected 
ADR)
4.  Probably Related: The reaction follows  a reasonably temporal sequence from 
administration of investigational product; is confirmed by 
discontinuation of the investigati onal product or by re-challenge; 
and cannot be reasonably explained by the known characteristics 
of the subjectโs clinical state. (Suspected ADR)
5.  Definitely Related: The reaction follo ws a reasonable temporal sequence from 
administration of investigati onal product; follows a known or 
expected response pattern to th e investigationa l product; and is 
confirmed by improvement on stoppi ng or reducing the dosage of 
the investigational pr oduct, and reappearance of the reaction on 
repeated exposure. (Suspected ADR)
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 66 of 909.2.3 Recording of Adverse Events
All clinical AEs are recorded in the AE Log in th e subjectโs study binder. The site should fill out 
the AE Log and enter the AE information into the Electronic Data Capture (EDC) system within 
48 hours of the site learning of a new AE or receiving an update on an existing AE.  
Please Note: SAEs must be reported to the CC w ithin 24 hours of the site learning of the SAE.
This applies regardless of whether the subject is taking study drug or not. Infusion reactions,
gastrointestinal perforations, tuberculosis, invasive  fungal infections, bacterial, viral and other 
infections due to opportunistic pathogens, elevated liver enzymes, neutropenia or 
thrombocytopenia, whether classified as SAEs or not, must also be reported within 24 hours. 
Entries on the AE Log (and into the EDC) will include the following: name and severity of the event, the date of onset, the date of resoluti on, relationship to inves tigational product, action 
taken, and primary outcome of event.  
9.3 Adverse Events and Serious Ad verse Events - Reportable Events
The following are considered reportable events and must be reported to the CC within 24 hours 
of the site being notified of the event. The CC must then report the events to Genentech Drug 
safety within 24 hours of learning of the even t, regardless of relationship to study drug:
xSAEs.
xNon-serious and serious AEs of special interest.
xPregnancies.
The Investigator must report new significant follow-up information for these events to the CC 
within 1 working day after becoming aware of the information. The CC must send this information to Genentech Drug Safety within 1 working day of receipt.  New significant information includes the following:
xNew signs or symptoms or a change in the diagnosis.
xSignificant new diagnostic test results.
xChange in causality based on new information.
xChange in the eventโs outcome, including recovery.
xAdditional narrative information on the clinical course of the event.
Investigators must also comply with local requi rements for reporting SAEs to the local health 
authority and IRB/EC.
All serious adverse events (SAEs) for which there is a reasonable possibility the experience may 
have been caused by Tocilizumab (this applies to both expected and unexpected events) should 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 67 of 90be recorded on a MedWatch 3500A Form and em ailed to the NCRI Project Manager and the 
Medical Monitor (contact informa tion found in the study manual) .
The Coordination Center will then forwar d this form within 24 hours of receipt to:
Genentech Drug Safety
Tel: (888) 835-2555Fax: (650) 225-4682 or (650) 225-4683
The Coordination Center will use the safety reporting fax sheet in Appendix V. 
MedWatch 3500A Reporting Guidelines:
In addition to completing appropriate patient de mographic and suspect medication information, 
the report should include the following informati on within the Event Description (section 5) of 
the MedWatch 3500A form:
xTreatment regimen (dosing fre quency, combination therapy)
xProtocol description (and  number, if assigned)
xDescription of event, severity, treatment, and outcome if known
xSupportive laboratory results and diagnostics
xInvestigatorโs assessment of the relationship of the adverse event to each investigational 
product and suspect medication
Follow-up information:  
Additional information may be added to a previously submitted report by any of the following 
methods:
xAdding to the original MedWatch 3500A report and submitting it as follow-up
xAdding supplemental summary information and submitting it as follow-up with the 
original MedWatch 3500A form 
xSummarizing new information and faxing it with a cover letter including subject 
identifiers (i.e. D.O.B. initial, subject number), protocol description and number, if 
assigned, suspect drug, brief adverse event description, and notation that additional or 
follow-up information is being submitted  (The patient identifiers are important so that 
the new information is added to the correct initial report)
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 68 of 90Occasionally Genentech may contact the reporter for additional information, clarification, or 
current status of the subject for whom and advers e event was reported.  For questions regarding 
SAE reporting, you may contact the Genentech  Drug Safety representative noted above.
The following are also considered reportable events and must be reported to the CC within 24 
hours of the site being notified of the event. 
oDosage Changes (Dose Management)
oInvestigational Product Suspen sion, Reduction or Re-challenge
oInvestigational Pr oduct Discontinuation
oKey Study Events:
oSubject Final Disposition
oFeeding Tube Placement
oPermanent Assisted Ventilation (PAV)*
oTracheostomy
oMortality
oPregnancy
oDiaphragm Pacing System (DPS) device implantation
* Permanent Assisted Ventilation (PAV) is define d as more than 22 hours daily of non-invasive 
mechanical ventilation for more than one week (7 days).  The date of onset of PAV is the first 
day of the seven days.
STUDY CLOSE-OUT
Any study report submitted to the FDA by the Sponsor or designee should be copied to 
Genentech. This includes all I ND annual reports and the Clinic al Study Report (final study 
report). Additionally, an y literature articles that are a resu lt of the study should be sent to 
Genentech. 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 69 of 9010 DATA AND SAFETY MONITORING AND STATISTICAL ANALYSIS PLAN
10.1 Data and Safety Monitoring Board
An independent Data and Safety Monitoring Board (DSMB) will be assembled for the trial. The 
DSMB receives the blinded and unblinded summary reports of the frequency of all clinical AEs
and safety laboratory tests for planned peri odic meetings approximately every 3 months 
throughout the study. The DSMB can ask to receive the SAE reports more frequently. Meetings 
will be held via teleconference. In additi on, the DSMB Chair may call ad hoc meetings. 
Summaries of SAEs and enrollment will be provided approximately monthly to the DSMB by 
the Study Biostatistician. Serious infusion reacti ons or deaths occurring within 24 hours of 
dosing, infusion reactions, tuberculosis, invasive fungal infections, bacter ial, viral and other 
infections due to opportunistic pathogens, elevated liver enzymes, neutropenia or 
thrombocytopenia, and any severe unexpected SAEs are considered events of interest and will be 
reported to the DSMB prior to their meeting on a quarterly basis.  As necessary, the DSMB can 
review the frequencies of clinical and laboratory abnormalities.  Recommendations for 
modification or termination of the trial based on safety data will be made by the DSMB to the 
PIs and Steering Committee.  The DSMB will review safety data throughout the trial and may 
stop the trial for safety if they determine that there is a significant difference in the rate of a particular AE that would indicate a risk that is greater than the possible benefit of the study drug.  
A notable increase in the frequency of any AE s hould be examined by the DSMB although it 
may not lead to a recommendation by the DSMB. There will not be early stopping for efficacy in 
this trial. 
Prior to each DSMB meeting, the CC will provide  an update to the DSMB on enrollment, data 
quality (missing data) and protoc ol adherence.  The CC will be  responsible for communication 
with the DSMB.  
Complete information can be found in the Da ta and Safety Monitoring Board Charter.
If 2 or more serious AEs are deemed to be defin itely, probably, or possibly related to study drug 
occur, the DSMB will review these events prom ptly and make recommendations about potential 
changes to the study including possible changes to protocol, updates to the informed consent 
form, or even ending the study early.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 70 of 9010.2 Safety Monitoring
10.2.1 Safety Management Resource Team 
The CC Safety Management Resource Team (S MaRT) is comprised of physicians, Project 
Managers, Data Managers, and Systems personnel.  
On a periodic basis, the SMaRT group will revi ew blinded reports of AEs, SAEs, abnormal 
laboratory measurements and protoc ol deviations as detailed in the studyโs Safety Management 
Plan.
10.2.2 Medical Monitoring
The designated Medical Monitor for the study is identified in the study operations manual. Site 
personnel should contact the Medical Mon itor for assistance with the following:
xMedically-related protocol questions
xSafety concerns, including AEs and SAEs
xProtocol deviations
xUnblinding questions
xProtocol eligibilty questions
xDose changes
10.3 Statistical Considerations
10.3.1 Statistical Methods
Given the difficulty with generalizing the safety and tolerability of tocilizumab to ALS patients, 
it is important to assess this as a primary outcome measure if a future phase 3 trial is to be 
considered. We will assess safety of tocilizumab treatment based on mortality, occurrence of SAEs, overall rates of AEs, clinically significan t abnormal laboratory tests,  and changes in vital 
signs. We will focus on events at least possibly related to study drug of moderate or severe 
intensity by comparing participants receiving at least one dose of tocilizumab to those on placebo 
for time to mortality and time to first SAE by  Cox regression, for overall rate of AEs or 
abnormal laboratory tests by  negative binomial regression, and for rates of change in vital signs. 
Tests will be two-tailed at alpha  = 0.10 to increase power. With 16 participants randomized to 
tocilizumab and followed for safety outcomes, the study will have 80% power to detect adverse events expected to occur in at least 10% of  patients. Although under-powered for comparing 
rates of rare events, the study will have 80% power to detect treatment differences in events 
expected to occur, for example, in 50% of pl acebo participants if tocilizumab increases the 
hazard 4.2-fold.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 71 of 90Tolerance of tocilizumab treatment  will be judged on the proportion of participants remaining on 
study drug through all 3 doses and remaining on  study and free from possibly drug-related and 
dose-limiting SAEs to the end of follow-up. Th e study will have 80% power to declare 
tocilizumab treatment tolerable based on non-inferiority to 50% tolerance with a one-sided 95% 
exact confidence bound if the true tolerance rate is at least 81%
We will assess successful target engagement by comparing rates of qualitative gene expression 
response in PBMCs between the two treatment  groups. We will estimate the proportion of 
participants who experience a 2-fold or greater decline between baseline and the average of all 
follow-up assessments in at least 2 of the 3 pro-inflammatory genes. The study will have 80% power for this comparison if no more than 5% of placebo participants experience such a change and at least 30% of tocilizumab participants do. Assuming that at least 80% of participants are 
truly in a high inflammatory state given our enro llment criteria, that would correspond to roughly 
6% vs. 38% response among susceptible patien ts randomized to placebo or tocilizumab, 
respectively. We will have greater power to detect quantitative changes in expression of pro-inflammatory genes. Serial measures of pro-inflammatory gene expression levels will be log-
transformed and analyzed in repeated-measu res ANOVAs with unstructured covariance over 
time. With an expectation of rapid change in gene expression, we will compare treatments on the 
basis of change from a shared baseline to the mean of all follow-up assessments using linear 
contrasts. The study will have 80%  power to detect a difference in expression equal to an effect 
size of 1.11 based on two-ta iled testing at or an effect size  of 1.50 based on tw o-tailed tests at 
alpha = 0.017, applying a Bonferroni correction for multiple comparisons over 3 inflammatory 
genes.
Clinical responses to tocilizumab treatment, m easured as change in ALSFRS-R, SVC, and HHD 
megascores will be analyzed in linear mixed  models with shared baseline and random 
participant-specific intercepts and slopes. If  we conservatively estimate power for detecting 
treatment-dependent differences in 16-wk change from a simple two-group t-test, the study will 
have 80% power for effect sizes of 0.76. With a sta ndard deviation for ALSFRS-R rate of change 
equal to 1.58 units/month based on the follow-up sc hedule of this trial and variance component 
estimates from the Ceftriaxone trial, the study would have 80% power if tocilizumab reduces
decline in ALSFRS-R by 2.0 units/month base d on a two-tailed at alpha = 0.05. Power will be 
greater using the proposed linear mixed model.
Change in average [
11C]-PBR28 SUV 60-90 min in pre-defined regions of interest focused on the 
left and right precentral gyri for both the gr ay matter and the underlying white matter will be 
compared between participants receiving tociliz umab vs. placebo in a shar ed-baseline repeated-
measures ANOVA with unstructured within-person covariance.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 72 of 9010.3.2 Analysis Populations
The primary analyses, whether for safety, tolerability, target engagement, efficacy, or PET/MRI, 
will use an as-treated sample that includes all participants classified according to the treatment 
actually received. This choice of an analysis sample reflects our interest in assessing mechanisms of action and potential efficacy rather than clinical effectiveness. For the purposes of planning 
future trials, a secondary efficacy analysis will use an intent-to-treat (ITT) sample that includes
all randomized participants grouped according to their randomized treatment assignment.
10.4 Missing Data
Analyses will attempt to avoid bias due to intolerance by including all participants who initiate 
treatment regardless of their compliance with their assigned treatment. Every effort will be made 
to obtain follow-up information for all subjects whether or not they continue on treatment. 
10.4.1 Stopping Rules
The DSMB will review safety data throughout th e trial and may stop the trial for safety.  Any 
unexpected death or death unrelated to disease progression will lead to prompt review by the 
DSMB.  Two or more of the same SAE deemed pr obably or definitely related to study drug by 
SIs will lead to prompt review by the DSMB. In addition, if there is one death in the treatment 
group deemed probably or definitely related to study drug by the DMSB, the study will be 
stopped immediately.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 73 of 9011 DATA COLLECTION, MANAGEMENT AND MONITORING
11.1 Role of Data Management
Data Management (DM) is the development, execution and supe rvision of plans, policies, 
programs, and practices that control, protect , deliver, and enhance th e value of data and 
information assets.
All data will be managed in compliance with NEALS po licies, and applicable Sponsor and 
regulatory requirements. Site personnel will collect, transcribe , correct, and transmit the data 
onto source documents, Case Re port Forms (CRFs), and other forms used to report, track and 
record clinical research data.  Clinical sites will be monitored to ensure compliance with data 
management requirements and G ood Clinical Practices.  DM is responsible for developing, 
testing, and managing clinical data management activities.
11.1.1 Data Entry and Checks
The site personnel are instructed to enter info rmation into the Electronic Data Capture (EDC) 
System within 5 days of a visit.  Data collection is the responsibility of the staff at the site under 
the supervision of the SI.  During the study, the SI must maintain complete and accurate 
documentation for the study.
The EDC includes password protection. An edit checking and data clarification process will be 
put in place to ensure accuracy and completeness of the database.  Logic and range checks as 
well as more sophisticated rules will be built in to the EDC to provide immediate error checking 
of the data entered.  The system has the capability to automatically create electronic queries for forms that contain data that are out of range, out of window, missi ng or not calculated correctly.  
The sites will only have access to the queries concerning their subjects.  
11.1.2 Data Lock Process
The application will have the ability to lock the database to prevent any modification of data once the study is closed.  Once this option is ac tivated, every user will have Read-Only access to 
the data. The database can only be locked after each SI has signed off on their subjects and all 
queries have been resolved.  
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 74 of 9011.1.3 Quality Assurance
Protocol procedures are reviewed with the SI a nd associated personnel prior to the study to 
ensure the accuracy and reliability of data. Each SI must adhere to the protocol detailed in this 
document and agree that any changes to the pr otocol must be approved by the CC prior to 
seeking approval from the site IRB.  Each SI will be responsible for enrolling only those study 
subjects who have met protocol eligibility criteria.
11.2 Clinical Monitoring
Study Monitors will visit each study site to re view source documentation materials, informed 
consent forms, and confirm entered data and that data queries have been accurately completed, 
and again at a study close-out visit.  Study Monitors will also verify that SAEs and protocol 
deviations have been reported appropriately, as required.  The Study Monitors will also review clinical facilities, resources and procedures for evaluating study subjects and study drug dispensing.  Subsequently, the Study Monitors will provide monitoring reports to the Project 
Manager and, if requeste d, will provide reports of  protocol compliance to the Study Principal 
Investigator and the Steering Committee.  Completed informed consent forms from each subject must be available in the subjectโs file and verified for proper documentation.  A document 
outlining the monitoring plan is provided to each Study Monitor.
11.3 Data Handling and Record Keeping
The SI is responsible to ensure the accuracy, comp leteness, legibility, an d timeliness of the data 
reported.  All source documents shoul d be completed in a neat, legibl e manner to ensure accurate 
interpretation of data.  Dark ink is required to ensure clarity of  reproduced copies.  When making 
changes or corrections, cross out the original entry with a single line, and initial and date the change.  Do not erase, overwrite, or use correction fluid or tape on the original. 
Source document templates (SDTs) will be provided for use and maintained for recording data 
for each subject enrolled in the study.  Data reported in the eCRF derived from source documents 
should be consistent with the source documents  and discrepancies should be explained.  The CC
will provide guidance to SIs on making corrections to the source documents and eCRFs.
11.3.1 Confidentiality
Study subject medical information obtained by this study is confidential, and disclosure to third parties other than those noted below is pr ohibited. Upon the subjectโs permission, medical 
information may be given to his or her personal physician or othe r appropriate medical personnel 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 75 of 90responsible for his or her welfare. All local an d federal guidelines and regulations regarding 
maintaining study subject confidentiality of data will be adhered to.
Data generated by this study must be available for inspection by representatives of the Office for 
Human Research Protections (OHRP), the sponsor, all pertinent national and local health and 
regulatory authorities, the CC or their representa tive, Study Monitoring personnel, and the IRBs.
11.3.2 Study Discontinuation 
The study can be terminated at any time.  Reasons for terminating the study may include the following:
xThe incidence or severity of AEs in this or  other studies indicates a potential health 
hazard to study subjects.
xStudy subject enrollment is unsatisfactory.
xData recording is inaccurate or incomplete.
xSponsor withdraws funding.
11.3.3 Retention of Records
US FDA regulations (21 CFR 312.62[c]) require that  records and documents pertaining to the 
conduct of this study and the distribution of inve stigational drug, including  CRFs (if applicable), 
consent forms, laboratory test re sults, and medical inventory record s, must be retained by the 
Site Investigator (SI) for two years after marketin g application approval.  If no application is 
filed, these records must be kept for two years af ter the investigation is discontinued and the US 
FDA and the applicable national and local health authorities are notified.  The Coordination Center or their representative will notify the Site Investigators of these events. The SiteInvestigators should retain all study documents a nd records until they are notified in writing by 
the Sponsor or their representative. 
11.3.4 Publications
The Principal Investigator, Shafeeq Ladha, MD, and the study Steering Committee will be 
responsible for publications of results from th is trial. Their respons ibilities will include the 
following:
xAnalyze and interpret data gathered in this study, and write publications from these data.
xSubmit manuscripts to selected journals and address peer reviewersโ comments.
xSubmit abstracts to selected meetings and present data at the meetings.
xDetermine authorship on the basis of the Uniform Requirements for Manuscripts.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 76 of 9012 LITERATURE REFERENCES
1. Bellingham, M.C., A review of the neural mechanisms of action and clinical 
efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther, 2011. 17(1): p. 4-31.
2. Cudkowicz, M.E., et al., Toward more efficient clinical trials for amyotrophic 
lateral sclerosis. Amyotrophic Lateral Sclerosis. 11(3): p. 259-65.
3. Actemra [package insert] . 2013, Genentech, Inc.: San Fransicso, CA.
4. Mizwicki, M.T., et al., Tocilizumab attenuates inflammation in ALS patients 
through inhibition of IL6 receptor signaling. Am J Neurodegener Dis, 2012. 1(3): 
p. 305-15.
5. Liu, G., et al., Neuronal phagocytosis by inflammatory macrophages in ALS 
spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis, 
2012. 1(1): p. 60-74.
6. Graves, M.C., et al., Inflammation in amyotrophic lateral sclerosis spinal cord and 
brain is mediated by activated macrophages, mast cells and T cells. Amyotroph 
Lateral Scler Other Motor Neuron Disord, 2004. 5(4): p. 213-9.
7. Fiala, M., et al., Tocilizumab infusion therapy normalizes inflammation in sporadic 
ALS patients. Am J Neurodegener Dis, 2013. 2(2): p. 129-39.
8. Appel, S.H., et al., The microglial-motoneuron dialogue in ALS. Acta Myol, 2011. 
30(1): p. 4-8.
9. Sarantopoulos, A., et al., Tocilizumab treatment leads to a rapid and sustained 
increase in Treg cell levels in rheumatoid arthritis patients: comment on thearticle by Thiolat et al. Arthritis Rheumatol, 2014. 66(9): p. 2638.
10. Mรคrz P, et al., Role of Interleukin-6 and soluble IL-6 Receptor in Region Specific 
Induction of Astrocytic Differentiation and Neurotrophin Expression. Glia, 1999. 
26: p. 191-200.
11. Mรคrz P, C.J.-C., Gadient RA, Patterson P, Stoyan T, Otten U, Sympathetic 
Neurons can produce and respond to Interleukin-6. Proc Natl Acad Sci 1998. 95:
p. 3251-3256.
12. Zรผrcher, N.R., et al., Increased in vivo glial activation in patients with amyotrophic 
lateral sclerosis: Assessed with [11C]-PBR28. NeuroImage: Clinical, 2015. 7: p. 
409-414.
13. Alshikho, M.J., et al., Glial activation colocalizes with structural abnormalities in 
amyotrophic lateral sclerosis. Neurology, 2016. 87(24): p. 2554-2561.
14. Zhang, X., et al., Disease-drug-drug interaction studies of tocilizumab with 
cytochrome P450 substrates in vitro and vivo. Clin Pharmacol Ther 2009. 85: p. 
0009-9236.
15. Schmitt, C., et al., Disease-drug-drug interaction involving tocilizumab and 
simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther, 2011. 
89(5): p. 735-40.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 77 of 9016. Hammond, E.R., et al., Needle type and the risk of post-lumbar puncture 
headache in the outpatient neurology clinic. J Neurol Sci, 2011. 306(1-2): p. 24-8.
17. Quinn, C., et al., Post-lumbar puncture headache is reduced with use of 
atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener, 
2013.
18. Owen, D.R., et al., An 18-kDa Translocator Protein (TSPO) polymorphism 
explains differences in binding affinity of the PET radioligand PBR28. J Cereb 
Blood Flow Metab, 2012. 32(1): p. 1-5.
19. Posner, K., et al., Columbia Classification Algorithm of Suicide Assessment (C-
CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry, 2007. 164(7): p. 1035-43.
20. Zetterberg, H., et al., Low incidence of post-lumbar puncture headache in 1,089 
consecutive memory clinic patients. Eur Neurol, 2010. 63(6): p. 326-30.
21. Beck, M., et al., Comparison of maximal voluntary isometric contraction and 
Drachman's hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve, 1999. 22(9): p. 1265-70.
22. Catana, C., et al., Toward implementing an MRI-based PET attenuation-
correction method for neurologic studies on the MR-PET brain prototype. Journal 
of nuclear medicine : official publication, Society of Nuclear Medicine, 2010. 51(9): p. 1431-8.
23. Catana, C., et al., MRI-assisted PET motion correction for neurologic studies in 
an integrated MR-PET scanner. Journal of nuclear medicine : official publication, 
Society of Nuclear Medicine, 2011. 52(1): p. 154-61.
24. Debruyne, J.C., et al., PET visualization of microglia in multiple sclerosis patients 
using [11C]PK11195. European journal of neurology : the official journal of the 
European Federation of Neurological Societies, 2003. 10(3): p. 257-64.
25. Watson, C.C., New, faster, image-based scatter correction for 3D PET. IEEE 
Transactions on Nuclear Science, 2000. 47(4): p. 1587-1594.
26. Brown, A.K., et al., Radiation dosimetry and biodistribution in monkey and man of 
11C-PBR28: a PET radioligand to image inflammation. Journal of nuclear 
medicine : official publication, Society of Nuclear Medicine, 2007. 48(12): p. 
2072-9.
27. Fischl, B., FreeSurfer. NeuroImage, 2012. 62(2): p. 774-81.
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 78 of 9013 APPENDICES
13.1 APPENDIX I: EL ESCORIAL WO RLD FEDERATION OF NEUROLOGY 
CRITERIA FOR THE DIAGNOSIS OF ALS
Information obtained from the web site: www.wfnals.org .
The diagnosis of Amyotrophic Late ral Sclerosis [ALS] requires: 
A - The presence of:
(A:1) evidence of lower motor neuron (LMN) dege neration by clinical, el ectrophysiological or 
neuropathologic examination, 
(A:2) evidence of upper motor neuron (UMN) de generation by clinical examination, and 
(A:3) progressive spread of symptoms or signs within a region or to other regions, as 
determined by history or examination, together with
B - The absence of:(B:1) electrophysiological and pathological evidence of other disease processes that might 
explain the signs of LMN and/or UMN degeneration, and 
(B:2) neuroimaging evidence of other disease processes that might explain the observed 
clinical and electrophysiological signs. 
CLINICAL STUDIES IN THE DIAGNOSIS OF ALS
A careful history, physical and neurological examination must search for clinical evidence of 
UMN and LMN signs in four regions [brainstem, cer vical, thoracic, or lumbosacral spinal cord] 
(see Table A1) of the central nervous system [CNS]. Ancillary tests should be reasonably 
applied, as clinically indicated, to exclude other disease processes. These should include 
electrodiagnostic, neurophysiological, neuroimaging  and clinical laboratory studies.  Clinical 
evidence of LMN and UMN degeneration is require d for the diagnosis of ALS.  The clinical 
diagnosis of ALS, without pathological confirma tion, may be categorized into various levels of 
certainty by clinical assessment alone depending on the presence of UMN and LMN signs together in the same topographical anatomic regi on in either the brainstem [bulbar cranial motor 
neurons], cervical, thoracic, or lumbosacral spinal  cord [anterior horn motor neurons]. The terms 
Clinical Definite ALS and Clinically Probable ALS are used to describe these categories of 
clinical diagnostic certainty on clinical criteria alone:
A. Clinically Definite ALS is defined on clinical evidence alone by the presence of UMN, as 
well as LMN signs, in three regions. 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 79 of 90B. Clinically Probable ALS is defined on clinical evidence alone by UMN and LMN signs in at 
least two regions with some UMN signs necessarily rostral to (above) the LMN signs.
C. Clinically Probable ALS - Laboratory-supported is defined when clinical signs of UMN and 
LMN dysfunction are in only one region, or when UMN signs alone are present in one region, 
and LMN signs defined by EMG criteria are present in at least two limbs, with proper application of neuroimaging and clinical laboratory protoc ols to exclude other causes.
D. Clinically Possible ALS is defined when clinical signs of UMN and LMN dysfunction are 
found together in only one region or UMN signs are found alone in two or more regions; or LMN signs are found rostral to UMN signs a nd the diagnosis of Clinically Probable -
Laboratory-supported ALS cannot be proven by evid ence on clinical grounds in conjunction with 
electrodiagnostic, neurophysiologic, neuroimaging or  clinical laboratory studies. Other diagnoses 
must have been excluded to accept a diagnosis of Clinically Possible ALS.
Table A1
Brainstem Cervical Thoracic Lumbosacral
Lower motor 
neuron signsweakness,atrophy,
fasciculations jaw, face, 
palate,tongue, larynx neck, arm, hand,
diaphragm back,
abdomen back, abdomen, 
leg, foot 
Upper motorneuron signs
pathologic spread 
of reflexes, clonus, etc. clonic jaw
gag reflex
exaggerated 
snout reflexpseudobulbar features
forced yawning
pathologic DTRs
spastic tone clonic DTRs 
Hoffman reflex
pathologic 
DTRsspastic tone
preserved reflex 
in weak wasted limb loss of 
superficial 
abdominal 
reflexespathologic DTRs
spastic tone clonic DTRs -
extensor plantar 
response
pathologic DTRsspastic tone
preserved reflex in 
weak wasted limb 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 80 of 9013.2 APPENDIX II: ALS FUNCTIONAL RATING SCALE โ REVISED (ALSFRS-R)
ALSFRS-R
QUESTIONS: SCORE:
1. Speech
4 = Normal speech processes
3 = Detectable speech disturbances2 = Intelligible with repeating
1 = Speech combined with nonvocal communication
0 = Loss of useful speech
2. Salivation
4 = Normal
3 = Slight but definite excess of saliva in mouth; may have nighttime drooling2 = Moderately excessive sali va; may have minimal drooling
1 = Marked excess of saliva with some drooling
0 = Marked drooling; requires constant tissue or handkerchief
3. Swallowing
4 = Normal eating habits
3 = Early eating problems โ occasional choking2 = Dietary consistency changes1 = Needs supplemental tube feeding
0 = NPO (exclusively parenteral or enteral feeding)
4. Handwriting
4 = Normal
3 = Slow or sloppy; all words are legible2 = Not all words are legible1 = No words are legible but can still grip a pen 
0 = Unable to grip pen
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 81 of 905a. Cutting Food and Handling Utensils (patients without gastrostomy)
4 = Normal3 = Somewhat slow and clumsy, but no help needed2 = Can cut most foods, although cl umsy and slow; some help needed
1 = Food must be cut by someone, but can still feed slowly
0 = Needs to be fed
5b. Cutting Food and Handling Utensils (alternate scale for patients with gastrostomy)
4 = Normal3 = Clumsy, but able to perform  all manipulati ons independently
2 = Some help needed with closures and fasteners
1 = Provides minimal assistance to caregivers
0 = Unable to perform any aspect of task
6. Dressing and Hygiene
4 = Normal function
3 = Independent, can complete self-care with effort or decreased efficiency2 = Intermittent assistan ce or substitute methods
1 = Needs attendant for self-care
0 = Total dependence
7. Turning in Bed and Adjusting Bed Clothes
4 = Normal function
3 = Somewhat slow and clumsy, but no help needed2 = Can turn alone, or adjust sheets, but with great difficulty
1 = Can initiate, but not turn or adjust sheets alone
0 = Helpless
8. Walking
4 = Normal
3 = Early ambulation difficulties2 = Walks with assistance
1 = Nonambulatory functional movement only
0 = No purposeful leg movement
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 82 of 909. Climbing Stairs
4 = Normal3 = Slow
2 = Mild unsteadiness or fatigue
1 = Needs assistance0 = Cannot do
R-1. Dyspnea
4 = None3 = Occurs when walking
2 = Occurs with one or more of the following: eating, bathing, dressing
1 = Occurs at rest, difficulty breathing when either sitting or lying0 = Significant difficulty, considerin g using mechanical respiratory support
R-2 Orthopnea
4 = None3 = Some difficulty sleeping at night due to shor tness of breath, does not routinely use more than 
two pillows
2 = Needs extra pillow in order to sleep (more than two)1 = Can only sleep sitting up0 = Unable to sleep without mechanical assistance
R-3 Respiratory Insufficiency
4 = None
3 = Intermittent use of BiPAP
2 = Continuous use of BiPAP during the night1 = Continuous use of BiPAP during the night and day0 = Invasive mechanical ventilation by intubation or tracheostomy
Evaluatorโs Initials: _____ _____ ______
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 83 of 9013.3 APPENDIX III: COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) 
BASELINE VERSION
Information obtained from: http://www.cssrs.columbia.edu/ SUICIDAL IDEATION 
Ask questions 1 and 2. If both are negative, proceed to โSuicidal Behaviorโ section. If the answer 
to question 2 is โyesโ, ask questions 3, 4 and 5. If the answer to question 1 and/or 2 is โyesโ, 
complete โIntensity of Ideationโ section below. Lifetime: 
Time 
He/She Felt 
Most 
Suicidal 
1. Wish to be Dead 
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up. 
Have you wished you were dead or wished you could go to sleep and not wake up? If yes, describe: Yes No 
ฦฦ
2. Non-Specific Active Suicidal Thoughts 
General, non-specific thoughts of wanting to end oneโs life/commit suicide (e.g., โIโve thought about killing myselfโ )
without thoughts of ways to kill oneself/associated methods, intent, or plan. 
Have you actually had any thoughts of killing yourself? If yes, describe: Yes No 
ฦฦ
3. Active Suicidal Ideation with Any Me thods (Not Plan) without Intent to Act 
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is different 
than a specific plan with time, place or method details worked out (e.g., thought of method to kill self but not a specific 
plan). Includes person who would say, โI thought about taking an overdose but I never made a specific plan as to when, 
where or how I would actually do itโฆand I would never go through with it.โ 
Have you been thinking about how you might do this? 
If yes, describe:Yes No 
ฦฦ
4. Active Suicidal Ideation with Some Intent to Act, without Specific Plan 
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as opposed to โI 
have the thoughts but I definitely will not do anything about them.โ 
Have you had these thoughts and had some intention of acting on them? 
If yes, describe: Yes No 
ฦฦ
5. Active Suicidal Ideation with Specific Plan and Intent 
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out. 
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? 
If yes, describe: Yes No 
ฦฦ
INTENSITY OF IDEATION 
The following features should be rated with respect to the most severe type of ideation (i.e., 1-5 from above, 
with 1 being the least severe and 5 being the most severe). Ask about time he/she was feeling the most 
suicidal. 
_____ _________________________________________________ 
Most Severe Ideation: 
Type # (1-5) Description o f Ideation Most 
Severe 
Frequency 
How many times have you had these thoughts? 
(1) Less than once a week (2) Once a week (3) 2-5 times in week (4) Daily or almost daily (5) Many times each day ____ 
Duration When you have the thoughts ,how long do they last? 
(1) Fleeting - few seconds or minutes (4) 4-8 hours/most of day 
(2) Less than 1 hour/some of the time (5) More than 8 hours/persistent or continuous 
(3) 1-4 hours/a lot of time ____ 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 84 of 90Controllability 
Could/can you stop thinking about killing yourself or wanting to die if you want to? 
(1) Easily able to control thoughts (4) Can control thoughts with a lot of difficulty 
(2) Can control thoughts with little difficulty (5) Unable to control thoughts (3) Can control thoughts with some difficulty (0) Does not attempt to control thoughts ____ 
Deterrents 
Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from 
wanting to die or acting on thoughts of committing suicide? 
(1) Deterrents definitely stopped you from attempting suicide (4) Deterrents most likely did not stop you 
(2) Deterrents probably stopped you (5) Deterrents definitely did not stop you 
(3) Uncertain that deterrents stopped you (0) Does not apply ____ 
Reasons for Ideation 
What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldnโt go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? 
(1) Completely to get attention, revenge or a reaction from others (4) Mostly to end or stop the pain (you couldnโt go 
on 
(2) Mostly to get attention, revenge or a reaction from others living with the pain or how you were feeling) (3) Equally to get attention, revenge or a reaction from others (5) Completely to end or stop the pain (you couldnโt go 
on 
and to end/stop the pain. living with the pain or how you were feeling) 
(0) Does not a pply ____ 
SUICIDAL BEHAVIOR 
(Check all that apply, so long as these are separate events; must ask about all types) Lifetime 
Actual Attempt: 
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought 
of as method to kill oneself. Intent does not have to be 100%. If there is any intent/desire to die associated with the act, 
then it can be considered an actual suicide attempt. There does not have to be any injury or harm , just the 
potential for injury or harm. If person pulls trigger while gun is in mouth but gun is broken so no injury results, this is 
considered an attempt. Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or 
circumstances. For example, a highly lethal act that is clearly not an accident so no other intent but suicide can be 
inferred (e.g., gunshot to head, jumping from window of a high floor/story). Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred. 
Have you made a suicide attempt? 
Have you done anything to harm yourself? Have you done anything dangerous where you could have died? 
What did you do? Did you______ as a way to end your life? Did you want to die (even a little) when you_____? Were you trying to end your life when you _____? Or did you think it was possible you could have died from_____? 
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve 
stress, feel better, get sympathy, or get something else to happen)? 
(Self-Injurious Behavior without suicidal 
intent) 
If yes, describe: 
Has sub ject en gaged in Non-Suicidal Self-In jurious Behavior? Yes No 
ฦฦ
Total # of 
Attempts 
______ 
Yes No 
ฦฦ
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 85 of 90Interrupted Attempt: 
When the person is interrupted (by an outside circumstance) from starting the potentially self-injurious act (if not for that, 
actual attempt would have occurred). Overdose: Person has pills in hand but is stopped from ingesting. Once they ingest any pills, this becomes an attempt 
rather than an interrupted attempt. Shooting: Person has gun pointed toward self, gun is taken away by someone else, or 
is somehow prevented from pulling trigger. Once they pull the trigger, even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grabbed and taken down from ledge. Hanging: Person has noose around neck but 
has not yet started to hang - is stopped from doing so. 
Has there been a time when you started to do something to end your life but someone or something 
stopped you before you actually did anything? 
If yes, describe: Yes No 
ฦฦ
Total # of 
interrupted 
______ 
Aborted Attempt: 
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have 
engaged in any self-destructive behavior. Examples are similar to interrupted attempts, except that the individual stops 
him/herself, instead of being stopped by something else. 
Has there been a time when you started to do something to try to end your life but you stopped 
yourself before you actually did anything? 
If yes, describe: Yes No 
ฦฦ
Total # of 
aborted 
______ 
Preparatory Acts or Behavior: 
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or 
thought, such as assembling a specific method (e.g., buying pills, purchasing a gun) or preparing for oneโs death by suicide (e.g., giving things away, writing a suicide note). 
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as 
collecting pills, getting a gun, giving valuables away or writing a suicide note )?
If yes, describe: Yes No 
ฦฦ
Suicidal Behavior: 
Suicidal behavior was present during the assessment period? Yes No 
ฦฦ
Answer for Actual Attempts Only Most 
Recent 
Attempt 
Date: Most 
Lethal 
Attempt 
Date: Initial/First 
Attempt 
Date: 
Actual Lethality/Medical Damage: 
0. No physical damage or very minor physical damage (e.g., surface scratches). 
1. Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains). 
2. Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat 
responsive; second-degree burns; bleeding of major vessel). 
3. Moderately severe physical damage; medical hospitalization and likely intensive care 
required (e.g., comatose with reflexes intact; third-degree burns less than 20% of body; 
extensive blood loss but can recover; major fractures). 
4. Severe physical damage; medical hospitalization with intensive care required (e.g., 
comatose without reflexes; third-degree burns over 20% of body; extensive blood loss 
with unstable vital signs; major damage to a vital area). 
5. Death Enter 
Code 
______ Enter 
Code 
______ Enter Code 
______ 
Potential Lethality: Only Answer if Actual Lethality=0 
Likely lethality of actual attempt if no medical damage (the following examples, while having 
no actual medical damage, had potential for very serious lethality: put gun in mouth and 
pulled the trigger but gun fails to fire so no medical damage; laying on train tracks with 
oncoming train but pulled away before run over). 
0 = Behavior not likely to result in injury 
1 = Behavior likely to result in injury but not likely to cause death 
2 = Behavior likely to result in death despite available medical care Enter 
Code 
______ Enter 
Code 
______ Enter Code 
______ 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 86 of 9013.4 APPENDIX IV: COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS) 
SINCE LAST VISIT VERSION
Information obtained from: http://www.cssrs.columbia.edu/
SUICIDAL IDEATION 
Ask questions 1 and 2. If both are negative, proceed to โSuicidal Behaviorโ section. If the answer to 
question 2 is โyesโ, ask questions 3, 4 and 5. If the answer to question 1 and/or 2 is โyesโ, complete 
โIntensity of Ideationโ section below.  Since 
Last 
Visit  
1. Wish to be Dead 
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up. 
Have you wished you were dead or wished you could go to sleep and not wake up?  
If yes, describe: Yes No 
ฦ     ฦ  
2. Non-Specific Active Suicidal Thoughts  
General, non-specific thoughts of wanting to end oneโs life/commit suicide (e.g., โIโve thought about killing myselfโ ) without 
thoughts of ways to kill oneself/associated methods, intent, or plan during the assessment period.  
Have you actually had any thoughts of killing yourself? If yes, describe: Yes No 
ฦ     ฦ 
3. Active Suicidal Ideation with Any Me thods (Not Plan) without Intent to Act 
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is different tha n a 
specific plan with time, place or method details worked out (e.g., thought of method to kill self but not a specific plan). Inc ludes 
person who would say, โI thought about taking an overdose but I never made a specific plan as to when, where or how I would 
actually do itโฆand I would never go through with it.โ  
Have you been thinking about how you might do this? 
If yes, describe: Yes No 
ฦ     ฦ 
4. Active Suicidal Ideation with Some Intent to Act, without Specific Plan  
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as opposed to โI have the 
thoughts but I definitely will not do anything about them.โ  
Have you had these thoughts and had some intention of acting on them? 
If yes, describe: Yes No 
ฦ     ฦ  
5. Active Suicidal Ideation with Specific Plan and Intent 
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out.  
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? If yes, describe: Yes No 
ฦ ฦ   
INTENSITY OF IDEATION 
The following features should be rated with respect to the most severe type of ideation (i.e., 1-5 from above, with 1 
being the least severe and 5 being the most severe).  
Most Severe Ideation: _____ _________________________________________________  
Type # (1-5) Description of Ideation  Most 
Severe  
Frequency 
How many times have you had these thoughts? 
(1) Less than once a week (2) Once a week (3) 2-5 times in week (4) Dail y or almost dail y (5) Man y times each da y  ____ 
Duration 
When you have the thoughts, how long do they last?  
(1) Fleeting - few seconds or minutes (4) 4-8 hours/most of day  
(2) Less than 1 hour/some of the time (5) More than 8 hours/persistent or continuous  
(3) 1-4 hours/a lot of time  ____ 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 87 of 90Controllability 
Could/can you stop thinking about killing yourself or wanting to die if you want to?  
(1) Easily able to control thoughts (4) Can control thoughts with a lot of difficulty  
(2) Can control thoughts with little difficulty (5) Unable to control thoughts  
(3)Can control thou ghts with some difficult y (0) Does not attem pt to control thou ghts  ____ 
Deterrents 
Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting 
to die or acting on thoughts of committing suicide?  
(1) Deterrents definitely stopped you from attempting suicide (4) Deterrents most likely did not stop you 
(2) Deterrents probably stopped you (5) Deterrents definitely did not stop you  
(3) Uncertain that deterrents sto pped you (0) Does not a pply  ____ 
Reasons for Ideation 
What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the 
pain or stop the way you were feeling (in other words you couldnโt go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both?  
(1) Completely to get attention, revenge or a reaction from others (4) Mostly to end or stop the pain (you couldnโt go on  
(2) Mostly to get attention, revenge or a reaction from others living with the pain or how you were feeling)  
(3) Equally to get attention, revenge or a reaction from others (5) Completely to end or stop the pain (you couldnโt go on  
and to end/stop the pain living with the pain or how you were feeling)  
(0) Does not a pply  ____ 
SUICIDAL BEHAVIOR 
(Check all that a pply, so lon g as these are se parate events; must ask about all t ypes) Since Last 
Visit 
Actual Attempt: 
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as 
method to kill oneself. Intent does not have to be 100%. If there is any intent/desire to die associated with the act, then it can be 
considered an actual suicide attempt. There does not have to be any injury or harm , just the potential for injury or 
harm. If person pulls trigger while gun is in mouth but gun is broken so no injury results, this is considered an attempt.  
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumsta nces. 
For example, a highly lethal act that is clearly not an accident so no other intent but suicide can be inferred (e.g., gunshot to head, 
jumping from window of a high floor/story). Also, if someone denies intent to die, but they thought that what they did could be  
lethal, intent may be inferred.  
Have you made a suicide attempt? 
Have you done anything to harm yourself?  
Have you done anything dangerous where you could have died? What did you do? Did you______ as a way to end your life? Did you want to die (even a little) when you_____? Were you trying to end your life when you _____? Or did you think it was possible you could have died from_____?  
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, 
feel better, get sympathy, or get something else to happen)? 
(Self-Injurious Behavior without suicidal intent)  
If yes, describe: 
Has subject engaged in Non-Suicidal Self-Injurious Behavior?  Yes No 
ฦฦ
Total # of 
Attempts 
______  
Yes No 
ฦฦ
Interrupted Attempt: 
When the person is interrupted (by an outside circumstance) from starting the potentially self-injurious act (if not for that, actual 
attempt would have occurred).  
Overdose: Person has pills in hand but is stopped from ingesting. Once they ingest any pills, this becomes an attempt rather th an 
an interrupted attempt. Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow 
prevented from pulling trigger. Once they pull the trigger, even if the gun fails to fire, it is an attempt. Jumping: Person is  poised 
to jump, is grabbed and taken down from ledge. Hanging: Person has noose around neck but has not yet started to hang - is stopped from doing so.  
Has there been a time when you started to do something to end your life but someone or something 
stopped you before you actually did anything?  
If yes, describe: Yes No 
ฦฦ
Total # of 
interrupted  
______  
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 88 of 90Aborted Attempt: 
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in 
any self-destructive behavior. Examples are similar to interrupted attempts, except that the individual stops him/herself, inst ead 
of being stopped by something else.  
Has there been a time when you started to do something to try to end your life but you stopped 
yourself before you actually did anything?  
If yes, describe: Yes No 
ฦฦ
Total # of 
aborted 
______  
Preparatory Acts or Behavior: 
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought,
such as assembling a specific method (e.g., buying pills, purchasing a gun) or preparing for oneโs death by suicide (e.g., givi ng 
things away, writing a suicide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as 
collecting pills, getting a gun, giving valuables away or writing a suicide note )? 
If yes, describe: Yes No 
ฦฦ
Suicidal Behavior: 
Suicidal behavior was present during the assessment period?  Yes No 
ฦฦ
Suicide: Yes No 
ฦฦ
Answer for Actual Attempts Only Most Lethal 
Attempt Date: 
Actual Lethality/Medical Damage: 
0. No physical damage or very minor physical damage (e.g., surface scratches).  
1. Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains).  
2. Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree burns; bleeding of major vessel).  
3. Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes 
intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major fractures).  
4. Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third-degree 
burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area).  
5. Death Enter Code  
______ 
Potential Lethality: Only An swer if Actual Lethality=0 
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had 
potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; layin g on 
train tracks with oncoming train but pulled away before run over).  
0 = Behavior not likely to result in injury  
1 = Behavior likely to result in injury but not likely to cause death 
2 = Behavior likely to result in death despite available medical care Enter Code  
______ 
Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 89 of 9013.6 APPENDIX V: SAFETY REPORTING FAX COVER SHEET
SAFETY REPORTING FAX COVER SHEET
Investigator Sponsored Trials
SAE FAX No: (650) 225-4682
Alternate Fax No: (650) 225-4683
Study Number
(Genentech study number)
Principal Investigator
Site Name
Reporter name
Reporter Telephone #
Reporter Fax #
Initial Report Date(DD/MON/YYYY)____ / _____ /_____
Follow-up Report Date
(DD/MON/YYYY)____ / _____ /_____

Tocilizumab in ALS
Version 8.0
Version date 05/30/2017
Page 90 of 90Subject Initials
(Please enter a dash if the patient has no middle name)____ - ____ -____
PLEASE PLACE MEDWATCH REPORT or IN D SAFETY REPORT BEHIND THIS COVER 
SHEET
Please contact Genentech Safety for any ques tions regarding SAE or IND Safety reporting 
at (888) 835-2555
Page 1 of ___
Cover Page โ Statistical Analysis Plan  
 
 
 
 
 
Study Official Title: A Phase 2 Randomized, Placebo-
Controlled Trial of Tocilizu mab in Amyotrophic Lateral 
Sclerosis (ALS)
 
 
NCT #: [STUDY_ID_REMOVED] 
 
Version Date of the Document: May 30, 2017  
 
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 1 of 20 
 STATISTICAL ANALYSIS PLAN (SAP)
Title A Phase 2 Randomized, Placebo-Controlled Trial of
Tocilizumab in Amyotrophic Lateral Sclerosis (ALS)
Regulatory Sponsor Shafeeq Ladha, MD
Current Protocol Version 8.0
Current Protocol Date 30 May 2017
Statistical Analysis Plan
Version1.0
Statistical Analysis Plan
Date01 Mar 2019
SAP APPROVAL SIGNATURES
Shafeeq Ladha, MD
Principle Investigator and SponsorDate
Eric A. Macklin, PhD
Study BiostatisticianDateEric A. Macklin  Digitally signed by Eric A. Macklin  
DN: cn=Eric A. Macklin, o=Massachusetts General Hospital, ou=MGH  
Biostatistics Center, email=emacklin@mgh.harvard.edu, c=US  
Date: 2019.03.14 23:14:34 -04'00'  
3/11/2019
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 2 of 20 
 SAP REVISION HISTORY
Version Date Description of Changes
1.0 01Mar2019 Initial version
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 3 of 20 
 Table of Contents
1. Introduction................................................................................................................. .......... 5
2. Study Design .................................................................................................................. ........ 5
2.1 Overview.................................................................................................................... ..... 5
2.2 Study Objectives ............................................................................................................. 5
2.3 Study Populations............................................................................................................ 5
2.4 Participant Flow and Site Approval ................................................................................ 62.5 Treatment Al location....................................................................................................... 6
2.6 Treatment Administration ............................................................................................... 62.7 Allocation Concealment.................................................................................................. 62.8 Schedule of Assessments ................................................................................................ 7
3. General Statistical Considerations....................................................................................... 8
3.1 Statistical Software......................................................................................................... .8
3.2 Summary Statistics.......................................................................................................... 83.3 Precision................................................................................................................... ....... 8
4. Analysis Samples .............................................................................................................. ..... 8
5. Study Endpoints ............................................................................................................... ..... 8
5.1 Safety Endpoints ............................................................................................................. 8
5.2 Tolerability Endpoint ...................................................................................................... 95.3 Efficacy Endpoints.......................................................................................................... 95.4 Effect Modi fiers ............................................................................................................ 1 0
6. Measurement De finitions.................................................................................................... 10
6.1 Target Engageme nt Measures ....................................................................................... 10
6.1.1 Expression of pro-inflammatory genes in PBMCs.................................................... 106.1.2 Concentration of CRP by R&D Systems ELISA ...................................................... 116.1.3 Concentration of pro-inflammatory cytokines by MSD V-PLEX............................. 126.1.4 Concentration of sIL-6R, IL-6, and gp130 by R&D Systems ELISA....................... 13
6.1.5 IL6R genotyping for Asp358Ala polymorphism....................................................... 13
6.1.6 Brain glial activation measured by [
11C]-PBR28 PET .............................................. 14
6.2 Clinical Progression Measures...................................................................................... 14
6.2.1 ALSFRS-R................................................................................................................ 146.2.2 SVC....................................................................................................................... .... 14
6.2.3 Handheld dynamometry............................................................................................ 146.2.4 Grip strength ............................................................................................................. 1 5
7. Power Calc ulations........................................................................................................... ... 15
8. Participant Characterization.............................................................................................. 16
8.1 Baseline Char acteristics ................................................................................................ 16
8.2 Participant Disposition .................................................................................................. 16
9. Statistical Analyses.......................................................................................................... .... 16
9.1 Safety M easures ............................................................................................................ 16
9.1.1 Mortality ................................................................................................................. .. 16
9.1.2 Treatment-emergen t Adverse Events ........................................................................ 16
9.1.3 Suicidality ............................................................................................................... .. 17
9.1.4 Safety Labs................................................................................................................ 17
9.1.5 Anthropometrics and Vital Signs .............................................................................. 17
9.2 Study Drug Tolerance ................................................................................................... 179.3 Target Engageme nt Measures ....................................................................................... 17
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 4 of 20 
 9.3.1 Primary Analysis....................................................................................................... 17
9.3.2 Secondary Analysis................................................................................................... 189.3.3 Subgroup Analyses.................................................................................................... 18
9.4 Efficacy M easures......................................................................................................... 19
9.4.1 Primary Analysis....................................................................................................... 199.4.2 Secondary Analysis................................................................................................... 19
9.5 Additional Considerations............................................................................................. 19
9.5.1 Multiplicity Adjustments .......................................................................................... 199.5.2 Missing Data ............................................................................................................. 19
10. References.................................................................................................................. ...... 20
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 5 of 20 
 1. Introduction
This statistical analysis plan (SAP) defines the outcome measures and analysis samples and
specifies the planned analyses of data from Dr. Shafeeq Ladha's Tocilizumab trial. The SAPsupplements the clinical protocol. Please refer to the clinical protocol for details on the rationalefor the intervention, eligibility criteria, conduct of the trial, clinical assessments and the timing oftheir use in the trial, definitions and reporting of adverse events, data management conventions,and regulatory oversight and compliance procedures. In case of discrepancies between the SAPand the clinical protocol concerning matters of d ata analysis, the SAP is authoritative. On all
other matters, the clinical protocol is authoritative.
2. Study Design
2.1 Overview
This is a multicenter, double-blind, placebo-controlled, two-arm, parallel-group, phase 2
randomized controlled trial to examine the safety and tolerability of tocilizumab in sporadic ALSpatients. Trial participation includes a screening visit, randomization to 8 mg/kg tocilizumab orplacebo administered every 4 weeks by intravenous infusions, 8 weeks of follow-up on studydrug, and 4 weeks of follow-up after last dose of stu dy drug. A subset of participants receive pre-
and post-treatment MR-PET scanning to measure glial activation. The trial is registered atClinicaltrials.gov as study [STUDY_ID_REMOVED] (see https: //clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]).
2.2 Study Objectives
The primary objective of the trial is to determine whether 8 mg/kg tocilizumab administered
every 4 weeks by intravenous infusions for 8 weeks is safe and tolerable. Safety will be assessedby the occurrence of severe adverse events (SAEs), rates of adverse events (AEs) classified toMedDRA system organ class and preferred term, frequency of clinically significant abnormal
laboratory tests, and changes in vital signs. Tolerability will be assessed by the proportion ofparticipants who complete all three infusions and remain on study and free from any possibly ordefinitely drug-related and dose-limiting AEs to the week 16 visit.
Secondary objectives include assessing the ability of tocilizumab to reduce the expression of pro-
inflammatory genes in peripheral blood mononuclear cells (PBMCs), to reduce concentrations of
pro-inflammatory cytokines in plasma and cerebrospinal fluid (CSF), to reduce concentration ofsoluble IL-6 receptor (sIL-6R) in the CSF, to reduce glial activation measured by [
11C]-PBR28
PET, and to slow progression of clinical measures of function and strength. The trial also aims totest whether the Asp358Ala polymorphism of the IL6R gene (SNP rs2228145) modifies effects
of tocilizumab on expression of pro-inflammatory genes in PBMCs and cytokine and C-reactiveprotein (CRP) levels in the plasma and CSF.
2.3 Study Populations
Individuals eligible for trial participation as an ALS participant are men or women age 18 to 75
years who meet the El Escorial criteria of possible, laboratory-supported probable, probable, ordefinite criteria for a diagnosis of ALS, have either a 3-fold up-regulation of IL-6 geneexpression or a 2-fold up-regulation of both IL-6 and either IL-8 or MMP1 in PBMCs relative toa pooled healthy control sample, have a slow v ital capacity (SVC) at least 40% of that expected
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 6 of 20 
 based on age, sex, and height, and are free of conditions that contraindicate use of tocilizumab.
Detailed inclusion and exclusion criteria are specified in the clinical protocol.
Participants will be recruited from approximately 5 clinical sites in the Northeast ALS (NEALS)
Consortium located across the US.
2.4 Participant Flow and Site Approval
After a site receives local IRB approval and is activated, site staff may recruit participants.
Individuals with sporadic ALS must provide written informed consent to initiate screening. Afterbeing determined eligible, approximately 24 ALS p articipants will be randomized to receive 8
mg/kg tocilizumab or placebo in a 2:1 ratio, stratified by clinical site. The first dose of studydrug is administered by intravenous infusion at the baseline visit. If tolerant, participants receivetwo additional study drug infusions at 4-week interv als over 8 weeks. After baseline, participants
complete in-clinic evaluations at weeks 4, 8, 12, and 16. Participants are contacted by telephone
24 to 48 hours after the lumbar punctures (LPs) at baseline and week 8 to assess for AEs.Participants who discontinue study drug should remain on study following the normal scheduleof assessments. Patients withdrawing consent are asked to delay withdrawing consent until afterthey return for a final safety visit and after a final telephone call scheduled 28 days after their lastdose of study drug.
Detailed descriptions of study procedures and timing are specified in the clinical protocol.
2.5 Treatment Allocation
Prior to the baseline visit, eligible ALS parti cipants are randomly allocated to receive 8 mg/kg
tocilizumab or placebo in a 2:1 ratio according t o a permuted-block ra ndomization schedule,
stratified by site. The randomization schedule  was prepared by computer program by the
unblinded study statistician.
2.6 Treatment Administration
Study drug will be administered as a 100 mL intravenous infusion over 60 min. An unblinded
research pharmacist at each site will prepare study drug infusion bags. Tocilizumab will bemixed in 0.9% sodium chloride solution at 8 mg/kg, up to a maximum 800 mg. Placeboparticipants will receive 0.9% sodium chloride solution.
2.7 Allocation Concealment
The randomization schedule is known only by the unblinded study statistician who generated the
schedule and by unblinded research pharmacists at each site. Concealment of the true treatmentallocation of specific participants is facilita ted by the equivalent appearance of infusion bags
containing tocilizumab (active arm) and those containing only saline (placebo arm). Plasma andCSF sIL-6R levels will be determined by a central lab not otherwise involved in the trial and sentonly to the unblinded statistician prior to locking the trial database. Although no otherbiomarkers are expected to be unblinding, levels of CRP and pro-inflammatory cytokines inplasma and CSF will be handled similarly. Clinical members of the Steering Committee, siteinvestigators and other site staff, clinical coordi nation and data management staff, the medical
monitor, and all participants are blinded to participant treatment allocations. The Data and SafetyMonitoring Board (DSMB) members are provided treatment-specific information in order to
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 7 of 20 
 monitor the trial but such information is masked by use of coded values to identify the treatment
groups. The DSMB may request the true treatment identities.
2.8 Schedule of Assessments
ActivityScreening
Visit1Baseline
VisitWeek 4 Week 8 Week 12 Week 16
Visit 1 Visit 2 Visit 3 EOS Visit
Written Informed Consent X      
Inclusion/ExclusionReview X X     
Medical History X      
Demographics X      
ALS Diagnosis History X      
Physical Examination X     X
Neurological Exam X     X
Columbia Suicide Severity Rating Scale (C-SSRS)  XXXXX
Vital Signs2including Height3a n d W e i g h t XXXXXX
Lumbar Puncture (LP)  X4  X4   
ALSFRS-R  XXXXX
S l o w V i t a l C a p a c i t y ( S V C ) XXXXXX
Hand Held Dynamometry (HHD) and Grip Strength  X  X  X
Electrocardiogram (12-Lead ECG) X      
PA and Lateral Chest X-Ray X      
Quantiferon or T-SPOT TB Blood Test X      
Safety Labs5XXXXXX
PBMC Collection X X6 XXXX
Plasma Biomarker Collection  XXXXX
Blood Collection for IL-6R genotype, Genentech sample  X     
C o n c o m i t a n t M e d i c a t i o n R e v i e w XXXXXX
Adverse Event Review7XXXXXX
Randomization8 X     
Administer Study Drug  XXX   
Exit Questionnaire      X
[11C]-PBR28 PET  X9  X10   
MRI Safety Questionnaire X X  X   
Upper Motor Neuron Burden Scale X X  X   
Blood draw for TSPO X11      
1Screening procedures must be completed within 28 days prior to Baseline Visit.
2Vital signs include systolic and diastolic pressure in mmHg, respiratory rate/minute, heart rate/minute and
temperature.
3Height measured at Screening Visit only.
4Telephone call will be made 24-48 hours post lumbar puncture (LP) to assess for adverse events (AEs) related to
the LP. Baseline LP occurs prior to the first infusion. Week 8 LP should occur 2.5 to 3.5 hours post-infusion.
5Safety labs include hematology (CBC with differential), chemistry panel, hepatitis B panel, urinalysis. For women
of child-bearing potential, pregnancy will be tested by serum hCG at the Screening Visit and by urine pregnancy test
at each subsequent visit.
6Collection at Baseline to occur prior to infusion
7Adverse events that occur after signing the informed consent form will be recorded.
8Randomization should occur immediately prior to the Baseline Visit.
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 8 of 20 
 9Pre-dose [11C]-PBR28 PET will be performed one time only at the Baseline visits. ( -2W e e k s )
10Post-dose [11C]-PBR28 PET will be performed one time only at the Week 8 visit ( -2 Weeks).
11Blood draw for TSPO affinity testing to occur at the Screening visit, if not previously determined.
3. General Statistical Considerations
3.1 Statistical Software
All statistical analyses will be performed us ing SAS (SAS Institute, NC, USA) or R (R
Foundation for Statistical Computing, Vienna, Austria).
3.2 Summary Statistics
Data will be summarized with respect to disposition, demographics, pre-treatment
characteristics, safety outcomes, tolerability, and efficacy outcomes. Summary statistics forcontinuous variables will include the number of subjects, the mean, median, standard deviation,
and range. For categorical data, summaries will include counts and percentages.
3.3 Precision
Results will generally be reported to 3 significant f igures. Percentages will generally be reported
to 0.1 percentage points. P-values will be repor ted to two digits when greater than or equal to
0.095, to three digits when greater than or equal to 0.00095 and less than 0.095, and as <0.001for all smaller values.
4. Analysis Samples
The following analysis samples will be used for testing safety, tolerability, and efficacy
endpoints:
xSafety and Tolerability (ST) Sample: Participants who are eligible, randomized, and initiateat least the first infusion of study drug, classified according to the actual treatment received.Observations made after premature permanent discontinuation of study drug are included inthis sample, should such participants remain on study.
xEfficacy As-treated (AT) Sample: Participants who are eligible, randomized, and initiate atleast the first infusion of study drug, classified according to the actual treatment received.Observations made after premature permanent discontinuation of study drug are included inthis sample, should such participants remain on study.
xEfficacy Modified Intent-to-treat (mITT) Sample: Participants who are eligible, randomized,and initiate at least the first infusion of study drug, classified according to their randomizedtreatment assignment. Observations made after premature permanent discontinuation of study
drug are included in this sample, s hould such participants remain on study.
5. Study Endpoints
5.1 Safety Endpoints
The following safety endpoints will be evaluated:
xTime to mortality
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 9 of 20 
 xTime to first treatment-emergent SAE
xProportion of participants experiencing and number of unique events of each type of
treatment-emergent adverse event (TEAE) and serious TEAE classified by MedDRA systemorgan class and preferred term
xProportion of participants experiencing and n umber of unique events of TEAEs classified by
seriousness, severity, relatedness to study drug, action taken with study drug, and outcome,summarized across all MedDRA terms
xProportion of participants experiencing and number of unique events of each type of
treatment-emergent adverse event (TEAE) and serious TEAE classified by MedDRA systemorgan class and preferred term
xInstances of treatment-emergent laboratory abnor malities judged to be clinically significant
by assay
xMean change from baseline and percent change from baseline in weight, systolic blood
pressure, and diastolic blood pressure
xProportion of participants reporting any treatment-emergent suicidal ideation
xMaximum post-baseline suicidal ideation planning, frequency, duration, controllability,
deterrents, and reasons
xProportion of participants reporting any post-baseline suicidal behavior, actual attempts, non-
suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or
behaviors, or completed suicide
xMaximum post-baseline suicidal behavior lethality and potential lethality
Reported proportions will use as their denominator all participants in the ST sample.
5.2 Tolerability Endpoint
Participants will be judged tolerant of study drug if they complete all three infusions and remain
on study and free from any possibly or definitely drug-related and dose-limiting AEs to the week16 visit. Tolerability will be summarized as the proportion of participants in a treatment group
who are tolerant of study drug. Reported proportions will use as their denominator allparticipants in the ST sample.
5.3 Efficacy Endpoints
Secondary efficacy endpoints include measur es of target engagement and measures of clinical
progression. Assessments of target engagement will focus on changes from baseline to the week12 visit, the end of the study drug exposure interval. Assessments of possible effects on clinicalprogression will focus on mean rates of change over the 16-week follow-up interval.
Target engagement measures:
xproportion of participants who experience a 2-fol d or greater decline between baseline and
the average of all follow-up assessments in relative expression of at least 2 of the following 3pro-inflammatory genes measured in PBMCs: IL-6, IL-8, and MMP1 (primary targetengagement measure)
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 10 of 20 
 xrelative expression levels of the following pro-inflammatory gene s in PBMCs by Applied
Biosystems quantitative polymerase chain reaction (qPCR): IL-6, IL-8, and MMP1
xconcentrations of CRP in plasma and CSF by R&D Systems enzyme-linked immunosorbent
assay (ELISA)
xconcentrations of the following pro-infla mmatory cytokines in plasma and CSF by Meso
Scale Discovery (MSD) V-PLEX multiplexed sandwich immunoassay: IL- ศIL-6, IL-8, IL-
17A/F, and TNF- ฤฎ
xconcentrations of the following analytes in plasma and CSF by R&D Systems sandwich
ELISA: sIL-6R, IL-6, and gp130
xbrain glial activation measured by [11C]-PBR28 PET
Clinical progression measures:
xALS Functional Rating Scale-Revised (ALSFRS-R) total score
xSlow vital capacity (SVC) as percent of predicted normal volume
xHandheld dynamometry (HHD) of the following maneuvers: left and right shoulder flexion,
left and right elbow flexion and extension, left and right wrist extension, left and right first
dorsal interosseous, left and right hip flexion, left and right knee flexion and extension, andleft and right ankle dorsiflexion
xGrip strength of left and right hands
5.4 Effect Modifiers
IL6R genotype for the Asp358Ala polymorphism (SNP rs2228145, A > C) will be investigated
as a potential modifier of tocilizumab target engagement. IL6R genotype will be analyzed using
an additive model for penetrance, with particip ants carrying more copies of the C allele expected
to have higher sIL-6R levels and greater sensitivity to treatment with tocilizumab.
6. Measurement Definitions
6.1 Target Engagement Measures
6.1.1 Expression of pro-inflammatory genes in PBMCsPBMCs will be separated from whole blood using BD Vacutainer Cell Preparation Tubes (CPT
Sodium Citrate tubes, catalog #362761). Sites will ship CPT tubes on ice to Dr. Robert Bowserโslaboratory at Barrow Neurological Institute (BNI) for analysis on the day collected. PBMCs beisolated and frozen -80ยฐC. RNA will be extracted from isolated PBMCs using a Qiagen RNeasyextraction kit (catalog #74106) using the manufacturerโs protocol.
Expression levels of RNA for three pro-inflammatory genes (IL-6, IL-8, and MMP1) and one
reference gene (GAPDH) will be estimated by quantitative real-time polymerase chain reaction(qPCR). The analysis will use an Applied Biosystems Quantstudio 6 qPCR system, ThermoFisher TaqMan Gene Expression Assay system rev erse transcription reagent and amplification
solution (catalog #4331182) and TaqMan Fast Advanced Master Mix (catalog # 4444556). Theprimer and probe set used for each gene are as follows (Thermo Fisher catalog #4453320):
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 11 of 20 
 Gene Primer and Probe Set
IL-6 Assay ID Hs00985639_m1
IL-8 Assay ID Hs00174103_m1MMP1 Assay ID Hs00899658_m1
GAPDH Assay ID Hs99999905_m1
Each run of study samples will include RNA from pooled PBMCs from healthy controls for
reference. Each study sample and the pooled contro l sample will be run in triplicate on each
plate. A No Template control reaction will also be included in each run where nuclease-freewater replaces the cDNA template. Complementary DNA (cDNA) templates will be synthesizedfor each sample from 0.5 ศg of total RNA using a Thermo Fisher High-Capacity RNA-to-cDNA
Kit (catalog #4387406).
For each qPCR run, the reaction set up and volume for each well of a 96-well plate will include:
Component Volume
2X TaqMan Fast Advanced Master Mix 10 ศL
20X TaqMan Gene Expression Assay 1 ศ/
Nuclease-free water 7 ศ/
cDNA template from each sample 2 ศ/
The TaqMan Fast qPCR protocol specifications will be:
A quantification cycle (C
q) value will be obtained from each well to determine relative
expression using standard วปวปCt, log2-fold change calculations. Specifically, replicate C qvalues
will be averaged for each gene, and the difference of each pro-inflammatory gene mean C qfrom
the reference gene mean C qwill be calculated separately for study samples and the pooled
control sample วปCq). The negative difference of differences (- วปวปCq) calculated as the pooled
controlวปCqminus the sample วปCq, the log-base 2 of the fold-change between study and control
samples, will be the measure of gene expression used for analysis. Higher values indicate greater
relative expression of pro-inflammatory genes.
6.1.2 Concentration of CRP by R&D Systems ELISA
Plasma and CSF samples will be frozen and stored at sites at -70ยฐC or colder prior to being
shipped to Dr. Robert Bowserโs laboratory at BNI  for analysis. At the end of the study, all
samples will be assayed as a single batch. Measurement of CRP will be performed using theR&D Systems Human C-Reactive Protein DuoSet ELISA kit (catalog #DY1707) following theqPCR Step Temp Time
Incubation with uracil-N-glycosylase
Polymerase activation
PCR denaturation
PCR annealing and extension50ยฐC
95ยฐC95ยฐC60ยฐC120 s
20 s
1 s
20 s
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 12 of 20 
 manufacturerโs instructions. Briefly, plasma will be diluted 1:200 in Tris-buffered saline (TBS).
CSF will be diluted 1:100 in TBS. Diluted samples will be incubated in the 96-well platepreviously coated with 2.0 ฮผg/mL capture antibody for 1.5 hrs. After washes, 100 ฮผLo f9 0
ng/mL detection antibody will be added per wel l for 1.5 hrs, wells washed, streptavidin-HRP
added for 20 min, and tetramethylbenzidine reaction product generated for 15 min. Standard
curves will be generated using purified CRP pr otein in the following dilution series:
Specimen Standard concentration sequence (ng/mL)
Plasma 25, 8.33, 2.78, 0.926, 0.309, 0.103, 0.034,0
CSF 1.0, 0.5, 0.25, 0.125, 0.063, 0.031, 0.016, 0
The geometric mean of replicate concentration estimates will be used for analysis.
Concentrations of CRP in plasma and CSF will be reported as ศJP/ and ng/mL, respectively.
6.1.3 Concentration of pro-inflammatory cytokines by MSD V-PLEXPlasma and CSF samples will be frozen and stored at sites at -70ยฐC or colder prior to being
shipped to Dr. Robert Bowserโs laboratory at BNI  for analysis. At the end of the study, all
samples will be assayed as a single batch. The concentration of the following cytokines will beassayed: IL- ศIL-6, IL-8, IL-17A/F, and TNF- ฤฎ. Measurements for IL- ศIL-6, IL-8, and
TNF-ฤฎZLOO be performed using an MSD V-PLEX Proinflammatory kit (catalog #K15053).
Measurements for IL-17 will be performed using an MSD V-PLEX IL-17A/F kit (catalog #K151WN). Plasma samples will be diluted 1:2. CSF samples will be used undiluted. A totalsample volume of 50 ฮผl will be assayed per well. Samples will be analyzed in duplicate.
Standard curves will be generated using the following concentrations for each pure protein:
Cytokine Standard concentration sequence (pg/mL)
IL-ศ 576, 144, 36, 9, 2.25, 0.563, 0.141, 0
IL-6 764, 191, 47.8, 11.9, 2.98, 0.746, 0.187, 0
IL-8 621, 155, 38.8, 9.7, 2.43, 0.606, 0.152, 0IL-17 5430, 1360, 339, 84.8, 21.2, 5.3, 1.33, 0TNF-ฤฎ 369, 92.3, 23.1, 5.77, 1.44, 0.36, 0.0901, 0
Lower limit of detection (LLOD) ranges and lower limits of quantitation (LLOQ) are the
following:
Cytokine LLOD
(pg/mL)LLOQ
(pg/mL)
IL-ศ 0.01-0.17 0.646
IL-6 0.05-0.09 0.633IL-8 0.03-0.14 0.591
IL-17 0.930 7.57
TNF-ฤฎ 0.01-0.13 0.690
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 13 of 20 
 The geometric mean of replicate concentration estimates will be used for analysis.
Concentrations will be reported as pg/mL.
6.1.4 Concentration of sIL-6R, IL-6, and gp130 by R&D Systems ELISAPlasma and CSF samples will be frozen and stored at sites at -70ยฐC or colder prior to being
shipped to BNI, inventoried, and sent to Dr. Carolanne Milligan's laboratory at Wake ForestSchool of Medicine for analysis. At the end of the study, all samples will be assayed as a singlebatch. The concentrations of the following proteins will be assayed by R&D Systems sandwichELISA: sIL-6R, IL-6, and gp130.
Protein Assay Control(s)
sIL-6R Catalog #DR600
lot #P185493 (first six plates)
lot #P191955 (last two plates)
IL-6 Catalog #Q6000B
lot #P186912
gp130 Catalog #DGP00
lot #P161984Catalog #QC05
lot #1279937 (low control)
lot #1279938 (medium control)lot #1279939 (high control)
Catalog #QC193
lot #732-180404
Catalog #QC23
lot #P180985
All samples, controls, and standards will be run in triplicate following kit instructions. For sIL-
6R, plasma samples will be diluted 1:100 or more as needed and CSF sample will be assayedundiluted. For IL-6, all plasma and CSF samples will be assayed undiluted. For gp130, plasmasamples will be diluted 1:100 and CSF sample wi ll be diluted 1:9. The following standard
concentration series will be used for IL-6: 0, 0.75, 1.5, 3, 6, 12, and 30 pg/mL.
For sIL-6R and gp130, plates will be read five minutes after the stop solution is added on a
BioTek Epoch plate reader (BioTek Instruments , Winooski, VT) set to 450 nm, with wavelength
correction at 570 nm. For IL-6, relative light units (RLUs) will be determined using a Victor 3plate reader (PerkinElmer Life Science, Boston, MA) with the luminometer set for a lag time of1.0 sec and a read time for wells of 0.5 sec.
If the three replicates have a coefficient of variat ion (CV) greater than 15%, the most disparate
value will be eliminated, and the average of the remaining two wells will be used. If the CV isstill above 15% after removing any outlier, then the sample will be re-run.
Concentrations will be estimated from OD values fit to a four-parameter logistic curve for sIL-
6R and gp130 assays and from RLU values fit to a quadratic curve for IL-6 assay using PRISMsoftware (GraphPad Software, San Diego, CA). The mean of replicate concentration estimateswill be used for analysis.
6.1.5 IL6R genotyping for Asp358Ala polymorphism
Blood for determining IL6R genotype will be frozen and stored at sites at -70ยฐC or colder prior to
being shipped to BNI, inventoried, and sent to Dr. Carolanne Milligan's laboratory at WakeForest School of Medicine for analysis. At the end of the study, all samples will be assayed as asingle batch.
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 14 of 20 
 DNA will be purified from whole blood using Qiagen chemistry on the Gentra AutoPure
platform. Absorption ratio at 260/280 nm will be used to determine DNA concentration andpurity. A 9 ng sample of DNA will be genotyped according to manufacturerโs instructions usinga commercially available and validated Applied Biosystems TaqMan SNP genotyping assay(catalog # 4351379) for the IL6R Asp358Ala polymorphism (SNP rs2228145 A>C, assay ID
C    16170664_10, lot #P160407-000 C10). The genotype at that locus will be read using anallelic discrimination protocol on an Applied Biosystems qPCR (model 7300, Foster City, CA).Each gene expression plate will be run with three control samples that had been fully sequencedand are known to carry one of the three genotypes, and three no-template controls.
Each participant will be scored for the IL6R Asp358Ala polymorphism as the count of the minor
C allele, with CC homozygous participants expected to be more sensitive to treatment withtocilizumab.
6.1.6 Brain glial activation measured by [
11C]-PBR28 PET
Glial activation will be estimated in a subset of participants by magnetic resonance positron
emission tomography (MR-PET) using the [11C]-PBR28 ligand. The subset excludes individuals
homozygous for the T/T allele of the Ala147Thr TSPO polymorphism (rs6971) associated withlow affinity for [
11C]-PBR28. Glial activation will be quantified as a mean standardized uptake
value (SUV) using PET images acquired from 60 to 90 minutes post-injection of approximately430 MBq [
11C]-PBR28. FreeSurfer v6.0 (https://surfer.nmr.mgh.harvard.edu) will be employed
to circumscribe a region of interest (ROI) defined anatomically as the precentral gyrus and theanterior portion of the paracentral lobule, bilaterally. SUV of the ROI will be normalized to theSUV of the whole brain and expressed as a SUV rat io (SUVR) to control for inter-individual
variability in the global [
11C]-PBR28 PET signal.
6.2 Clinical Progression Measures
6.2.1 ALSFRS-RThe ALSFRS-R (Cedarbaum et al. 1999) is a 12-item  clinician-completed interview scale for
assessing participantsโ function in four domain s: bulbar, fine motor, gross motor, and respiratory.
Each item is scored from 0 to 4 with higher scores indicating greater function. The ALSFRS-Rtotal score is the sum of all items (range 0 to 48).
6.2.2 SVCSlow vital capacity (SVC) is the maximum volume of air that can be slowly exhaled after slow,
maximal inhalation. Trained technicians coach participants through 3 to 5 maneuvers using anEasyOne Plus spirometer (ndd Medical Technologies, Inc., Andover, MA). Assessments will beanalyzed if at least two acceptable maneuvers are recorded. The maximum volume expired isconverted to percent of predicte d normal. Normal values are calculated based on sex, age, and
height using equations published by Knudsen et al . (1983). Higher values indicate better
pulmonary function.
6.2.3 Handheld dynamometryHandheld dynamometry (HHD) will be used by traine d technicians to estimate isometric strength
using a MicroFET2 HHD (Hoggan Scientific, Salt Lake City, UT). Nine upper and lowerextremity muscles or muscle groups will be examined: shoulder flexion, elbow flexion, elbowextension, wrist extension, first dorsal interosseo us contraction, hip flexion, knee flexion, knee
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 15 of 20 
 extension, and ankle dorsiflexion. Each muscle or muscle group will be measured twice or three
times bilaterally. The average of the two highest measurements will be analyzed.
Two measures will be derived from HHD data: (1) upper and lower extremity megascores at each
visit, and (2) time from baseline to first loss of measurable strength in any of the 18 muscles ormuscle groups.
To calculate megascores, the mean and standard deviation of each muscle or muscle group,
without regard to laterality, will be calculated from the baseline assessment of all participants inthe AT sample. Maneuvers that cannot be completed by a participant due to weakness will bescored as zero kg. Strength estimates of each bilateral muscle or muscle group will be convertedto Z scores by subtracting the relevant mean an d dividing by the relevant standard deviation. Z
scores for all upper extremity measurements (shoulder flexion, elbow flexion, elbow extension,wrist extension, and first dorsal interosseous contraction) and all lower extremity measurements(hip flexion, knee flexion, knee extension, and ankle dorsiflexion) will be averaged to yieldupper and lower extremity megascores. Larger values indicate greater strength.
6.2.4 Grip strengthGrip strength of the left and right hand will be measured using a study-approved Jamar hand
dynamometer (Performance Health, Warrenville, IL or Lafayette Instrument Company,Lafayette, IN). At each assessment, two trials will be completed with each hand. The averageisometric strength recording of the stronger ha nd, measured in kg of force, will be analyzed.
7. Power Calculations
With 16 participants randomized to tocilizumab and followed for safety outcomes, the study will
have 80% power to detect adverse events expected to occur in at least 10% of patients. Although
under-powered for comparing rates of rare even ts, the study will have 80% power to detect
treatment differences in events expected to occur, for example, in 50% of placebo participants iftocilizumab increases the hazard 4.2-fold.
The study will have 80% power to declare tocilizumab treatment tolerable based on non-
inferiority to 50% tolerance with a one-sided 95% exact confidence bound if the true tolerancerate is at least 81%
The study will have 80% power to detect a significant treatment-dependent difference in the
proportion of participants who experience a 2-fold o r greater decline between baseline and the
average of all follow-up assessments in at least 2 of the 3 pro-inflammatory genes if no morethan 5% of placebo participants experience such a change and at least 30% of tocilizumabparticipants do. Assuming that at least 80% of participants are truly in a high inflammatory stategiven our enrollment criteria, this condition would correspond to roughly 6% vs. 38% responseamong susceptible patients randomized to placebo or tocilizumab, respectively. We will havegreater power to detect quantitative changes in expression of pro-inflammatory genes. The studywill have 80% power to detect a significant difference in expression equal to an effect size of1.50 based on two-tailed tests at alpha = 0.017, a pplying a Bonferroni correction for multiple
comparisons over 3 inflammatory genes.
If we conservatively estimate power for detecting treatment-dependent differences in 16-wk
change in ALSFRS-R, SVC, and HHD megascores using a simple two-group t-test, the studywill have 80% power for effect sizes of 0.76. With a standard deviation for ALSFRS-R rate of
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 16 of 20 
 change equal to 1.58 units/month based on the fo llow-up schedule of this trial and variance
component estimates from the Ceftriaxone trial,  the study would have 80% power if tocilizumab
reduces decline in ALSFRS-R by 2.0 units/mont h based on a two-tailed at alpha = 0.05.
8. Participant Characterization
8.1 Baseline Characteristics
Each analysis sample will be summarized overall and by treatment group for the following
characteristics: randomization site; age, sex, race, ethnicity, El Escorial diagnosis, years sinceALS symptom onset, delay between symptom onset and ALS diagnosis, site of ALS symptomonset, use of riluzole at baseline, and baseline levels of IL-6, IL-8, and MMP1 gene expression,CRP and cytokines in plasma and CSF by MSD V-PLEX, sIL-6R, IL-6, and gp130 in plasmaand CSF by R&D System ELISA, ALSFRS-R total score, SVC, HHD upper and lower extremitymegascores, and grip strength.
8.2 Participant Disposition
The number of participants who consented and were screened, randomized, completed scheduled
follow up, and prematurely withdrew will be summarized overall and by treatment group.
Reasons for screen failure and for withdrawal from study will be tabulated and quantified as apercentage of consented and randomized participants, respectively.
9. Statistical Analyses
9.1 Safety Measures
9.1.1 MortalityIf any mortality is observed, time to mortality will be estimated starting at date of treatment
initiation by Kaplan-Meier product-limit estimates in the ST sample. Association with treatmentwill be tested by log-rank test. The hazard ratio for treatment with tocilizumab vs. placebo willbe estimated by Cox regression with 90% confidence bounds.
9.1.2 Treatment-emergent Adverse EventsTime to first treatment-emergent SAE will be estimated starting at date of treatment initiation by
Kaplan-Meier product-limit estimates in the ST sample. Association with treatment will be testedby log-rank test. The hazard ratio for treatment with tocilizumab vs. placebo will be estimated byCox regression with 90% confidence bounds.
The incidence of TEAEs and serious TEAEs will be summarized for the ST sample by the
number of events of a given classification experienced by participants in each treatment groupand by the number and proportion of participants experiencing such an event in each treatmentgroup in the ST sample. TEAEs will be summarized in aggregate across all MedDRA terms andseparately by MedDRA system organ class and pre ferred term. For each type of TEAE or serious
TEAE, the association with tocilizumab will be tested by Poisson regression for counts of eventsper participant and by Fisher's exact test for the proportion of participants experiencing the giventype of event. Association of tocilizumab with the overall TEAE rate will be tested by negativebinomial regression.
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 17 of 20 
 TEAEs will also be summarized by tabulating treatme nt-specific frequency distributions for the
following characteristics: (a) seriousness, (b) severity, (c) relatedness to study drug, (d) action
taken with study drug, and (g) outcome. For each level of a given TEAE characteristic,summaries will include the number of events of a given classification and the number andproportion of participants for which that level of a characteristic was the worst they experienced(treating any unknown characteristic as not worst). For each characteristic, the association withtocilizumab will be tested by exact Cochrane-Armitage test for the proportion of participantsexperiencing a given level of the characteristic
9.1.3 SuicidalityThe proportion of participants in the ST sample who report any post-baseline suicidal ideation or
any post-baseline suicidal behavior will be summarized by treatment group. Suicidal behaviors
will include: actual attempts, non-suicidal self-injurious behavior, interrupted attempts, abortedattempts, preparatory acts or behaviors, and completed suicide. The most severe ideation,maximal frequency, maximal duration, minimal controllability, minimal deterrents, maximalreasons for ideation, maximal actual lethality or medical damage, and maximal potential lethalitywill be summarized as means, standard deviati ons, medians, and ranges by treatment group.
9.1.4 Safety LabsThe absolute level and the absolute change from baseline for each safety laboratory assay will be
summarized as means, standard deviations, median s, and ranges at each visit by treatment group
among participants in the ST sample. The proporti on of participants with abnormal and clinically
significant safety lab levels will be summarized by treatment group by visit and at any post-baseline visit. For each safety lab, the association of clinically significant safety lababnormalities with tocilizumab will be tested by Fisher's exact test.
9.1.5 Anthropometrics and Vital SignsThe absolute level and the percent change from baseline for weight, systolic blood pressure, and
diastolic blood pressure will be summarized as means, standard deviations, medians, and rangesat each visit by treatment group among participants in the ST sample. Associations withtocilizumab will be tested in a shared-baseline, linear mixed model with fixed terms for monthsince baseline and treatment x month interaction and random participant-specific intercepts andslopes with unstructured covariance.
9.2 Study Drug Tolerance
The number of completed infusions of study drug among participants in the ST sample will be
summarized by treatment group. The proportion of p articipants classified as tolerant of study
drug will be summarized for each treatment group. Associations with tocilizumab will be testedby Fisher's exact test. The relative risk of intolerance will be estimated with exact confidencebounds.
9.3 Target Engagement Measures
9.3.1 Primary AnalysisThe primary analysis of target engagement measures will compare the proportion of participants
in the AT sample who experience a 2-fold or greater decline between baseline and the average ofall follow-up assessments in at least 2 of the 3 pro-inflammatory genes. Participants lost to
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 18 of 20 
 follow-up prior to any follow-up blood collection will be assumed to have not experienced a 2-
fold or greater decline. Associations with tocilizumab will be tested by Fisher's exact test. Therelative risk of intolerance will be estimated with exact confidence bounds. The following SAS
code specifies the analysis, with
trt a 0/1 indicator variable indicating treatment with 4/mg/kg
tocilizumab and response a 0/1 indicator variable indicating a 2-fold or greater decline in at least 2
of the 3 pro-inflammatory genes:
proc freq data=xxx; 
tables trt * response / fisher; 
exact relrisk(method=score column=1); 
A relative risk greater than 1 significant at two-tailed p < 0.05 would indicate successful target
engagement.
9.3.2 Secondary AnalysisSecondary analysis of target engagement measures  will use data from the AT sample in a shared-
baseline, repeated-measures mixed model of log-transformed gene expression, CRP, cytokine,sIL-6R, or gp130 levels with fixed terms for visi t (5 levels: baseline and weeks 4, 8, 12, and 16),
treatment group (2 levels: placebo and 4 mg/kg tocilizumab) x post-baseline visit (4 levels) andrandom participant-specific visits with unstructured covariance. The interaction between fixedterms for treatment group and visit will be restricted to post-baseline visits by including anumeric indicator variable (0 pre-treatment, 1 post-treatment) in the interaction. Data from anyearly termination visits will be assigned to the next scheduled post-baseline visit. The followingSAS code specifies the model:
proc mixed data=xxx method=reml; 
class id trt visit; 
model Value = visit post*trt*visit; 
random visit / subject=id type=un; 
Treatment-dependent differences in the change from baseline to the average of all follow-up
visits and to week 16 specifically will be estimated by linear contrasts and tested using a two-tailed Wald-test at alpha = 0.05. The following SAS code specifies the linear contrasts (with thesort order for treatment group being placebo first and 4 mg/kg tocilizumab second, and the sortorder for visit being chronological):
estimate "3|TCZ vs PLB|dWeek 16" post*trt*visit 0 0 0 0 -1 0 0 0 0 1 / cl; 
estimate "3|TCZ vs PLB|dWk 4-16" post*trt*visit 0 -1 -1 -1 -1 0 1 1 1 1 / cl divisor=4; 
The estimates and their 95% confidence bounds will be back-transformed for reporting as a
treatment-dependent ratio of post-baseline an d week 16 concentration relative to baseline.
Additional contrasts will be used to estimate treatment- and visit-specific concentrations withback-transformation for reporting on their original scale of measurement.
9.3.3 Subgroup AnalysesDifferences in the effect of tocilizumab on target engagement measures dependent on IL6R
genotype will be estimated by adding minor allele count, minor allele count x visit, and minor
allele count x treatment x post-baseline visit interaction terms to the primary target engagementmodel.
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 19 of 20 
 9.4 Efficacy Measures
9.4.1 Primary AnalysisThe primary analysis of clinical efficacy measures will use data from the mITT sample in a
shared-baseline, random-slopes mixed model w ith fixed terms for month from treatment
initiation and treatment group (2 levels: placebo and 4 mg/kg tocilizumab) x month fromtreatment initiation interaction and random participant-specific intercepts and slopes withunstructured covariance. Data from any early termination visits will be at their observed follow-up time. The following SAS code specifies the model and the linear contrast used to estimate thetreatment-dependent difference in rate of change per month:
proc mixed data=xxx method=reml; 
class id trt; 
model Value = month trt*month; 
random intercept month / subject=id type=un; 
estimate "3|TCZ vs PLB|Slope/mn" intercept 0 month 0 trt*month -1 1 / cl; 
9.4.2 Secondary Analysis
A secondary analysis of clinical efficacy measures will use the same shared-baseline, repeated-
measures mixed model described for secondary analysis of target engagement measures withmodification of the visit term to reflect the schedule of assessment for each measure (ALSFRS-Rand SVC = 5 levels [baseline and weeks 4, 8, 12, and 16]; HHD and grip strength = 3 levels[baseline and weeks 8 and 16]). The same estimates of treatment- and visit-specific changes frombaseline and treatment-dependent differences in change from baseline will be used.
9.5 Additional Considerations
9.5.1 Multiplicity AdjustmentsTests of treatment-dependent differences in time to mortality, time to first treatment-emergent
SAE, overall TEAE rate, and distribution of TEAE characteristics will be declared significantbased on two-tailed p < 0.10 without adjustment for multiple comparison. Tests of treatment-dependent differences in other safety outcomes will be declared significant based on two-tailed p
< 0.05 without adjustment for multiple comparison. These criteria increase the probability oftype 1 errors but also increase power for det ecting true differences should any exist. Both
unadjusted and step-down Bonferroni-adjusted p-values will be reported for secondary analysesof target engagement measures. Both unadjusted and step-down Bonferroni-adjusted p-valueswill be reported for clinical efficacy measures.
9.5.2 Missing DataBaseline values for target engagement and clinical efficacy endpoints will be determined from
the last non-missing data collected prior to the first dose of study medication. The planned mixedmodels yield estimates that are unbiased conditional on the observed scores under a missing atrandom assumption. Sensitivity analyses may be pursued to impute missing values or otherwiseconstruct models for unobserved outcomes if more than 20% of participants are missing follow-
up data for any reason.
Ladha (PI) Tocilizumab Trial: Statistical Analysis Plan Version 1.0, 01 Mar 2019
Page 20 of 20 
 10. References
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The
ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of
respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-
2):13-21.
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B . Changes in the normal maximal expiratory
flow-volume curve with growth and aging. Am Rev Respir Dis. 1983 Jun;127(6):725-34.